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ABSTRACT 
 A wide array of molecular modeling tools were utilized to design and develop inhibitors 
against cysteine protease of P. Falciparum Malaria and Severe Acute Respiratory Syndrome 
(SARS). A number of potent inhibitors were developed against cysteine protease and 
hemoglobinase of P. falciparum, referred as Falcipains (FPs), by the structure-based virtual 
screening of the focused libraries enriched in soft-electrophiles containing compounds. Twenty 
one diverse, non-peptidic, low micromolar hits were identified. A combined data mining and 
combinatorial library synthesis approach was performed to discover analogs of virtual screening 
hits and establish the structure-activity relationships (SAR). However, the resulting SAR of the 
identified hits was unusually steep in some cases and could not be explained by a traditional 
analysis of the interactions (electrostatics, van der Waals or H-bond). To gain insights, a 
statistical thermodynamic analysis of explicit solvent in the ligand binding domain of FP-2 and 
FP-3 was performed that explained some of the complex trends in the SAR. Furthermore, the 
moderate potency of a subset of FP-2 hits was elucidated using quantum mechanics calculations 
that showed reduced reactivity of the electrophilic center of these hits. In addition, solvent 
thermodynamics and reactivity analysis also helped to elucidate the complex trends in SAR of 
peptidomimetic inhibitors of FP-2 and FP-3 synthesized in our laboratory. Multi nanosecond 
explicit solvent molecular dynamics simulations were carried out using the docking poses of the 
known inhibitors in the binding site of SARS-3CL
pro
, a cysteine protease important for 
replication of SARS virus, to study the overall stability of the binding site interactions as well as 
iii 
 
identify important changes in the interaction profile that were not apparent from the docking 
study. Analysis of the simulation studies led to the identification of certain protein-ligand 
interaction patterns which would be useful in further structure based design efforts against 
cysteine protease (3CL
pro
) of SARS. 
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1.1. Introduction 
Proteases are an important class of enzymes involved in the hydrolysis of peptide bonds 
in protein. Proteases can be subdivided into five major categories based on their mechanism of 
peptide hydrolysis: Aspartic, Serine, Cysteine, Threonine and Metalloprotease 
2
. They play a 
vital role in a variety of cellular and physiological events in lower order, viruses extending up to 
higher organisms including humans, making them attractive targets for further considerations 
3
. 
Among these proteases, cysteine proteases, with their unique mechanism and diverse array of 
functions, have become important targets for drug design. 
Cysteine proteases are classified in three structurally distinct groups, namely papain-like 
(e.g., clan CA, the cathepsins, falcipain), ICE-like (e.g., clan CD, the caspases) and picornain-
like (e.g. clan PA (C), SARS 3CL
pro
) 
4
. Different cysteine proteases are associated with a variety 
of clinical conditions in humans, for example, Caspase-I (psoriasis, inflammation), Cathepsin S 
(autoimmune or inflammatory disorders) and Cathepsin K (osteoporosis) 
5
. They are also present 
in the life cycle of protozoa, for example, falcipain from P. falciparum (malaria) and cruzain 
from T. cruzi (chaga‟s disease), as well as in viruses such as HRV 3CLpro from the rhinovirus 
(common cold) 
6
 and SARS 3CL
pro
, an etiological agent responsible for the Severe Acute 
Respiratory Syndrome (SARS) infection 
7
.  
The proteolytic mechanisms of cysteine proteases involve a nucleophilic attack of the 
thiolate anion from the catalytic cysteine on the carbonyl carbon of the labile peptide bond. This 
leads to the formation of an acyl-enzyme (tetrahedral) intermediate, stabilized by the hydrogen-
bonding to the residues of the oxyanion hole. Subsequent hydrolysis of the tetrahedral 
intermediate releases the free enzyme 
3
. Although, selectivity among the members of cysteine 
protease from the same family is of great concern, some inhibitors have now entered into various 
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phases of pre-clinical or clinical development 
5
, which has attracted the attention of researchers 
for further  drug design against this target. 
The present chapter highlights various rational approaches adopted for the discovery of 
peptidic and non-peptidic inhibitors against parasitic cysteine proteases: falcipains, a papain-like 
protozoal cysteine protease, and SARS 3CL
pro
, a chymotrypsin-like viral cysteine protease. 
Although these two proteases are quite different from each other in structure and specific 
biological functions they exhibit in protozoa or virus, similarity exist in drug design approaches 
against both proteases. The drug design approaches discussed below include knowledge-based 
drug design, structure-guided drug design, virtual and high-throughput screening, 
peptidomimetic design and natural product-based drug discovery that provide an absolute 
understanding of drug discovery process against both the targets. Particular emphasis has been 
given to the computational approaches adopted for the design of inhibitors or understanding the 
mechanism of inhibitor binding. The drug design strategies discussed in the next sections are 
introduced here briefly in the context of cysteine proteases. 
Knowledge-based drug design initiates drug discovery efforts based on the similarity of a 
cysteine protease under consideration with other members of the same or different protease 
family. This approach merges information obtained from the knowledge of the substrate 
requirement of a given protease with the known inhibitors of the homologous proteases while 
design of inhibitors against the protease under consideration. Knowledge-based drug design is 
particularly important when only a limited option exists for the treatment against a particular 
disease. For example, during the outbreak of SARS, in the absence of efficacious drugs, 
analogues of rupintrivir (a rhinovirus  protease inhibitor belonging to the C3 family and 
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approved for the clinical trials in humans for treatment of cold) served as a starting point for the 
drug design against SARS-CoV M
pro
 (member of the C30 family of cysteine proteases) 
8
. 
Structure-guided drug design considers the design of the inhibitors based on the X-ray 
crystal structure 
9-11
 or homology model of the given protease 
12, 13
 taking into consideration the 
nature of the specificity subsites and interactions with the key residues of the active site. 
Rupintrivir developed by Pfizer Inc. is the best example of the application of structure-guided 
drug design in lead discovery 
14
. Peptidomimetics design against cysteine protease usually 
involves an address element that mimics the natural peptide sequence and sometimes the 
secondary structures of protein such as β-turn 15. The addressing element is important for subsite 
recognition and binding to the target enzyme. A warhead group or electrophilic deficient center 
is present in addition to the addressing element, which replaces the scissile amide bond of the 
substrate and is capable of reacting in reversible or irreversible fashion with the active site thiol 
16
. Improved pharmacokinetics properties of the peptidomimetics due to their stability against 
hydrolytic enzymes as well as reduced toxicity to the human host suggest the preference of 
peptidomimetics design over the natural peptide 
17
.  
  Highthroughput screening (HTS) provides an opportunity to simultaneously screen a 
large number of compounds originated from the diverse chemotypes with the help of a sensitive 
and robust assay method
18
. Structure-based virtual screening involves in silico evaluation of a 
database of molecules against an experimentally determined structure or a homology model of 
protein target using a docking program. The docking poses thus obtained are ranked based on a 
scoring function to identify putative binders. Thus, only a small set of compounds are selected 
and evaluated in a biological assay as compared to the high throughput screening of an entire 
compound library 
19
.  
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  The following sections describe comprehensive drug discovery efforts conducted against 
FPs and SARS-3CL
pro
 based on rationale drug design approaches discussed above. The drug 
development strategies described below could also be applied for the design of inhibitors of 
cysteine protease present in existing and future emerging pathogens, humans or design of 
inhibitors for all cysteine proteases in general.  
1.2. Malarial cysteine protease “falcipain”: genesis, function and structural requirements 
Malaria is a global health issue, causing close to a million deaths annually according to recent 
death statistics from the World Health Organization (WHO) 
20
. It is caused by four major species 
of the Plasmodium (P) genus in humans: P. falciparum, P. vivax, P. ovale, and P. malaria. The 
most virulent strain of malaria-causing pathogen is P. falciparum, responsible for the highest 
morbidity, mortality and spread of the disease 
21
. The regions where malaria is endemic include 
tropical and subtropical regions of Africa, Asia and South America.
22
. Falciparum malaria is a 
particular threat for Africans, especially children under the age of five. Approximately 90% of 
malaria cases are reported from developing countries in Asia, South America, and Sub-Saharan 
Africa, and so there is a particular need for inexpensive, easy to use, and well-tolerated malaria 
treatments
23
. A number of drugs are currently available to treat malaria
24
, however, treatment is 
complicated by the toxicity, high cost, and diminishing efficacy of different agents. The first 
known treatment of malaria occurred in 1631 with the bark of the cinchona tree, from which 
quinine was later purified
25
. As quinine is not well tolerated, new therapeutics were developed, 
including chloroquine and related aminoquinolines, antifolates, and mefloquine. However, 
strains of P. falciparum resistant to all these therapeutics have been observed.
26-28
 Artemisinin, a 
natural product from Artemisia annua, and its derivatives have been identified as rapidly active 
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and highly efficacious antimalarials
28
. In recent years the standard of care for the treatment of 
uncomplicated falciparum malaria has moved to artemisinin-based combination therapy, 
including an artemisinin component (artesunate, artmether, or dihydroartemisinin) combined 
with a longer acting agent
29
. However, P. falciparum strains have been found showing decreased 
responsiveness to artemisinin therapy, in particular near the Thailand-Cambodia border
26
. This 
finding validates a continued need for effective alternative therapeutics targeting key pathways in 
the life-cycle of malaria parasites. 
Several proteases play an essential role in the life cycle of the P. falciparum, which 
includes aspartic protease “plasmepsins”, cysteine protease “falcipains” and the metalloprotease 
“falcilysin” 30-32. Among these proteases, falcipains have gained increasing attention due to their 
critical roles in the survival of protozoa. The P. falciparum genome contains 33 open reading 
frames (ORFs) expressing four different cysteine proteases of the papain family (clan CA), 
collectively known as falcipains 
33-36
. These include falcipain-1 (FP-1), falcipain-2 (FP-2), 
falcipain-2‟ (FP-2‟) and falcipain-3 (FP-3) 37.  
The biological roles of falcipains are reviewed elsewhere in detail
38
. In brief, their 
suggested roles involve erythrocytic invasion, hydrolysis of hemoglobin and erythrocytic 
rupture. Among FPs, FP-2 and FP-3, encoded by nearby genes, are localized to the P. falciparum 
food vacuole, the site of hydrolysis of large quantities of hemoglobin by erythrocytic parasites. 
FP-2 and FP-3 have been shown to be hemoglobinases
38
, and they appear to be responsible for 
the hydrolysis of the host erythrocyte hemoglobin to provide amino acids required for protein 
synthesis in protozoa
34, 36, 39
. Knockout of FP-2 led to parasites with diminished hemoglobin 
hydrolysis
39
. Knockout of FP-3 was not possible, strongly suggesting that this protease is 
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essential for erythrocytic parasites
37
. Functions of the other falcipains are less well understood. 
FP-1 activity was associated with erythrocyte invasion by P. falciparum merozoites
40
, but 
knockout of the protease did not alter erythrocytic parasites
41
, and its primary function is more 
likely in mosquito-stage parasites
42
. FP-2' is a near-identical copy of FP-2, but knockout of FP-2' 
had no apparent phenotype, indicating that the protease is not essential
37
. In particular, inhibition 
of FP-2 and -3 by covalent irreversible cysteine protease inhibitors blocked hemoglobin 
hydrolysis and formed characteristic swollen, dark-stained food vacuoles due to accumulation of 
unhydrolysed globin
43, 44
. These morphological abnormalities are typical characteristics of 
cysteine protease inhibition not elicited by inhibitors of other food vacuole proteases such as 
aspartic protease
45
. In any events, inhibition of FP-2 and FP-3, blocks parasite development, 
enabling these enzymes as viable targets for the development of antimalarial chemotherapy.  
During the early phases of the drug discovery against these plasmodial hemoglobinase in 
the absence of the X-ray crystal structure, several homology models were reported 
13, 46-48
. 
Multiple crystal structures of FP-2 and FP-3 became available later on 
49-52
 which not only 
revealed the overall topology of FP-2 and FP-3 but also provided an opportunity to rationally 
explore the structural determinant of falcipains 
49
. The crystal structure of FP-2 (3BPF, protein 
data bank (PDB) code) shown in Figure 1.2.1a) has been discussed briefly here. FP-2 has a 
distorted ellipsoidal shape, a typical attribute of the papain-like cysteine proteases. In addition to 
a classic papain-like fold, FP-2 has two distinct domains, left domain (L) and right domain (R)    
(Figure 1.2.1a). The L domain is made up of α-helices whereas the R domain is mainly 
composed of antiparallel β-sheets 49. Both FP-2 and FP-3 have two unique structural features 
designated as N-terminal extension and hemoglobin binding insert that distinguish them from all 
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other structurally characterized papain family enzymes 
50
. N-terminal extension is involved in 
the folding of enzyme into its mature form whereas hemoglobin binding insert captures the host 
erythrocyte hemoglobin 
49
. The substrate-binding site is located at the junction of these two 
domains bearing a catalytic triad formed by Cys-42, His-174 and Asn-204. Figure 1.2.1b 
displays a magnified view of the substrate-binding site of FP-2 in complex with an irreversible 
epoxysuccinate (E-64) inhibitor. Subsites S1, S1‟, S2, S3 and the P1, P1‟, P2 and P3 side chain 
of E-64 are shown in Figure 1.2.1b.  
Both FP-2 and FP-3 share a high sequence identity of 66.7% 
50
. The homology models 
and the X-ray crystal structures of FP-2 and FP-3 revealed major differences in the S2 pocket of 
the active site with more flexible Glu 243 in FP-3 as compared to Asp 234 in FP-2 as well as 
bulkier Tyr 93 in FP-3 with corresponding Leu 84 in FP-2 
13, 50
. The presence of the bulkier 
residues narrow down the S2 binding pocket of FP3 as compared to FP2 and might be 
responsible for the kinetic difference between these closely related enzymes 
50
. These two 
proteases contribute almost equally to the hemoglobin degradation with the former expressing at 
the earlier stages in the life cycle of protozoa 
36
. The similarity in the functions exhibited by FP-
2, FP-2‟ and FP-3 point towards the combined drug discovery efforts against these subtypes 35, 53. 
Substrate-cleavage assays suggest marked preference for hydrophobic residue, particularly Leu 
at P2 for FP-2 
34
 and FP-3 
36
. These studies gave important insights for the designing of 
inhibitors against both the enzymes. 
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Fig. 1.2. (a) Overall topology of FP-2; (b) Magnified view of the substrate-binding pocket of FP-
2 with co-crystallized ligand E-64. Subsites S1, S1‟, S2 and S3 of the enzyme (black), the P1, 
P1‟, P2 and P3 side chains of E-64 (red) and residues of FP-2 binding sites (white) are shown. 
 
1.3. Drug Design Approaches Against FPs 
1.3.1. Knowledge-Based Drug Design 
The drug design efforts were initiated against FPs with the previous knowledge of 
inhibitors of other cysteine proteases such as papain, cathepsins, calpain, and cruzain having 
reversible electrophilic isostere such as peptidic aldehyde 
54, α-keto carbonyl 55, 56, nitriles 57 as 
well as irreversible warhead groups such as halo methyl ketones 
58
, epoxysuccinyl 
59
 and 
vinylsulphones 
60
 etc. 
Early efforts for the validity of FP-2 (formerly known as trophozoite cysteine proteinase 
or TCP) by Rosenthal and colleagues as a possible chemotherapeutic target led to the evaluation 
of a panel of peptidyl fluoromethyl ketones (FMKs) against TCP. Benzyloxycarbonyl (Z)-Phe-
Arg-CH2F (1, Figure 1.3.1), was found to inhibit TCP proteolytic activity in the sub-nanomolar 
concentration (IC50 = 0.36 nM) and parasite killing (IC50 = 64 nM) in the nanomolar range 
43
. In 
addition, Morpholine urea (Mu)-Phe-Homophe(HPhe)-CH2F (2), one of the FMK inhibitors, 
cured 80% of P. vinckei-infected mice under test conditions having biochemically similar 
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cysteine protease as P. falciparum 
61
. However, severe toxicity associated with the use of FMKs 
in animal models restricted their further development 
62
. 
Epoxysuccinyl peptides derived from E-64 (3, Figure 1.3.1) containing trans-
epoxysuccinic acid as electrophilic element are selective inhibitors of cysteine proteases from the 
papain superfamily and involve the irreversible activation of the enzyme by alkylation of the 
active site cysteine 
63
. Several groups have reported the efficacy of E-64 and its derivatives as an 
antiplasmodial agent with activities in the nanomolar range against falcipains as well as cultured 
parasites 
34, 43, 64, 65
. However, their lack of selectivity against different members of the papain 
family limits their further development as drugs.    
Various mechanism-based vinylsulphone inhibitors were reported against closely related 
cysteine proteases during the late 90‟s 60. Rosenthal et al. performed the synthesis of a previously 
identified potent cysteine protease inhibitor 4 as well as closely related compounds with different 
side chains of P1 and P2 amino acids and evaluated the antimalarial potential of vinyl sulphones 
62
. Among the synthesized compounds, compound 4 effectively inhibited the P. falciparum 
(IC50= 3 nM) cysteine protease as well as blocked hemoglobin hydrolysis and development of 
parasites at nanomolar concentration. Further, orally bioavailable derivatives of vinyl sulphones 
were reported by replacing the morpholine urea group with the N-methyl piperazine urea 
66
. 
Also, the phenyl vinyl sulphone was replaced with a naphthalene vinyl sulphone. Compound 5 
(IC50 of 5 nM for P. falciparum cysteine protease) was active in-vivo against murine malaria 
(cured 40% of infected mice after oral doses of 50mg/kg twice a day) 
66
. Shenai et al. 
synthesized 39 new compounds having vinyl sulphones, vinyl sulfonamide and vinyl sulfonate 
esters as warhead groups to establish the structure activity relationships 
67
. Inhibitors with Leu at 
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the P2 position and homophenylalanine (HPhe) at the P1 position displayed potent inhibitory 
activity against both the enzymes as well as cultured parasites, which point towards importance 
of these residues for substrate specificity against FP-2. Vinyl sulphonate esters were the most 
active (compound 6, FP-2 IC50 = 0.9 nM, W2 IC50 = 9.7 nM), followed by vinyl sulfonamides 
(compound 7, FP-2 IC50 =2.3, W2 IC50 = 4.4 nM), and finally phenyl vinyl sulfones (compound 
8, FP-2 IC50 = 6.9 nM, W2 IC50 = 3.9 nM) among the synthesized series of compounds 
67
 (Figure 
1.3.1). (Note: W2 and D6 stand for chlorquine resistant and chloroquine sensitive strains of the 
P. falciparum, respectively).  
Further, conformationally restricted analogues of sulfones were designed with vinyl 
sulfone attached to the dipeptide sequence in order to improve their potency and metabolic 
stability. Compound 9 with trans (E) geometry of the double bond inhibited the enzyme as well 
as cultured parasite in micromolar range (FP-2 IC50 = 13.7 μM, W2 IC50 = 7.8 μM) 
68
. The 
substantial reduction in the activity of these compounds compared to corresponding acyclic 
analogs (for example 4) prompted the authors to predict the binding mode of 9 in the active site 
of the homologous enzyme, cruzain. The predicted conformation of compound 9  disfavored the 
Michael addition of cysteine to the β-carbon of the vinyl-sultam due to interference of the ring 
substitution on the α–carbon of the Michael acceptor and, therefore, could be responsible for a 
lower activity 
68
 (Figure 1.3.1). 
 The most concerning drawback of vinyl sulphone inhibitors includes irreversible 
alkylation of the active site cysteine residue by conjugate addition. To encounter these issues, 
closely related peptides bearing reversible warhead groups such as aldehyde and α-ketoamide 
were developed 
69
. Representative compounds from the aldehyde (compound 10 native FP-2 IC50 
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= 1 nM, W2 IC50 = 1.1 nM) and ketoamide series (compound 11 native FP-2 IC50 = 1 nM, W2 
IC50 = 2.9 nM) are shown in Figure 1.3.1. Both of these compounds were active against multiple 
strains of P.falciparum 
69
. 
 Phenolic Mannich bases were previously reported to possess anticancer as well as 
antimalarial properties 
70
. The bioactivities of these compounds were thought to involve in situ 
generation of α, β-unsaturated ketones possessing a higher affinity for cysteine thiols. Also, 
thiosemicarbazone scaffold-bearing compounds were reported to have a broad spectrum of 
chemotherapeutic activity including anti-malarial activity 
70
. These compounds are Schiff bases, 
having iron-chelator properties as well as acting as electrophilic warheads to attract cysteine 
thiol. Chipeleme et al. appended the phenolic mannich base group to various (thio) 
semicarbozaone entities and linked them with aminoquinolines (known to inhibit hemazoin 
formation). Compound 12 from this series exhibited potent inhibition of FP-2 (IC50 = 0.63 μM) 
and W2 strain of P. falciparum (IC50 = 0.27 μM, Figure 1.3.1) in the lower micromolar range 
70
.  
Aziridines compounds are selective and irreversible inhibitors of cysteine protease. They 
are aza analogues of epoxides 
71
. These compounds were previously evaluated against the 
cysteine protease of SARS, Leishmania, and Trypanosoma brucei, as well as cathepsin K, and 
they inhibited the protease by covalent adduct formation with cysteine thiol of the active site. 
Schulz et al. evaluated three class of aziridines, aziridine-2-carboxylic acid derivatives, N-
acylated aziridine-2, 3-dicarboxylic acid derivatives and aziridines-2-carboxylate containing a 
lysine residue, against FP-2 and FP-3 
72
. Two of the most active compounds, compound 12 from 
the aziridines 2-carboxylate series (FP2 IC50 = 2.5 µM, FP3 IC50 = 3.8 µM, W2 IC50 = 9.7 µM) 
and compound 13 from the N-acylated aziridine-2, 3-dicarboxylic acid series (FP2 IC50 = 0.079 
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µM, FP-3 IC50 = 0.25 µM, W2 IC50 = 0.43 µM) are shown in Figure 1.3.1 
72
. 
Recently, a multiple ligand approach was reported against FP-2, which involved the 
combination of artemisinin, a sesquiterpene lactone, and a potent antimalarial compound with 
dipeptidyl vinyl sulphones via a linker to combat multi-drug resistance in P. falciparum malaria 
73
. The compound 15 exhibited potent inhibitory activity of FP-2 (FP2 IC50 = 0.21 nM). Also, it 
had a superior activity profile against multiple strains of malaria as compared to artemisinin and 
chloroquine 
73
. 
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Figure 1.3.1. Representative peptidic inhibitors developed by knowledge-based drug design. 
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1.3.2. Structure-Guided Drug Design 
Sabnis et al. developed homology models of FP-2 and FP-3 and validated these models 
with the help of various structures/geometry tools as well as by the docking of substrate/known 
vinyl sulphone inhibitors 
13, 46
. The validated model was used to design novel non-peptidic 
analogs having clinically validated isoquinolines core. Two compounds were designed based on 
the intuitions from the docking studies. In-vitro evaluation of these compounds against FP-2 
showed activity in the micromolar range (most active compound 16 with FP-2 IC50 of 8 μM)
13
. 
Several isoquinolines and dihydroisoquinolines analogs were designed to further optimize the 
activity of compound 16, considering the interaction of designed analogs with Asp234 of the S2 
pocket as essential 
12
. The synthesized compounds vary in the IC50 range from 3 to 10 μM 
(representative compound 17, FP2 IC50 = 3μM, Figure 1.3.2). Docking predictions of the 
compounds from these series were in an excellent agreement with the in-vitro activity, having 
correlation coefficient of 0.94.  
Goud et al. addressed the de-novo design of novel non-peptidic inhibitors bearing the 
thiazoline scaffold 
74
. The thiazoline core was chosen because of the favored key interactions and 
the spatial arrangement of the designed trisubstituted thiazoles in the active site of FP-2. Also, 
the thizaole core was able to gain a planar conformation and could mimic the amino acid portion 
of the peptide bond in the molecular modeling studies. In addition to this, docking studies 
predicted a similar binding mode and interaction energies of these designed thiazole compounds 
to the known vinyl sulphone inhibitors. This led to the dedicated synthesis and biological 
evaluation of a series of trisubstituted thiazole analogs against FP-2 and FP-3 
74
. Compound 18 
was a dual inhibitor of both enzymes (FP-2 IC50=6.6 μM, FP-3 IC50=29.4 μM) as well as 
16 
 
showing activity against cultured malarial (W2 EC50= 13.8) and leishmanial parasites (EC50= 4.5 
μM) (Figure 1.3.2).  
 
Fig.1.3.2. Representative non-peptidic inhibitors developed by structure-guided drug design. 
1.3.3. Peptidomimetics Design   
Verissimo et al. undertook  modeling studies to compare the low energy conformations of 
their proposed peptidomimetics with vinyl sulphone inhibitor 4 by substituting leucine at P2 of 
vinyl sulphone with pyridone
75
. Their designed molecules adopted a similar low energy 
conformation to that of a vinyl sulphone inhibitor in 3D space. Synthesis of the designed 
peptidomimetics with pyridone as a P2 recognition element and different electrophilic isostere at 
P1‟ positions were performed. Compounds 19 and 20 with aldehyde and vinyl sulphone warhead 
groups showed an IC50 value of 10.9 μM and 19.0 μM, respectively, against FP-2 
75
 (Figure 
1.3.3). Although molecular modeling studies showed an excellent overlay of the peptidic 
counterparts of these compounds, the lower activity of the designed compounds suggested that 
the rigid pyridone moiety chosen was not suitable for the backbone modifications. 
 Nicola et al. designed aldehyde-based peptidomimetics with benzodiazepines (BDZ) 
scaffold as a mimetic of the fragment D-Ser-Gly of peptide and the aspartic aldehyde building 
block at C-terminal that was known to form a reversible covalent bond with the enzyme active 
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site 
76. They also considered the excellent bioavailability, tolerability and β-turn mimetic 
properties of BDZ scaffold in their peptidomimetics design. Effort towards the synthesis of the 
designed peptidomimetics discovered compound 21 with IC50 of 10.29 μM and 19.31 μM against 
FP-2 and FP-2‟, respectively. Also, these compounds were selective to malarial protease as 
evident by their inactivity against recombinant human caspases 1-9 for up to 50 μM 
concentration 
76
.  
Further, the P1 and P1-P1‟ positions of the most active compound 21 were modified to 
explore the structural requirements for this class of peptidomimetics. The aspartic aldehyde 
building block at the P1 position of 21 was replaced with an electrophilic vinyl sulphone moiety 
spanning the P1-P1‟ position (for covalent trapping of cysteine thiol of the active site) with 
different aromatic substitution (to explore the size and characteristics of the lipophilic P1‟ 
pocket) 
15
. A second modification involved HPhe at the P1 position (a residue known to boost 
the potency of FP-2 inhibitors) and, finally, the placement of glycine (Gly) at the same position 
(to evaluate the process of ligand recognition as well as its impact on inhibitory kinetics by the 
enzyme) 
15
.  As expected, compounds with the HPhe at P1 position showed higher second order 
rate constant as compare to glycine at the same position 
15
. The representative compound (22, 
Figure 1.3.3) from this series showed the highest inhibition of FP-2 coupled with good inhibition 
potency against the cultured parasites (W2 IC50 = 9.1 μM). Attempts were made to replace the 
vinyl sulphone moiety with vinyl phosphates, but only resulted in compounds exhibiting poor 
activity and selectivity profile 
77
. Recently, another strategy presented by the same group focused 
on the evaluation of the strength and efficacy of different α, β–unsaturated electrophilic 
withdrawing groups such as vinyl-ketones, amides, esters and nitriles against cysteine thiol 
77
. 
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Among the synthesized compounds, vinyl ester 23 displayed potent inhibition of FP-2 (Ki = 17 
nM) as well as significant inhibition of the P. falciparum FCBR strain (IC50 = 12 μM). However, 
this compound was also selective towards human cysteine protease, cathepsin B and L.  
 
Fig.1.3.3. Representative peptidomimetics developed against FP-2 and FP-3. 
 
1.3.4. Structure-Based Virtual Screening  
This section will review the discovery of the non-peptidic inhibitors developed against 
FP-2 and FP-3 by a structure-based virtual screening approach. Table 1.3.4 summarizes the 
commercial databases, methods, softwares and scoring functions used for virtual screening, hit 
ratio along with chemical structures of hits obtained. 
Ring et al. initiated the structure-based virtual screening efforts against cercarial elastase 
(a serine protease responsible for schistosomiasis) and TCP using a developed homology model 
78
. An earlier version of DOCK was used to screen the fine chemical directory of ~50,000 
compounds. A total of 8800 molecules were retained after the initial phase of docking, 
considering the shape complementary and force field-based scoring scheme. In the final stage of 
visual inspection, compounds exhibiting good fitness as well as potential H-bonding and 
electrostatic interactions were retained with reduced priority on the scoring scheme. A total of 31 
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compounds were biologically evaluated against TCP. All four inhibitors identified against TCP 
and cercarial elastases were from the shape-based and force field-based scoring scheme, 
respectively. The shape-based scoring functions worked well for the hydrophobic site of TCP 
whereas force-field based scoring performed well for the charged amino acid cavity (polar) of 
cercarial elastase. Compound 24, obtained with the shape-based scoring scheme, was found to 
have an IC50 value of 6 μM against TCP (Table 1.3.4, raw 1). The docking pose of 24 showed 
one naphthol group occupying the S2 pocket whereas another naphthol group was found to 
interact with the Trp173 of the S1‟pocket 78. Further, structural modifications of compound 24 
were carried out to reduce the conformational flexibility, enhance water solubility and 
electrostatic interactions, improve overall chemical/metabolic stabilities and to analyze the size 
and electronic characters of the subsite specificity pocket 
79
. The structural modifications 
resulted in a synthesis of a series of novel chalcone derivatives with good potency against the 
W2 and D6 strains of P. falciparum. (Representative compound 25, W2 IC50 = 0.24 μM, D6 IC50 
= 0.19 μM). Molecular modeling tools as well as experimental assay revealed the inhibitory 
action of this compound by the inhibition of TCP 
79
 (Table 1.3.4, raw 1).  
Joachimiak et al.  developed a homology model of FP-2 using the X-ray crystal structure 
of cathepsin K zymogen (PDB code: 1BY8) as a template for virtual screening of compounds 
from the Available Chemical Library (ACD) using DOCK 4.0 
47
. 5000 compounds were retained 
from the energy and shape-scoring schemes implemented in DOCK after initial docking. The 
final selection of the set of compounds was based on the knowledge of the specificity sites of FP-
2 along with the consideration of drug-like properties of small molecules (such as 
hydrophobicity, molecular weight and absence of reactive chemical functionalities with the 
tendencies to form covalent bond). A set of selected compounds were evaluated in a 
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fluorescence-based assay using a recombinant FP-2 enzyme. Eight inhibitors 26-33 were 
identified (IC50 of 1 to 7 μM. Table 1.3.4,  raw 2) in the enzyme assay, three of which 28, 29, 33 
were also active against the chloroquine resistant (W2) strain of P.falciparum (IC50 range < 26 
μM) 47. 
FP-2, FP-3, cruzain and cysteine protease from Leishmania donovani (L. donovani) share 
more than 40% homology in their mature domain and about 90% in the binding sites 
33
. To 
identify a broad spectrum inhibitor against these protozoa, Desai et al., screened the 
CHEMBRIDGE database against homology models of FP-2 and FP-3 developed in their 
laboratory 
13, 46, 80, 81
. Protein preparation for screening was carried out at pH 5 to mimic the 
acidic environment of the food vacuole of P. falciparum, where the enzyme is located. Prior to 
the docking studies, the database was processed to eliminate metal and counter ions, neutralize 
charged molecules, eliminate compounds with poor ADME properties and identify compatibility 
with the Lipinski rule. The docking protocol was pre-validated by predicting the experimental 
pose of a vinyl sulphone inhibitor in the available crystal structure of cruzain (1F2A, PDB code). 
The filtered databases were subjected to docking using GOLD software in three different 
settings: 7-8 times speed up mode, 2 times speed up mode and standard mode. As docking of the 
large databases can be computationally expensive, multispeed docking protocol was adopted to 
discard the compounds quickly in the initial stages, retaining only those which were 
complementary to the binding site topology. In the consequent stages (with the standard docking 
mode), more exhaustive docking runs were performed for predicting the binding modes and 
interactions of the remaining compounds with the active site. Considering the high sequence 
similarity in the active sites of these two enzymes with major differences in the size of S2 pocket 
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(narrower in FP-3 as compared to FP-2), it was thought that the compounds binding to FP-3 
would most likely fit into FP-2. Hence, the initial two rounds of docking were only conducted in 
FP-3 to reduce the computational time. The top 10% of compounds at the end of the second run 
were docked in both homology models using more rigorous standard mode of GOLD. Ten vinyl 
sulphone inhibitors were seeded as a positive control for periodic measure of the docking 
procedure efficiency at each stage. Finally, the top common hits for the two enzymes were 
visually inspected based on the geometry of the binding pose, proximity of the electrophilic 
center of the ligand to the catalytic cysteine and complementarity between ligand and protein 
surfaces in terms of spatial occupancy and hydrophobic/hydrophilic contacts. After visual 
inspection, eighty four compounds were biologically evaluated, twenty four of which showed 
inhibition against one or more cysteine protease. Twelve compounds were found as dual 
inhibitors of FP-2 and FP-3 (for example: 34-41, IC50 range: 1 to 63.4 μM for FP-2, 4.9 to 62.2 
μM for FP-3, Table 1.3.4, raw 3), with compound 34 having the highest dual activity. Compound 
40 showed an excellent profile against the chloroquine-sensitive (D6) and chloroquine resistant 
(W2) strains of P. falciparum, (W2 IC50 = 6.6 μM, D6 IC50 = 6.9 μM), falcipains (FP-2 IC50 = 
4.6 μM, FP-3 IC50 = 5.8 μM), L. donovani cysteine protease and L. donovani promastigotes with 
IC50 values of 112.9 and 8.8 µM, respectively. Compound 40, along with other compounds (for 
example, 34 and 35), suggested the possibility of developing broad spectrum antiprotozoal drugs 
80
 (see Table 1.3.4, raw 3).  
Desai et al. adopted similar protocol as described before using the ACD in their second 
attempt of virtual screening against parasitic cysteine proteases 
81
. Additionally, a toxicity filter 
was added in the initial processing of the database to remove potentially toxic functionalities 
22 
 
such as N-oxides, aldehydes, nitrogen and sulfur mustards, chloramines and isocyanides. The 
study led to the identification of 22 non-peptidic small molecule inhibitors of the parasitic 
cysteine protease, 18 were active against falcipains (representative examples 41-47 in Table 
1.3.4, raw 3, IC50 range: 1.4-54.3 μM), out of which eight compounds were common inhibitors 
of FP-2 and FP-3 (the most active compound 41, FP-2 IC50= 1.4 μM, FP-3 IC50= 11.4 μM). Four 
compounds inhibited L. donovani cysteine protease in micromolar concentration, and six 
compounds exhibited in-vitro inhibition of both P. falciparum and L. donovani promastigotes in 
the micromolar range (the most active compound 48, W2 IC50 = 0.44 μM,  L. donovani 
promastigotes IC50= 7 μM). Further, to identify common features of the diverse hits active 
against FP-2, a pharmacophore model was proposed using a Hip-Hop module of Catalyst. A 
four-feature hypothesis, which correlated well with the ligand-receptor interactions observed in 
the docking studies, was selected. The pharmacophoric features include two hydrogen bond 
acceptors and two hydrophobic regions. Mapping of the chemical features of previously 
identified FP-2 hits (from the chembridge database) on the developed model showed good fitting 
for more than 60% of the FP-2 inhibitors identified from the previous study. However, the 
developed model was unable to distinguish compounds with dual inhibitory (FP-2 and FP-3) 
activity from the exclusive inhibitors of FP-2 
81
 (Table 1.3.4, raw 4). 
Recently, a successful application of  virtual screening was reported by Li et al. using two 
parallel docking routes with Glide and GAsDock docking programs to screen the SPECS 
database against the crystal structure of FP-2 (2GHU, PDB code) 
82
. The rationale behind the 
screening of the database with two different docking programs was to highlight and explore the 
different aspects of the ligand binding. All the compounds were initially subjected to drug-like 
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filters 
83
. The top thousand compounds were selected from both routes after ranking the 
compounds with the Glide score (GScore) in case of Glide standard precision (SP) docking and 
with the energy score in GAsDock. Redocking of the compounds obtained after the first step in 
Glide docking was carried out with the more accurate Glide extra precision (XP) mode. The top 
200 compounds selected based on the GScore were visually inspected for complementarity 
between ligands and the hydrophobic S2 pockets and H-bond networks of ligands within the 
active site. 53 compounds retrieved from the Glide docking run were evaluated against FP-2. 
Similarly, after initial evaluation of the compounds with energy score of GAsDock, compounds 
were reranked based on the consensus scoring function (CScore) of five. The top 154 compounds 
thus selected were visually inspected using the criteria mentioned above. A total of 56 
compounds obtained from the GAsDock route were purchased from SPECS. 28 non-peptide 
molecules were identified from the pool of 81 compounds tested as non-peptidic inhibitors of 
FP-2 with IC50 ranging from 2.7 to 52.4 μM (see representative compounds 49-54 in Table 1.3.4, 
raw 5). The GAsDock outperformed the Glide in terms of hit ratios (38.8% for GAsDock and 
31% for Glide) in this study. The authors concluded that GOLD and DOCK scores performed 
well for apolar binding sites such as of FP-2 whereas FlexX and Chemscore-based GScore work 
well for polar binding sites. Their conclusion was based on the previous reports by Desai et al. 
80, 
81
 in conjunction with the analysis of binding site and the results obtained in their screening 
82
. 
Similarity analysis of the 28 active hits, calculated using the Tanimoto similarity index (average 
value= 0.25), showed structural diversity in identified hits. The shape analyses of each pair of the 
docked poses calculated using Ultrafast Shape Recognition (USR, which consider the shape of 
the molecules based on the relative position of its atoms) showed an average similarity score of 
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0.73. This finding raised the possibility of discovering novel chemical scaffold against FP-2 with 
similar steric shape and binding site requirements from chemically diverse datasets 
82
. Further, 
optimization and library synthesis of the most potent inhibitor 49 (FP-2 IC50= 2.7 μM) obtained 
from the virtual screening resulted in compound 55 having an IC50 value of 1.46 μM 
84
. Due to 
the ease of chemical modifications of compound 54, it was also considered for the library design 
and synthesis. The most active from this series, 56, had an IC50 of 10.0 μM against FP-2 
85
 
(Table 1.3.4, raw 5). 
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Table 1.3.4. Non-peptidic inhibitors identified against FP-2 by virtual screening approach 
Database 
Software/ 
Scoring 
function 
aHit 
ratio 
(%) 
Structure of the representative compounds 
Fine 
chemical 
library 
(55,313) 
78, 79 
 
DOCK 3.0/ 
shape and 
force field 
based 
scoring 
method 
12.9 
 
Available 
chemical 
library 
(195419) 
47 
Dock 4.0/ 
Energy-
scoring and 
shape-
scoring 
scheme 
15.9 
 
Chembridg
e 
database,20
01 (241000) 
80 
GOLD/ 
Gold score 
28.5 
 
Available 
chemical 
library 
(~355000) 
86 
GOLD/ 
GOLD 
Score 
22 
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SPECS 
(~287000) 
82, 84, 85 
GLIDE 
SP/XP/ 
GAsDock, 
Energy 
score, 
Cscore 
34.5 
 
 
a 
hit ratio is calculated by dividing the number of active hits retrieved against FP-2 by the number 
of compounds evaluated in the biological assay. The number in bracket in database column 
shows number of compounds available in the database at the time of virtual screening. 
 
1.3.5.   Natural Product-Based Drug Discovery 
E-64,(N-(L-3-Trans-carboxyoxiran-2-carobnyl)-L-leucyl)-amido(4-guanido)butane),  
isolated from the culture of Asperigillus japonicas, was an irreversible broad-spectrum inhibitor 
of papain-like cysteine proteases (clan CA, family C1) (compound 3,) 
63
. Recently, the X-ray 
crystal structure of FP-2 was published in a complex with E-64 (shown in Figure 1.2) that 
showed a covalent, irreversible hemithioketal formation between thiolate of Cys 42 in the FP-2 
active site and the epoxy carbon of E-64 
50
.  
Several chalcone derivatives were developed after the discovery of the antimalarial 
activity of lipochalcone A, a natural product obtained from Chinese liquorice root 
87
. These 
chalcone derivates exhibited potent antimalarial activity 
79, 88, 89
. Molecular modeling studies as 
well as experimental evaluation of the chalcones indicated that they exert antimalarial activity 
via multiple mechanisms, one of which involved the inhibition of FP-2. Representative 
compound (57) from the chalcone series is shown in figure 1.3.5 (compound 57, FP2 IC50 = 1.8 
μM) 90. 
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Isatin represents a natural product from the plants of the Isatis genus, which was a 
biologically validated starting point for the design and synthesis of chemical libraries against 
cysteine and serine proteases 
91, 92
. Several efforts were pursued to synthesize and evaluate the 
Isatin derivatives against FP-2 as well as cultured parasites. Resultant compounds vary in range 
from higher to lower micromolar activity 
93, 94
. Representative members of this class are shown 
in Figure 1.3.5 (compound 58, FP2 IC50 = 4.4 μM, compound 59, FP2 IC50 = 0.375μM). Both 
compounds also inhibited cysteine proteases of trypanosomes, rhodesin and cruzain. 
  
Figure 1.3.4. Natural product-based inhibitors of FP-2. 
In brief, P. falciparum cysteine protease „falcipains‟, can be a promising target for the 
development of novel malarial chemotherapy. Several peptidic inhibitors/peptidomimetics 
mainly from vinyl sulphone class as well as structurally diverse non-peptidic inhibitors displayed 
an excellent activity against falcipains and cultured parasites. Recently, published crystal 
structures of FP-2-E-64 (epoxysuccinate inhibitor) and FP-3-leupeptin (peptidic aldehyde 
inhibitor) provide more insights for structure guided drug designing. As noted before, the P2-Leu 
and P1-HPhe boost the inhibitory potencies towards FP-2. In addition, the polar residues (Asp 
234 and Ser 149 in FP-2, and Glu 243 and Ser 158 in FP-3) buried in the hydrophobic S2 pocket 
should be considered while designing selective inhibitors against these enzymes. Also, difference 
in the size of S2 pockets of FP-2 and FP-3, can be addressed for designing selective inhibitors of 
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these enzymes, although, combined drug discovery efforts targeting different subtypes of 
falcipains might be beneficial in reducing level of cultured parasites. Selection of suitable 
scoring functions plays major role in structure-based virtual screening approach. Published 
virtual screening studies against falcipains pinpointed suitability of GOLD and DOCK scoring 
functions for apolar binding sites of FP-2 over GScore. These findings are particularly important 
in future structure-based virtual screening studies against FP-2. Moreover, the sequence 
similarity of falcipains with several homologous parasitic cysteine proteases can be used to 
develop broad spectrum inhibitors against these targets as previously reported by our group 
80, 81
.  
The cysteine proteases discussed here are of the utmost importance for drug design 
considerations. For instance, several efforts are currently underway to develop effective 
antimalarials for encountering the parasite resistance to all front line drugs, including the most 
potent artemisinin derivatives 
95
. In such scenarios, falcipains manifests an emerging drug target 
due to its unique function in hemoglobin degradation and survival of the protozoa. Moreover, 
effective peptidic and non-peptidic inhibitors of falcipains (summarized above) with good 
inhibitory potency project this enzyme as a promising target for the development of antimalarial 
chemotherapy. 
In the next sections, various drug design approaches adopted against highly pathogenic 
SARS virus are discussed. 
1.4. SARS cysteine protease “3CLpro or Mpro”: genesis, function and structural 
requirements 
  SARS is a life threatening upper respiratory tract illness which reached an epidemic 
status in 2003. Within the short span of a year, this disease proliferated from the Guangdong 
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province of China, where it originated, to 32 countries of Asia, North America and Europe. The 
SARS epidemic infected nearly 8000 people and resulted in approximately 800 causalities from 
November 2002 to August 2004 
96-99
. A novel form of the coronavirus (CoV), SARS-CoV, was 
identified as an etiological agent for the disease 
7, 100-102
.  
The SARS-CoV genome has been reported to contain fourteen functional ORFs, which 
provide accessories for encoding the proteins for virus replication and transcription. Two large 
ORFs connected by a ribosomal frame shift constitute the replicase gene which transcribes two 
overlapping polyprotein (pp), ppla (~450 kDa) and pplb (~750 kDa), necessary for  viral 
propagation 
103
. These polyproteins are cleaved by virus proteases to generate the functional 
proteins required for replication of the virus. The SARS-CoV proteases responsible for this 
function involve papain-like proteases (PL
pro
) and a chymotrypsin-like protease (3C-like protease 
or 3CL
pro
) due to their distant relationship with 3C protease of picornaviruses. The 3CL
pro
 is also 
called  the main protease (M
pro
) because of its dominant role in the processing of viral 
polyproteins and control of  replicase complex activity 
103-106
. Due to the pivotal role of M
pro
 in 
viral replication and infection process, the enzyme demonstrates itself as an attractive target for 
the design of antivirals 
8
.  
During the outbreak of SARS, several homology models of SARS M
pro
 were developed 
by different groups shortly after its genome sequencing, based on its sequence similarity with 
other known CoV-like proteases such as human CoV (HCoV) or porcine transmissible 
gastroenteritis (TGEV) 
8, 103, 107
. Within a short time of the outbreak, multiple crystal structures 
of SARS M
pro
 were published 
104, 108-117
. The published structures revealed remarkable degree of 
conservation in the substrate-binding sites during SARS mutation and provide an opportunity for 
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the design and screening of inhibitors for anti-SARS activity. 
 The structure of the monomeric unit of SARS M
pro
 is shown in Figure 1.4a. SARS M
pro
 
is a functional homodimer in which each subunit is composed of three structural domains: I 
(residues 8-101), II (residues 102-184), and III (residues 201-301). Domains I and II show a β–
barrel fold resembling trypsin-like serine protease whereas domain III is α-helical. The substrate-
binding site is located in a cleft between domains I and II. The enzyme is atypical cysteine 
protease containing a catalytic dyad (His-41-Cys145) instead of a triad, which is required for 
proteolytic activity 
8, 116, 118
. The N-terminal is comprised of seven residues (N1-N7) known as 
“N-finger”. A 16-residue loop (residues 195-200) forms a bridge between domains II and III (see 
fig.1 (a)). While domains I and II are important for catalytic activity, domain III plays an 
essential role in the dimerization of M
pro
 and the maintenance of quaternary structure 
116, 119, 120
. 
N-finger is more important for enzyme activity than dimerization as confirmed by site-directed 
mutagenesis or deletion studies 
118, 121-123
. Figure 1.4b shows the magnified view of the active site 
of SARS-CoV M
pro
 with co-crystallized peptidic ligand (2AMD, PDB code) 
115
.  
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Fig.1.4 a) The overall topology of SARS 3CL
pro
. Individual domains, N-finger and catalytic 
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residues, Cys 145 and His 41 are shown; b) magnified view of the substrate-binding site in 
surface representation. P1-P5 and P1‟ groups (red) of peptidic inhibitor (gray), subsites S1‟, S1, 
S2 and S4 (black), and residues forming the substrate-binding pockets (white) are labeled.  
 
The substrate binding pockets S4, S2 and S1 are highly conserved among the CoV 
124
. 
Successful cloning and expression of recombinant SARS-CoV M
pro
 has unveiled important 
insights on the substrate-specificity data for this enzyme. Along with the absolute specificity of 
Glu at P1, recent data elucidated an equal preference for the P1-His containing substrate 
125, 126
. 
The S2 subsite of SARS-CoV can accommodate the side chains of Leu, Phe, Val, Met and Thr 
residues as opposed to traditional preference of only Leu/Ile at P2 for other CoV 
125, 126
. The side 
chain of P3 residue is mainly solvent-exposed in all CoV M
pro
 and is capable of accommodating 
side chains of a broad range of functionalities 
115
. Small residues such as Ser, Thr, Val, Pro and 
Ser, Ala, Gly can be tolerated at P4 and P1‟, residues respectively 124. The knowledge of 
substrate specificities has not only increased the understanding of polyprotein processing 
mechanism by the enzyme but also provided important clues for drug design 
125
.  
 
1.5. DRUG DESIGN APPROACHES AGAINST SARS-COV MPRO 
  During the epidemic of SARS, combinations of drugs were given to individuals suffering 
from this life threatening disease and these multi-drug treatments resulted in several post-therapy 
side effects 
127, 128
. As more information became available for the key components of the virus 
life-cycle, target-oriented drug design efforts were pursued to prepare against the possibility of 
the next epidemic of this disease. Early phases of drug discovery against SARS M
pro
 were 
centered on the structural modification of the known drugs with established safety profiles in 
humans in order to avoid painstaking efforts of finding and characterizing new drug entities in 
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the scenario of a global outbreak of SARS. The drug design efforts pursued against SARS 3CL
pro
 
are summarized below. 
1.5.1. Structure-guided drug designing 
   Anand et al. published a homology model of SARS M
pro
 using the X-ray crystal 
structures of HCoV 229E M
pro
 and TGEV M
pro
 (40 and 44% sequence identity respectively ) as a 
template to stimulate drug discovery efforts against this promising target 
8
. Also, they unveiled 
remarkable degrees of conservation among the substrate-binding sites of CoV as supported by 
the cleavage of the TGEV M
pro
 substrate by the recombinant SARS-CoV M
pro
. During the 
outbreak of SARS, rupintrivir (formerly designated as AG7088), a potent inhibitor of human 
rhinovirus (HRV) 3C protease, was in the early stages of drug development by Pfizer Inc. for the 
treatment of the common cold 
129-131
. Anand et al. addressed that Rupintrivir could partially fit 
into the putative binding pocket of SARS-CoV 3CL
pro
 based on the identical orientation of the 
hexapeptidyl chrloromethyl ketone (CMK) inhibitor 60 in TGEV M
pro
 and Rupintrivir 61 in 
HRV2 3C
pro
 and suggested a possibility to use rupintrivir as a model to develop inhibitors 
against SARS-CoV 3CL
pro 8
 (Figure 1.5.1). 
  Ghosh et al. carried out the modification of the P2 side chain of rupintrivir with P2-
benzyl 62 and prenyl 63 considering the P2-Phe substrate-specificity of SARS M
pro
 
132
 . Also, 
they developed another series by replacing the ketoethylene of compound (67) with 
hydroxyethylene 64. Compound 63, having a P2-prenyl group, was more potent than the 
corresponding analogue 62 with a P2-phenylmethyl group, which further indicated the possibility 
of accommodating other small side chain residue at the P2 position. The inhibitor with 
hydroxyethylene isostere 64 showed little inhibition of the SARS M
pro
 enzyme. To gain 
molecular level insights, an X-ray structure of SARS M
pro
 co-crystallized with 63 was resolved. 
33 
 
The crystal structure revealed the covalent binding mode for the inhibitor as expected. Also, the 
crystal structure offered insights about poor inhibitory activity of 64 was due to the loss of 
hydrogen bond interaction between the backbone amine nitrogen of Glu166 and the carbonyl 
group of the inhibitor 
132
 (Figure 1.5.1).   
Shie et al. designed novel analogs of rupintrivir and pursued combinatorial synthesis of a 
series of ketomethylene isosteres (representative compounds 65, 66 as well as tripeptidomimetic 
α, β unsaturated esters (representative compounds 67, 68 having lactam-glutamate or Phe at P1 
133
. Interestingly, compounds with L-phenylalanine at P1 were found to have enhanced activity 
compared to corresponding lactamglutamate (Compound 66, M
pro
 IC50 = 13 µM, Compound 68, 
M
pro
 IC50 = 11 µM). Although, rupintrivir 61 was found to be inactive at the concentration >100 
μM against SARS Mpro 133 as well as in a cell-based assay 134, the higher activity of its analogue 
66 motivated the authors to predict the binding mode of these compounds by molecular docking 
studies using previously reported crystal structures 
104
. Docking studies depicted that P1 and P2-
Phe of 66 fit well into the S2 and S3 pockets respectively, placing the conjugated ester moiety in 
the S1 pocket to interact with His163 and Gly 143. Also, 66 was stabilized by multiple H-bond 
interactions with the active site residues. However, the conjugated ester was still too far (> 4.5 
Å) from Cys145 for a covalent bond formation. In contrast, the docking of rupintrivir 61 showed 
an improper placement of the terminal ester group in the S1‟ pocket as a result of poor fitting of 
the P1-lactam moiety in the S1 pocket. In addition, P2-flurophenyl and P4- isoxazoyl moiety of 
61 exhibited steric clashes with the residues of S2 and S4 
133
. This might be responsible for the 
inactivity of 61 as well as the lower activity of corresponding lactamglutamate analogs (Figure 
1.5.1).   
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Based on the higher activity of Phe-Phe dipeptide inhibitors 66 and 68, several Phe-Phe 
dipeptide inhibitors were designed with two Michael acceptors at N and C-terminals mimicking 
pseudo C-2 symmetry. Dedicated synthesis of compounds from this series identified 69 
(JMF1521) with an IC50 value of 1 μM and a Ki value of 0.52 μM 
133
. Further, synthesis of a 
series of peptide anilide with L-phenylalanine as P1 residue attached with a 2-chloro-4-
nitroaniline moiety (considering the activity of niclosamide against replication of SARS-CoV 
135
) was pursued 
136
. Among the synthesized compounds, anilide 70 functioned as a potent 
inhibitor of enzymes having Ki and IC50 values of 0.06 and 0.03μM, respectively. SAR of 
various analogs of 70 confirmed that chloro, nitro and dimethylamino groups in 2-chrlo-4-
nitroaniline of 70 were indispensible for the activity. The key interactions of 70 as revealed by 
the docking studies involved interactions of a nitro group with the NH of Ala 46, 3 Å distance of 
chlorine from γ-S of Cys145 and ϵ-N2 of His41, as well as hydrophobic interaction of a 
(dimethylamino) phenyl moiety in the S2 pocket. Also, authors indicated the possibility of 
modifying P1 phenyl residue of 70 in the S1 pocket to enhance interactions with Phe140, 
His163, and Glu166 to further enhance activity 
136
 (Figure 1.5.1).  
  In search of the effective drug candidates, Chou et al. performed docking studies using 
previously developed homology model of SARS M
pro
 
8
 by modifying the bulkier p-flurobenzyl 
side chain of 61 with p-flurophenyl (KZ7088, 71) and the octapeptide AVLQSGFR to 
understand the binding interactions of SARS-CoV M
pro
 with its ligand 
137
. The octapeptide was 
chosen by considering its size to occupy protease-specificity sites, specificity of SARS-CoV for 
Gln↓(Ser, Ala, Gly) and for the rational designing of new peptidic analogs based on the 
“distorted key approach.” The distorted key approach involved modifications of the substrate-
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cleavage site by keeping other residues of the peptide (substrate) intact for tight binding. Such a 
substrate could behave as a distorted key which binds effectively in the enzyme active site but 
blocks the function of the enzyme. Also, this approach could help to identify the competitive 
inhibitors against this enzyme 
138
. Docking studies of 71 and AVLQSGFR revealed the presence 
of multiple hydrogen bonds between the SARS proteinase and respective ligands 
137
. However, 
the experimental binding affinity of 71 was not reported. Gen et al. confirmed the efficacy of 
octapeptide for the inhibition of the replication of SARS-CoV (EC50 = 0.031 μM) with no 
detectable toxicity on vero cells under experimental conditions. Sirios et. al. encoded the 
receptor interactions of 71 in pharmacophoric features and conducted a pharmacophoric search 
over 3.6 millions of compounds to identify only 0.03% of potential compounds for further 
experimental analysis 
127
 (Figure 1.5.1).  
  Du et al. studied catalytic interactions between the experimentally cleavable octapeptide 
AVLQSGFR and SARS M
pro
 using molecular mechanics (MM) and quantum mechanics (QM) 
calculation with the help of a previously developed homology model of SARS-CoV M
pro
 
8, 139
. 
The residues of catalytic dyad His 41 and Cys 145 were found to attract electron density of 
peptide bond between Gln and Ser, which accelerated the positive charge on C(CO) of Gln and 
the negative charge on N (NH) of Ser. The replacement of the carbonyl of Gln to CH2 or CF2 
distorted the π–bond system of the peptide bond, making it uncleavable by the enzyme, situation 
analogues to the “distorted key” approach discussed above 139. The modified octapeptide showed 
tight binding with the enzyme and represents a good starting point for the design of peptide 
based anti-SARS drugs (Figure 1.5.1).  
 
 
36 
 
 
 
 
37 
 
 
Figure 1.5.1. Inhibitors of SARS-M
pro
 identified by structure-guided drug design. 
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1.5.2. Knowledge-Based Drug Design 
  Anand et al. pinpointed the use of the rhinovirus protease inhibitor, rupintrivir, as a 
starting point for the design of inhibitors against SARS 3CL
pro
. Further development of inhibitors 
based on the structural modifications of rupintrivir has already been discussed in previous 
sections. 
Jain et al. performed the synthesis and biological evaluation of a series of keto-glutamine 
analogs with a phthalhydrazido group at the α-position against SARS Mpro 140. Their knowledge-
based approach was based on a previously identified lower micromolar reversible inhibitor 72 of 
the hepatitis A virus (HAV) 3C proteinase bearing a phthalhydrazido moiety 
141
 and preference 
of P1-glutamine by SARS M
pro
. Initial efforts for the synthesis of N, N-dimethylglutamine 
analogs with leucine, threonine, and valine at the P2, P3, and P4 positions respectively, resulted 
in compounds having higher micromolar activity (representative compound 73, M
pro
 IC50 = 28 
µM). Further, optimization and structure-activity relationships (SAR) identified cyclic glutamine 
analogs, among which compound 74 exhibited an IC50 of 0.6 μM against SARS M
pro
 
142
. 
Docking studies of 74 indicated that the active site of the enzyme had enough room to 
accommodate the bulkier phthalhydrazide group with minimal rearrangement of protein (Figure 
1.5.2).  
  Bacha et al. identified a cluster of serine residues (Ser139, Ser144 and Ser147) close to 
catalytic residues of the active site 
143
. Sequence alignment of this region among the proteases 
from other CoV revealed the presence of a conserved serine cluster among CoV. This 
observation motivated the authors toward designing inhibitors targeting serine cluster of the 
active site. Based on the knowledge of the reactivity of boronic acid compounds to the hydroxyl 
group of serine, inhibitory potencies of several boronic acid compounds were evaluated against 
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SARs-CoV M
pro
. Compound 75 found to have an inhibition constant (Ki) of 40 nM. Further 
studies revealed a reversible binding mode of 75 in an energetically favorable fashion, defining it 
as an attractive scaffold for further optimization 
143
 (Figure 1.5.2).  
  Meanwhile, Zhang et al. extended their knowledge from the studies of active caspase 
(another cysteine protease) inhibitor 76 toward the discovery of potential SARS-CoV M
pro
 
inhibitors 
144
. A series of dipeptides analogs were synthesized with N, N-dimethyl glutaminyl 
FMK at the P1 site and different amino acids (leucine/valine/phenylalanine) at the P2 site from 
the knowledge of a peptide-substrate recognition sequence by the enzyme. N, N-dimethyl-
glutamine analogs were specifically chosen to prevent possible cyclization of the free glutamine 
side chain with FMK 
145, 146
. Compound 77 was found to have an EC50 value of 2.5 μM in the 
CPE inhibition assay against 6109 strains of SARS-CoV with a selectivity index (SI) of >40, 
presumably through the inhibition of SARS CoV M
pro
 
144
 (Figure 1.5.2). 
  The nucleophilic attack of cysteine thiol to trifluoromethyl ketone (TFMK) leads to a 
tetrahedral adduct formation which mimics the substrate-enzyme intermediate 
147, 148
 and 
compounds bearing TFMK have a potential to be a serine/cysteine protease inhibitor. Syndes et 
al. designed and synthesized derivatives of Gln and Glu possessing a TFMK moiety considering 
the utility of TFMK as a warhead and P1-Glu preference of the enzyme 
149
. Compounds 78 and 
79 displayed Ki values of 134.5 μM and 116.1 μM, respectively. Further, structure-based 
optimization of 79 led to synthesis of mono-, di- and tripeptide analogs with modification in the 
halogen content of warhead as well as in the P1 side chain 
108
. Five inhibitors were identified 
with activity in the nanomolar range. One of the inhibitor 80 showed unexpected reversible 
inhibition of SARS 3CL
pro
 by forming a thioether complex with Cys145 of the active site, 
supported by the co-crystallized structure of 80 with SARS M
pro 108
. Regnier et al. noticed the 
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moderate activity of compounds might be due to possible cyclization of the free acid/amine side 
chains of 78 and 79 at P1 with TFMK as reported previously with FMK derivatives 
144
, which 
resulted in the poor binding of the cyclized compounds in the active site 
150
.  Several 
modifications were carried out in P1, P2, P3 side chains as well as warhead groups. Compound 
81 containing P1 pyrollidone and thiazolyl units as a warhead showed an IC50 of 2.2 µM against 
SARS M
pro 150
. Recently, Shao et al. synthesized a series of TFMK by variation in the amino acid 
at P1-P4 chains as well as incorporation of alkyl chains at P2-P4 
151
. Compound 82 with an 
identical arrangement of P1-P4 amino acids to the substrate inhibited SARS-CoV 3CL
pro
 in a 
time dependent manner with an IC50 of 0.8 µM and a Ki of 0.29 µM after a four hour incubation. 
The computational model of 82 pointed that the formation of a covalent bond between the 
cysteine thiol and inhibitor 82, as well as other key interactions of inhibitor with the active site 
residues, were favored only with the [S, S, S, S] isomer of 82 with R configuration of carbonyl 
carbon adjacent to the trifluoromethyl group 
151
 (Figure 1.5.2). 
Several Aza-peptide epoxides (APEs) were reported as inhibitors of clan CD proteases, 
for example, leguminases 
152
 and caspases 
153
. The architecture of APE involves an epoxide 
moiety attached to the carbonyl group of the P1 residue, nitrogen at the Cα position of P1 and 
target-specific side chain of P1 residue. Synthesis of APE possessing an azaglutamine (AGln) as 
the P1 residue was performed to evaluate their efficacy against SARS-CoV M
pro
 
154
. Micromolar 
quantities of the [S, S] diastereomer 83 showed strong inhibition for the cleavage of a peptidic 
substrate whereas the corresponding R, R diastereomer was inactive against M
pro
. Later, the 
crystal structures of the [S, S] diastereomer with M
pro
 revealed the formation of a covalent bond 
between the S
γ 
atom of catalytic Cys145 and the epoxide C3 atom of the aza-peptide component 
of the inhibitor, suggesting the irreversible mode of action of this class of cysteine protease 
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inhibitors. Models of different diastereomers of APEs revealed the importance of S 
configurations of the epoxide C3 atom of APE to avoid clashes with the active site residues and 
other components of azapeptide. Also, the S configuration of epoxide provided better geometry 
for a nucleophilic attack by active-site cysteine thiol 
154
 (Figure 1.5.2). 
Peptidyl aldehydes are effective against multiple proteases including serine protease 
155, 
156
, aspartic protease 
157, 158
, and cysteine protease 
159, 160
. Moreover, they possess reversible 
electrophilic isostere and are capable of mimicking the endogenous substrate by retaining an H-
bonding framework of backbone and addressing different subsites of enzyme with their side 
chains. Considering these advantages of the designing inhibitor with peptidic aldehyde scaffold, 
Al-gharabli et al. employed an efficient method for the synthesis of their designed peptidic 
library against SARS 3CL
pro
 
161
. They considered two approaches for the design of their peptidic 
aldehyde library. In the first approach, they carried out a sequence homology search using the 
extracted binding pockets of SARS 3CL
pro
. The information gained from the bound ligand 
fragments in homologous proteins were used for the modeling of the putative side chains for the 
corresponding sub-pockets of enzyme. In their second approach, natural and non-natural amino 
acids from the ACD and Sigma-Aldrich library were docked in the S1, S2 and S4 pocket of 
SARS 3CL
pro
 using the FlexX docking program. Amino acids which scored well for the 
respective pockets were selected for the designing. The peptide backbone was retained as in the 
complex structure of SARS-CoV 3CL
pro
 with a CMK inhibitor (1UK4, PDB code). Evaluation of 
the designed library identified 84 and 85 with IC50 of 7.5 µM as a reversible inhibitor of SARS 
M
pro 161
. The presence of the hydrophilic residue at the P2 position prompted the authors to 
predict non-canonical binding modes of compounds 84 and 85 as observed in the active 
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monomer A of SARS 3CL
pro 
(1UK4, PDB code) (Figure 1.5.2). 
 
Figure 1.5.2. Inhibitors of SARS-CoV M
pro
 obtain by knowledge-based drug design approach. 
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1.5.3. Structure-Based Virtual Screening  
This section will review the discovery of the non-peptidic inhibitors developed against 
SARS-CoV M
pro
 by a structure-based virtual screening approach. Table 1.5.3 summarizes the 
commercial databases, methods, softwares and scoring functions used for virtual screening, hit 
ratio along with the chemical structures of hits obtained. 
 In 2005, Liu et al. screened chemical databases (listed in Table 1.5.3, raw 1) against the 
“flexible homology model” developed by combined molecular dynamics (MD) simulation and 
multicanonical sampling protocol 
162
. The top 10% of docked compounds were retained based on 
their dock energy-score and contact-score. Subsequent filtration steps involved removal of 
compounds with pKi > 4.0 (to remove score bias caused by a single empirical function) followed 
by selection of the top 2000 compounds by score and Xcscore scoring functions 
162
. Final pools 
of compounds were subjected to a pharmacophore filter (developed using the POCKET module 
from LigBuilder) and evaluated using drug-like criteria for similarity to the original drug 
framework as well as to known antiviral compounds. After visual inspections, 48 compounds 
were subjected to an enzyme assay, out of which three compounds 86-88 including 
calmidazolium 86, a well known antagonist of calmodulin, were found to inhibit the enzyme 
with ki ranging from 61 to 178 μM 
162
 (Table 1.5.3, raw 1). 
  Chen et al. carried out the docking studies of compounds from the CMC database 
(comprised of drugs which have been used or are currently used against human) against 
previously developed homology model of SARS M
pro
 to expedite the screening process against 
the SARS epidemic 
107, 163
. The potential candidates were ranked using a consensus scoring 
function along with the scoring function implemented in AutoDock3.0. Cinanserin 89, a well 
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characterized serotonin antagonist found to inhibit the catalytic activity of SARS-CoV M
pro
 with 
IC50 of 5μM,) also interfered with SARS-CoV replication in cell culture (IC50 = 31 μM) (Table 
1.5.3, raw 2). 
  Chen et al. screenedthe SPECS database using dock 4.0. After the first phase of docking, 
the top 2000 compounds were selected based on the highest dock score and subjected to 
consensus scoring 
164
 and drug-like property calculations 
83
. Finally, a set of 256 compounds 
were evaluated in an integrated assay platform comprised of a Surface Plasmogen Resonance 
(SPR) assay (for measuring binding affinity of the candidate compound with the SARS-CoV 
M
pro
) and fluorescence resonance energy transfer (FRET) technologies-based assays (to measure 
the inhibition of proteolytic activity of SARS-CoV M
pro
). Eight novel inhibitors of SARS-CoV 
M
pro
 were discovered (representative compounds 90-96), resulting in IC50 values of 6.86 to 80.46 
μM 18 (Table 1.5.3, raw 3).  
  Lu et al. performed a virtual screening of the Maybridge database using a published X-
ray structure of SARS M
pro
 with a covalently bound CMK inhibitor (1UK4, PDB code) 
116, 165
. 
The molecules were first ranked by the fitness score component of GOLD score after docking to 
select the best pose followed by reranking of the compounds with the external H-bond energy 
term implemented in GOLD score for ranking the binding affinity of compounds. This was the 
first report, to the best of our knowledge, to use only H-bond energy term to rank and select 
compounds. The top 50 compounds were subjected to a SARS-CoV M
pro
 inhibition assay. Two 
active compounds 93 and 94 were identified from an enzyme inhibition assay. The core 
structures of these two hits, defined by the docking study, were used for further analogue 
searches. Twenty-one analogs derived from these two hits exhibited IC50 values below 50 μM, 
with the most potent one, 95, showing an IC50 of 0.3 μM 
165
 (Table 1.5.3, raw 4). 
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  Dooley et al. presented a genome-to-drug-lead approach which uses terascale computing 
to model flexible regions of protein and thus encodes genetic information to identify drug leads 
166
. A homology model of SARS-CoV M
pro
 complexed with a substrate fragment 
(ATVRLQ
p1
A
p1‟
) was developed by predicting the conformation of the flexible loop with a total 
of 200 simulations, and average structure (deposited in PDB, 2AJ5, PDB code) was used as a 
drug target in virtual screening for small-molecule inhibitors using the EUDOC docking 
program. A total of 3958 compounds were selected based on the total and Van der waals 
interaction energies. Twelve inhibitors were tested in a cell-based inhibition assay after removing 
compounds with poor solubility, poor cell permeability, multiple chiral centers and commercial 
unavailability. Compound 96 inhibited the SARS-CoV Toronto-2 strain with an EC50 of 23 µM. 
Further, screening of a similar set of compounds against two published crystal structures of 
protease failed to identify compound 96 
166
. This observation suggested that terascale computing 
could complement the crystallography, increase the hit rate in virtual screening and accelerate 
the process of drug discovery against emerging infectious diseases (Table 1.5.3, raw 5).  
  Tsai et al. carried out a structure-based virtual screening against Maybridge database 
167
. 
After the initial filtration of the database using drug-like filters, remaining compounds were 
docked into the co-crystallized structure of SARS-CoV M
pro
 with an octapeptide CMK inhibitor 
using DOCK4.0.2. 93 compounds were subjected for the inhibition assay, twenty one of these 
showed inhibition against SARS-CoV M
pro
 (IC50 ≤ 30 μM), with three of them found having a 
common substructures. In order to search analogs of these compounds, 2D substructure searches 
were carried out in the Maybridge, ChemBridge, and SPECS databases, which further identified 
25 compounds against SARS-CoV M
pro
 with an IC50 of 3-1000 μM (most active compound 97, 
IC50 =3 µM) 
167
 (Table 1.5.3, raw 6). 
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  Bacha et al. generated a pharmacophore model using low energy conformation of the 
most active compounds from a previously developed peptide library (mostly peptidic halomethyl 
ketones) with the pharmacophore application module of MOE 
108, 149
. A threshold of 1000 µM 
was selected (active = <1000 µM, inactive = >1000 µM) based on the distribution of Ki data in 
their developed library of compounds for the generation of the qualitative pharmacophore. 
Exclusion spheres were added for improving the ability of pharmacophore model to discriminate 
between actives and inactives. A pharmacophore-based database search conducted in a 
commercial database implemented in MOE resulted in 40 potential compounds, 38 of which had 
Ki <1000 µM. The most active hits 98-100 from this screening are shown in a Table 1.5.3, raw 7 
with Ki = 4.5-27 µM 
108
.   
  Mukherjee et al. conducted structure-based virtual screening of Asinex platinum 
collection against the crystal structures of SARS-CoV M
pro
 (PDB code: 1UK4, 2AMD) using the 
GOLD docking program 
19
. The initial database was prefiltered using various drug-like and 
ADME (absorption, distribution, metabolism and excretion) filters. The filtered database was 
subjected to multi-stage cascade docking involving computationally less intensive and faster 
docking protocol (GOLD 7-8 times speed up mode) at the early stages of the screening with 
computationally complex protocol (GOLD 2-times speed up mode and GOLD standard mode) 
towards the end. After the cascade docking, top-ranked poses (based on GOLD score) were 
rescored using a cumulative score obtained by summing six scores (Fscore, Gscore, Pmfscore, 
Dscore, and Chemscore calculated using Cscore module of Sybyl 6.9), including the GOLD 
score. The diversity analysis of the top 500 hits obtained after rescoring retained 100 molecules 
that were visually inspected for their ability to obtain key substrate specificity sites, geometric 
quality of the binding pose, hydrophobic/ lipophilic mismatches and complementarity of the key 
47 
 
interactions. Meanwhile, publication of the co-crystallized ligand structure of SARS M
pro
 
(2AMD, PDB code) as well as reports of several inhibitors prompted the authors to perform a 
scoring function-based enrichment study using the previously mentioned six scoring functions. 
Gscore followed by Dscore gave better enrichment of the true actives and were combined in the 
range-scaled format to generate a composite GDR score. In the extended phase of screening, 
pharmacophore filters based on the crystal pose of the peptidic inhibitor (2AMD, PDB code), 
docking pose-based descriptors as well as GDR scoring function were used to select the 
compounds for biological assay. Two hits were identified (101, 102) with IC50 of 17 and 18 µM, 
respectively (Table 1.5.3, raw 8) 
19
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
Table 1.5.3. Non-peptidic inhibitors of SARS-CoV M
pro
 obtained by an experimental HTS 
 
Database 
Crystal 
structure/ 
Homology 
model 
Method/ 
Software/ Scoring 
function used 
aHit 
ratio 
(%) 
Structure of the most active compounds 
National 
chemical 
institute 
diversity set 
(~230 000), 
ACD 3D 
2002.2 (~280 
000), MDDR-
3D 2002.2 
(~120 000) 
flexible 
homology 
model, 
1UK4, 
1UK3 
Docking / 
DOCK4.0/ Dock-
energy-score, 
Contact-score, 
XCscore 
Pharmacophore 
and Drug like filter 
7.5 
 
 
Comprehensive 
Medicinal 
Chemistry 
Database of 
Molecular 
Design Limited 
(MDL-CMC) 
(~8000 ) 
Homology 
model, 
1UK4 
Docking/Dock4.01, 
Dock score, Cscore 
0.013 
 
SPECS 
(81287) 
1UK4 
Docking/ DOCK 
4.01/ Dock score, 
Cscore & scoring 
function of 
Autodock 3.0 
3.12 
 
Maybridge 
(58 855) 
1UK4 
Docking, 
Similarity search/ 
GOLD2.1, fitness 
score and H-bond 
energy component 
of Gold score 
4 
 
 
361413 small 
molecules 
Homology 
model 
(2AJ5) 
Docking/EUDOC - 
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Maybridge, 
ChemBridge, 
SPECS 
1UK4 
Docking, 
Similarity search/ 
DOCK 4.0.2/ 
Internal ligand-
receptor binding 
energy term, 
electrostatic energy 
term 
7.63b 
 
MOE 
2006.0804 
- 
Pharmacophore/ 
MOE 
 
12.5 
 
Asinex 
platinum.2004 
1UK4, 
2AMD 
GOLD 2.2 
/composite GDR 
score 
1.8 
 
a
hit ratio is calculated by dividing the number of active hits retrieved against FP-2 by the 
number of compounds evaluated in the biological assay. 
b
Compounds having IC50 values 
below 30 µM were considered for the calculation of hit ratio. 
 
1.5.4. Hightroughput Screening (HTS) 
  HTS against SARS 3CL
pro
 implemented rapid and sensitive fluorescence resonance 
energy transfer (FRET) assay in most of the screening discussed below 
168
. The anti-SARS 
activities of the potential inhibitor identified through HTS were evaluated in a plaque reduction 
assay (PRA) or cytopathic effect (CPE) inhibition assay. HTS against SARS-CoV 3CL
pro
 can be 
classified into three approaches: experimental HTS where the in-vitro binding affinities of the 
screened hits were measured; virtual HTS where the binding affinities of the screen hits were 
only predicted; and finally, a novel dynamic ligand screening (DLS) methodology which 
perform the screening in a highthroughput manner, and has several advantages over conventional 
HTS. These approaches are summarized in the following sections. 
1.5.4.1. Experimental HTS 
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  Kao et al. screened the Chembridge database of structurally diverse 50,240 compounds 
using a continuous FRET assay against recombinant SARS-CoV M
pro
. Compound 103 inhibited 
SARS-CoV by an IC50 value of 2.5 µM and exhibited an EC50 value of 7 µM in cell-based 
antiviral assays 
169
. Blanchard and colleagues screened the small molecule library of 50,000 
drug-like compounds using a quenched FRET assay. Through a series of experimental and 
virtual filters, five novel inhibitors of SARS M
pro
 were discovered (IC50 = 0.5-7µM), the most 
potent compound 104 in their screening had an IC50 of 0.5 µM 
170
 (Figure 1.5.4.1).  
  Wu et al. carried out the screening of >10,000 compounds from the diverse source based 
on ELISA, immunofluorescence, flow cytometry and Western blot analysis. As a result of their 
efforts, compound 105 was found to have a Ki value of 0.6 μM against SARS-CoV M
pro
 
134
. The 
docking simulation of compound 105 revealed that the inhibitor is folded into a ring-like 
structure in the active site and was stabilized by multiple H-bonds and hydrophobic interactions 
with the active site residues. Compound 105 was previously reported as a transition state 
inhibitor of HIV protease and found to be a promising candidate for further development against 
SARS due to its established in vivo efficacy in cats for anti-AIDS effects 
134
 (Figure 1.5.4.1).  
  Goetz et al. conducted HTS of a library of compounds developed using known cysteine 
protease inhibitor scaffolds with the substrate-specificity data obtained by in-house screening of 
natural tetrapeptides against recombinant SARS-CoV 3CL
pro 126
. WRR495 (106) with dipeptidyl 
epoxyketone scaffold inhibited enzyme and viral replication (>50%) at a concentration of 10 
µM. Further optimization of 106 with the help of computational modeling as well as knowledge 
of substrate-specificity (valine at P3) identified WRR495 (107), which was 175 fold more potent 
than parent compound 107 with a k3/ki of 0.5 M
-1
S
-1
 against SARS 3CL
pro
 and an EC50 of 12 µM 
against SARS-CoV 
126
. The crystal structures of these compounds with SARS-CoV 3CL
pro
 were 
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developed which showed interesting binding mechanism. The cysteine mediated nucleophilic 
attack on epoxide C2 resulted in the formation of an alcohol group in the P1 position exhibiting 
direct as well as water-mediated H-bonds in the S1 pocket, but also shifted the alanine from P1 
to the P2 position. This observation raised the possibility of developing non-covalent inhibitors 
using this scaffold. Also, the P2-Ala side chain was exposed to a solvent supporting the less 
stringent P2 specificity for SARS M
pro
. The P3-Phe side chain seemed to form sulfur-arene 
interactions with Met 49 and Met 165 of the canonical S2 pocket. Higher activity of 107 might 
be due to the use of the preferred amino acid Val for the S3 pocket 
126
 (Figure 1.5.4.1).  
  Recently, Kuo et al. evaluated a compound library of 6800 compounds to find out 
individual and common inhibitors of coronavirus and picornavirus M
pro
. Five novel inhibitors of 
SARS M
pro
 were identified (IC50 = 3.3 to 10.6μM). Compound 108 inhibited all the proteases 
(SARS M
pro
, 229E M
pro
, CVB3 3CL
pro
, EV71 3CL
pro
, RV14 3CL
pro
) with an IC50 of < 10 µM 
171
. 
The synthesis of analogs of 108 identified 109 as a broad spectrum inhibitor against CoV 
proteases. Compound 109 exhibited an IC50 of 2.5 M against SARS M
pro
 as well as inhibited 
other CoV proteases  with an IC50 of < 3 µM 
171
. 
   Other known compounds identified by HTS against SARS M
pro
 include metal ions 
containing compounds (phenyl nitrate, thimerosal) 
172
, hexachlorophene and its analogs 
172, 173
, 
polyphenols from black tea 
174
, diuretic ethacrynic acid 
175
, isatin derivatives and plant-derived 
phenolic compound hesperetin 
176
.  
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Figure 1.5.4.1. Non-peptidic inhibitors of SARS-CoV M
pro
 obtained by an experimental HTS  
1.5.4.2. Virtual HTS 
Jenwitheesuk et al., carried out preliminary docking studies of 29 approved and 
experimental drugs against the homology model of the SARS-CoV proteinase as well as the 
experimental structure of the transmissible gastroenteritis virus (TGEV) proteinase to obtain an 
enzyme-inhibitor complex which was then refined by MD simulation protocol followed by final 
docking calculations to predict the binding affinity based on the lowest energy-solution 
177
. 
Docking calculations were performed using Auto Dock version 3.0.5, which employs the 
Larmarckian Genetic Algorithm (LGA) whereas MD simulations were carried out with the 
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NAMD (version 2.5b1) package in the TIP3 water shell using the X-PLOR force field. The 
inhibitory constant (Ki) was calculated according to Hess‟s law to define the binding affinity of 
the inhibitors. HIV-1 protease inhibitor, L-700417 110 showed the highest binding affinity with 
an identical binding mode to the substrate and has proposed as a good starting point for the 
designing of SARS-CoV 3CL
pro
 inhibitors 
177
 (Figure 1.5.4.2).  
Plewczynski et al. conducted structure-based in silico virtual HTS by extracting potential 
compounds from the protein-ligand complexes selected from the protein data bank (PDB) based 
on sequence similarity with SARS-CoV M
pro
 
178
.  Identified complexes mainly included the viral 
cysteine protease bearing the trypsin fold. Later, flexible docking was performed on the small 
molecules and peptides extracted from the protein-ligand complex in the crystal structure of 
SARS-CoV M
pro
 using eHITS (a flexible docking method for finding an accurate docking pose 
based on exhaustive positional and conformational searches in a timely manner). The best 
scoring compounds were then subjected to 2D similarity searches in Ligand.info Meta-Database 
(comprised of publically available database). A set of closely related structures bearing 2-
methyl-2, 4-pentanediol 111 scaffolds were identified as lead candidate compounds against 
SARS-CoV M
pro
 
178
 (Figure 1.5.4.2). 
Zhang et al. performed the docking studies of existing HIV, psychotic and parasitic drugs 
(lopinavir, ritonavir, PNU, UC2, niclosamide and promazine) against the crystal structure of M
pro
 
using the Hex docking program in a strategy of discovering new leads from old drugs. The 
estimated binding affinities of these compounds, especially lopinavir 112 and ritonavir 113 
against SARS-CoV M
pro
, indicated the potential of these drugs for designing  new inhibitors of 
SARS-CoV M
pro
 
179
. Meanwhile, Savarino et al. supported strong binding of ritonavir 113 with 
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SARS-CoV M
pro
 (Ki ~10
-5
 M) stabilized by multiple H-bond network in their independent MD 
simulation 
180
. Zhang et al. developed a pharmacophore model based on the previously predicted 
pose of six drugs 
179
 and the crystal pose of the CMK inhibitor (1UK4, PDB code) in SARS-CoV 
M
pro
 using the POCKET module in the LIGBUILDER program 
181
. The developed four-point 
pharmacophore model was used to search NCI database. A total of 30 drugs were selected after 
consideration of pharmacophoric criteria and preference for compounds with antiviral activity. 
Interestingly, six of the identified drugs already have known anti-SARS-CoV activity 
181
. 
Meanwhile, Wu et al. also evaluated HIV protease inhibitors, currently in clinic as inhibitors of 
SARS-CoV M
pro
, and discarded the possibility of ritonavir as a potential inhibitor of SARS-CoV 
M
pro
. However, lopinavir 112 showed moderate activity against SARS M
pro
 with an IC50 value of 
50 μM (Ki =14 μM) 
134
 (Figure 1.5.4.2).  
 
Figure 1.5.4.2. Proposed inhibitors of SARS-CoV M
pro
 by virtual HTS and DLS approach  
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1.5.4.3. Dynamic Ligand Screening (DLS) 
       Recently, Schmidth et al. reported the DLS approach for the discovery of non-peptidic 
inhibitors against SARS-CoV 3CL
pro
 
182
. This approach involves site-directed identification of 
low-affinity inhibitory fragments against a particular target by in situ formation of inhibitory 
species followed by its detection with a fluorogenic reporter substrate of that target (readers are 
referred to original reference 
182
 for more detail). This method presents several benefits over 
conventional HTS or fragment-based approach using NMR or X-ray crystallography, for 
example, possible detection of low affinity fragments with inhibition constant in milimolar 
range, requirement of minimal amount of protein for assay, exploration of a wide range of the 
chemical space, minimum requirements equipments and transformation of a moderately active 
peptide to an entirely non-peptidic inhibitor with a micromolar range. A “reverted” DLS 
methodology adopted for screening against SARS 3CL
pro
 successfully identified a lower 
micromolar non-peptidic inhibitor 114 of the enzyme (Figure 1.5.4.2) with an IC50 of 2 µM. 
In short, although, SARS has been contained, the virus is not eradicated yet. In these 
circumstances, high potency of the developed inhibitors of SARS-CoV M
pro
 illustrates this 
enzyme suitable for the development of anti-SARS therapy. Also, the availability of multiple 
crystal structures of SARS-CoV M
pro
 in complex with peptidic/non-peptidic inhibitors from 
diverse classes presents unique opportunities to discover promising inhibitors of this enzyme by 
structure based drug designing. As mentioned before, P1-Glu/His triggers the potency of SARS 
inhibitors and should be focused while designing of peptidomimetics. Moreover, S1, S2 and S4 
subsites which are highly conserved among Co-V can be targeted to develop broad spectrum 
inhibitors against Co-V related diseases. Also, structure analogs of Rupintrivir with established 
activity against 3C
pro
 of rhino and other Co-V protease can serve as a template for discovery of 
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common inhibitors of Co-V. In addition, with number of inhibitors in hand, efforts can be made 
to correlate the physical, chemical, biological properties of reported inhibitors with SARS-CoV 
M
pro
 activity in the form of 2D Quantitative Structure Activity Relationships (QSAR) model and 
can be used for virtual screening of chemical libraries to identify novel hits. Also, 3D QSAR 
modeling can be performed with the help of published crystal structures enabling structural 
alignment of known inhibitors.  
1.6. Conclusions 
 This chapter highlights a variety of the rational approaches for drug discovery against 
two cysteine proteases, protozoal protease “falcipain” and viral protease “SARS 3CLpro”. To the 
best of my knowledge, this chapter covers the peptidic and non-peptidic inhibitors from major 
classes of inhibitors reported against falcipain and SARS-CoV M
pro 
to date. The cysteine 
proteases discussed here are of the utmost importance for drug design considerations. For 
instance, several efforts are currently underway to develop effective antimalarials for 
encountering the parasite resistance to all front-line drugs, including the most potent artemisinin 
derivatives 
95
. In such scenarios, falcipains manifests an emerging drug target due to its unique 
function in hemoglobin degradation and survival of the protozoa. Moreover, effective peptidic 
and non-peptidic inhibitors of falcipains (summarized above) with good inhibitory potency 
project this enzyme as a promising target for the development of antimalarial chemotherapy. 
Likewise, although SARS has been contained, possible reemergence of the disease with mutated 
forms of the virus still remains a potential threat to human health. From this view, structurally 
and biochemically well-characterized SARS-CoV M
pro
, playing pivotal role in the virus 
replication, provide an opportunity for drug development in case of the next pandemic of SARS. 
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 As discussed above, knowledge-based drug design approaches have been effective for the 
rapid discovery of inhibitors against these targets, for example, evaluation of inhibitors of other 
cysteine proteases such as papain, cathepsins, calpain or cruzain against FP-2, identified vinyl 
sulphone class of inhibitors, the most potent inhibitors reported till date against this enzyme. 
Structure-guided drug design helped to optimize the potential or known compounds against the 
target protease with the help of three-dimensional structure and knowledge of the substrate 
specificity. For instance, structure modifications of rupintrivir (known rhinovirus protease 
inhibitor with no efficacy against SARS) identified potent inhibitors of SARS 3CL
pro
 with a 
nanomolar to lower micromolar activity range. In addition, structure-based virtual screening and 
HTS helped to discover non-peptidic inhibitors with diverse scaffolds against both enzymes. 
Taken together, although the cysteine protease discussed here are quite different from each other, 
the approaches presented here provide general guidelines for drug design against the cysteine 
protease of existing and possible emerging pathogens as well as those present in humans. In 
addition, the rational approaches described for developing inhibitors against SARS set successful 
examples to initiate drug design efforts against other viral pandemics such as the swine flu 
(H1N1) virus. 
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Chapter 2 
 
 
 
 
 
 
Identification of Falcipain-2 Inhibitors Using 
Structure-Based Virtual Screening of Focused 
Cysteine Protease Inhibitor Library 
 
 
 
 
 
 
 
 
 
 
 
Content of this chapter is published in: Shah
 
F., Mukherjee, P., Jiri G., Rosenthal, P., Tekwani 
B., Avery M. A. Identification of Novel Malarial Cysteine Protease Inhibitors Using Structure-
Based Virtual Screening of a Focused Cysteine Protease Inhibitor Library, Journal of Chemical 
Information and Modeling, 2011, 51 (4), 852. 
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2.1.  Introduction  
In the Chapter 1, extensive efforts conducted for the discovery of inhibitors against FPs using 
rational drug design approaches were described. In general, drug design efforts against FPs can 
be broadly classified in two main categories: peptide/peptidomimetic covalent inhibitors and 
non-peptidic small molecule inhibitors. The covalent irreversible inhibitors contain reactive 
warheads or electrophiles such as vinyl sulfones
67, 75
, epoxy-succinate
43, 50
, and fluoromethyl 
ketones (FMKs)
43, 61
 whereas compounds with electrophiles such as α-keto amide69, aldehydes69 
and nitriles
183
 function as a reversible covalent inhibitors of the FPs (Figure 2.1a and 2.1b). In 
particular, the covalent modifiers with reactive warheads blocked the hydrolysis of hemoglobin 
by erythrocytic parasites, formed hemoglobin-filled food vacuoles in trophozoites and, hampered 
parasites development
43, 60-62, 64, 184
. Despite their excellent invitro potency against cultured 
parasites, these compounds exhibited poor selectivity towards the parasitic cysteine protease over 
mammalian cysteine proteases
62, 77, 185
. In addition, potential toxicity associated with these 
compounds due to the formation of protein adducts restricted their further development as 
potential drug candidates. Moreover, peptidic nature of these inhibitors makes them susceptible 
to hydrolysis by host cell proteases. The other categories of FP-2 inhibitors include non-peptidic 
small molecule inhibitors of the enzymes (Figure 2.1c). Several structure based virtual screening 
attempts were made to identify non-peptidic reversible inhibitors against 3D models of FPs from 
the commercial databases
80, 86, 186
. However, to date, only a few non-peptidic inhibitors of FP-2 
are available with a lower micromolar (<10 μM) affinity as well as with the ability to inhibit 
cultured parasites. Thus, design of non-peptidic, non-covalent inhibitors of FPs is an important 
goal, with the likelihood of being able to develop compounds with desirable druggable 
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properties, good in vivo potency, and biochemical selectivity.  
 
Figure 2.1. Representative FP-2 inhibitors (a) covalent irreversible inhibitors
50, 75, 77
; (b) covalent 
reversible inhibitors 
69, 75
 and, (c) non-peptidic small molecule inhibitors
80, 86, 186
. 
 
Over the past decade, structure-based virtual screening (SBVS) has gained attention and 
successfully identified novel scaffolds against different targets 
187
. In brief, SBVS involves the 
computational docking of a commercial database into the active site of the 3D structure of the 
target, followed by the selection of putative binders using scoring functions
188-191
. With this 
approach, only a small set of compounds is selected and evaluated in a biological assay, as 
opposed to the high throughput screening of an entire compound library
192, 193
. As a part of our 
efforts to discover non-peptidic reversible inhibitors of FP-2, we conducted SBVS against the 
crystal structure of FP-2 (PDB code: 2GHU) 
49
 using the Glide docking program. We first built a 
focused cysteine protease inhibitor (FCPI) library by substructure searching for compounds 
bearing soft electrophiles of interest from the pool of several commercial databases. The 
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developed FCPI library was then screened against the crystal structure of FP-2 (PDB code: 
2GHU, apo form of the enzyme) to discover novel non-covalent inhibitors of the enzyme. 
Evaluation of the selected set of compounds identified 21 diverse non-peptidic inhibitors of FP-2 
with lower micromolar potency and a potential for further structural optimizations in to the lead 
candidates. Four compounds also inhibited FP-3. Two compounds showed corresponding 
inhibition of the cultured parasites. In addition, selected compounds were evaluated against 
mammalian cysteine proteases (cathepsin B, K and L) of the papain-family. One compound was 
found to be a selective inhibitor of FP-2. Finally, an assessment of electrophilicity of 
electrophiles in selected target compounds was carried out by calculation of LUMO density of 
each atom. The results suggested the soft-nature of electrophiles in identified hits. 
2.2. Methods 
2.2.1. Computational Tools. All calculations were performed on a Linux workstation equipped 
with four parallel Intel Xeon X5460 processors (3.16 GHZ) with 8 GB total RAM. LigPrep
157
 
was used to produce low energy 3D structures of compounds. Glide docking program
194
 was 
used for pose validation, enrichment study and SBVS. QikProp
195
 was used to calculate chemical 
properties of the FCPI library. Phase
196
 was used to build docking pose based pharmacophore 
query. Diversity analyses of the final hits were performed using the Dissimilarity module 
available in Sybyl
197
. Geometry optimization and measurement of electrophilicity of identified 
compounds were performed using Atomic Fukui indices implemented in Jaguar
198
. All images 
were created using Pymol
199
. 
2.2.2. Building the Focused Cysteine Protease Inhibitor (FCPI) Library. The selected soft-
electrophiles of interest used for building of FCPI library include α-heteroatom substituted 
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ketones, α-heteroatom substituted amides, azetidinones, α-keto amide, α-keto acid and α-keto 
ester (Figure 2.2.2). Substructure searches were conducted with single line notations (SLN) of 
the soft electrophiles (Figure 2.2.2) as a query in Asinex platinum (http://www.asinex.com), 
Chembridge (http://www.hit2lead.com), Specs (http://www.specs.net), Enamine 
(http://www.enamine.net), IBScreen (http://www.ibscreen.com) and Aurora Fine Chemicals Ltd 
(http://www.aurorafinechemicals.com), using the dbsearch command from the Unity search 
module of Sybyl 8.1 (Tripos Inc., St. Louis, MO). The identical compounds obtained from a pool 
of different databases were removed. Thereafter, the database was filtered using chemical 
properties calculated by QikProp, such as molecular weight (MW) = 250-550, H-bond acceptor 
1-10, H-bond donar = 0-5 and no. of rotatable bonds = 0-10.  In addition, compounds containing 
problematic groups, such as metals, N-oxides, chloramines, aldehydes, and peroxides, were 
removed from the FCPI library. The dbslnfilter utility of the Unity module of Sybyl 8.1 was used 
to carry out database filtration. Around 65,000 compounds with desired soft-electrophiles were 
thus stored in the FCPI library. 
 
 
 
 
Figure 2.2.2. Soft-electrophiles used in the substructure search to build FCPI library. 
2.2.3. Protein Preparation. In the present SBVS study, we utilized a recently published crystal 
structure of FP-2 available in the apo form (PDB code: 2GHU)
49
. The residues within 14 Å of 
the Cys42 were included in the binding site definition. The PPREP utility of Maestro 
63 
 
(Schrodinger, LLC, Portland, OR) was used for protein preparation. The protein preparation was 
carried out at pH 5 to mimic the acidic environment of the P.falciparum food vacuole (pH = 4-6) 
where the enzyme is located. Acidic residues Asp and Glu and basic residues Arg and Lys were 
treated as charged unless they were surrounded by hydrophobic residues. Figure 3a shows the 
magnified view of the FP-2 active site with subsites S1, S1‟, S2 and S3 labeled. Protein with all 
hydrogens added was then submitted to restrained molecular mechanics refinement using the 
OPLS2001 force field incorporated in the IMPREF (Schrodinger, LLC, Portland, OR) protein 
structure refinement utility, and minimization was continued until the root mean square deviation 
(RMSD) reached 0.3 Å. The final refined structure was used for the docking calculations. 
2.2.4. Pose Validation, Enrichment Study and Docking Pose-Based Pharmacophore Query. 
In the absence of the co-crystallized structure of FP-2, a preliminary docking study was carried 
out in the homologous cysteine protease cruzain, the major cysteine protease of T. cruzi, co-
crystallized with a vinyl sulfone (VS) inhibitor (PDB ID: 1F2A)
200
. The criteria for selecting 
cruzain as a surrogate platform to establish a docking protocol are as follows: (a) both cruzain 
and falcipains are papain family cysteine proteases; (b) the superimposition of FP-2 (2GHU) and 
cruzain (1F2A), using DaliLite server
201, matches 209 α-carbons with an RMSD of 1.6 Å, a Z 
score of 30.4 and, with an overall sequence identity of 38% (Figure 2.2.4.1). Both proteins were 
found to have 62% of sequence identity and, RMSD of 2.6 Å in the ligand binding domain as 
defined by 10 Å radius from catalytic cysteine (Cys42 in FP-2 and Cys25 in cruzain, see Figure 
S0); (c) vinyl sulfone inhibitors, for example, shown in Figure 2.1(a) is a common inhibitor of 
both enzymes 
67, 200
.  
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Figure 2.2.4.1. Superimposition of FP-2 (shown in cyan) and Cruzain (shown in orange) using  
DaliLite server.  
 
Structural alignment of cruzain complexes, for example, with the irreversible covalent vinyl-
sulfone inhibitor (PDB code: 1F2A, 2OZ2) as well as the reversible covalent inhibitors such as 
hydroxyl methyl ketones (PDB code: 1ME3) and a purine nitrile (PDB code: 3I06) using 
superimposition module of maestro showed an average RMSD of 0.45 Å. This suggests that 
receptor structure does not change substantially upon the binding of inhibitors from different 
chemotypes. Therefore, rigid receptor docking protocol implemented in glide was used 
throughout the study. Once initial docking protocol is established in cruzain, subsequent 
enrichment and docking studies were performed in the crystal structure of FP-2.  
A pose validation study was performed using the Glide XP mode without any docking 
constraints. The top ranking pose obtained for the VS inhibitor in cruzain using the Gscore 
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scoring function was closest to its experimental binding mode (Figure 2.2.4.2b). The RMSD 
between predicted and experimental poses of VS inhibitor was found to be 0.97 Å, which was 
quite satisfactory considering the number of rotatable bonds of VS (structure shown in Figures 
2.2.4.2b and 2.2.4.2d). Subsequent docking of VS inhibitor in FP-2 active site reproduced the 
arrangements of P1-P3 groups as observed in X-ray structure of cruzain. Moreover, hydrogen 
bonds of VS inhibitor with Trp177, Gln19, Gly66, and Asp158 of cruzain binding site were 
reproduced in the FP-2 active site. 
The actives from the previous SBVS study 
80, 86
 (having FP-2 IC50 ≤ 30 µM, see Figure 2.2.4.3 
and Table 2.2.4.1) were selected for the enrichment study. Active compounds were seeded with a 
total of 1000 decoys downloaded from the Directory of Useful Decoys (DUD) database
202
. 
Decoys were selected by considering the chemical properties such as MW (250-550), no. of 
HBD (2-4), no. of HBA (2-8) of known actives. Selection of the diverse sets of decoys 
resembling properties of known actives made the enrichment study quite challenging. 
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Figure 2.2.4.2 (a) Magnified view of the substrate-binding pocket of FP-2 (PDB code: 2GHU). 
Subsites S1, S1‟, S2 and S3 of the enzyme are shown; (b) Pose validation study: superimposition 
of co-crystallized pose (green) and the top-ranked pose (cyan) obtained through docking; (c) 
Enrichment study: a bar graph showing percentage of actives recovered at 5% (blue), 10% (red) 
and 30% (green) of the ranked database with Gscore and Emodel scoring functions; (d) Docking 
pose-based pharmacophore query: HBD= hydrogen bond donor; HBA=hydrogen bond acceptor; 
HY=hydrophobic. P1, P1‟, P2 and P3 side chains of VS and interacting residues Gln36, Cys42, 
Gly83, Tyr78, Leu84, Leu172 and Ala175 of FP-2 binding site are shown. 
 
b. 
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Figure 2.2.4.3. Chemical structures of previously reported FP-2 hits (IC50 <=30μ M) used in 
enrichment study
80, 86
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Table 2.2.4.1 Reported IC50 of previously identified FP-2 hits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, a receptor-based pharmacophore pre-filter was generated based on the docking 
pose of the peptidic vinyl sulfone in the crystal structure of FP-2 (2GHU, PDB code) encoding 
key receptor-ligand interactions. Phase 3.0 was used to build the pharmacophore query. The 
pharmacophore shown in Figure 2.2.4.3d consists of two hydrophobic features (green) mapped 
onto the P2 and P3 side chains of VS interacting with hydrophobic residues of S2 and S3 
pockets, a hydrogen bond donor feature (cyan) mapped onto the –NH of the P3 side chain 
forming H-bond with Gly83 and, a hydrogen bond acceptor (pink) forming the H-bond with the 
residues of oxyanion hole (Cys42 and Gln36). As in the S2/S3 pockets, there is no strict 
requirement for the ring aromatic feature, the built-in definition for the directional ring aromatic 
feature was excluded for performing the search against the FCPI library, and the SMART 
Compound  
Code 
FP-2
a 
IC50 
(μM) 
Compound  
Code 
FP-2
b 
IC50 
(μM) 
1 1.0 16 7.5 
2 1.4 17 10.4 
3 1.6 18 10.8 
4 2.1 19 12.4 
5 2.2 20 13.2 
6 2.9 21 13.8 
7 3.9 22 14.3 
8 4.6 23 15.3 
9 5.4 24 19.0 
10 5.7 25 20.8 
11 6.2 26 22.5 
12 6.2 27 26.6 
13 6.5 28 27.3 
14 7.0 29 31.1 
15 7.5  - 
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patterns for aromatic rings were included in the hydrophobic feature definition.                 
2.2.5. Structure-based virtual screening protocol. The FCPI library consisting of ~65,000 
compounds was prepared for virtual screening using the ligprep module of Schrodinger (see 
Figure 2.2.5). Compounds were subjected to hydrogen additions, removal of salt, ionization, and 
generation of low energy ring conformations. The chiralities of the original compounds were 
preserved. Finally, the low energy 3D structures of all compounds were produced. To curtail the 
database prior to docking, a prepared database was prefiltered using a four-point structure-based 
pharmacophore query based on the docking pose of vinyl sulfone. Compounds matching a 
minimum 3 out of 4 features of the pharmacophore query were retained. At this stage, filtered 
compounds were expected to possess soft electrophiles of interest and relevant pharmacophoric 
features of FP-2 inhibitors, which increase the probability for docking of more relevant 
compounds in the active site of FP-2. Approximately 30,000 compounds thus retained were 
subjected to docking in the crystal structure of FP-2 using the previously validated Glide XP 
protocol. The top 3,000 molecules (top 10%) ranked on the basis of Emodel score were selected 
for eMBrAce minimization calculation (Macromodel). The eMBrAcE energy minimization in 
the energy difference mode was carried out for the protein-ligand complexes to study the 
association of ligands with the receptor. The energy difference was calculated as follows: 
 
where ΔE= energy changes upon association; E complex = energy of the receptor-ligand complex; 
E ligand  = energy of ligand alone, and E protein = energy of protein alone. Based on EMBrACE 
score, the top 500 molecules were selected. 
Next, compounds were visually inspected for the following criteria: a) presence of the soft 
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electrophile in the vicinity of catalytic Cys42; b) key hydrophobic (Leu172, Leu84) or H-
bonding interactions (Gln36, Gly83) between ligand atoms and protein residues; c) the internal 
geometry of the ligand in the binding site; d) occupancy of the S2 sub-pocket by the hydrophobic 
group of the ligand (hemoglobin cleavage studies demonstrated strong  preference for cleavage 
sites with Leu at P2 position as a major determinant of the specificity against this enzyme
203
, 
therefore, hydrophobic interactions of ligand in S2 sub-site were considered essential); and, e) 
commercial availability of putative hits. Based on these criteria, 200 molecules were selected and 
subjected to diversity analysis using the Dissimilarity module of Sybyl 8.1 (Tripos Inc., St. 
Louis, MO). A total of 50 diverse compounds were purchased from respective vendors. The 
Tanimoto similarity matrix was generated to calculate an average pair-wise Tanimoto similarity 
index of identified hits using Similarity/Distance matrix utility implemented in Canvas, version 
1.2 (Schrödinger, LLC, New York, NY, 2009), using atom-pair fingerprints. The comparisons of 
the obtained hits in the present study with those from previous SBVS studies were carried out 
using the dbcmpr utility of Sybyl 8.1 (http://www.tripos.com). The comparison was done by 
constructing a UNITY database of each set using Sybyl 8.1. 
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Figure 2.2.5. A flow chart depicting the virtual screening protocol utilized in the study. W2 
stands for chloroquine resistance strain of P.falciparum. 
 
2.2.6. Biological Evaluation. The selected 50 compounds were evaluated for inhibition of FP-2, 
FP-3 and against chloroquine resistant (W2 strain) P.falciparum parasites. To determine IC50 
values, recombinant FP-2 and FP-3 were incubated for 30 minutes at room temperature in 100 
mM sodium acetate, pH 5.5, and 10 mM dithiothreitol with different concentrations of inhibitors 
prepared from stocks in DMSO (maximum concentration of DMSO in the assay was 1%). After 
30 minutes, the substrate Z-Leu-Arg-AMC (benzoxycarbonyl-Leu- Arg-7-amino-4-methyl-
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coumarin) in the same buffer was added to a final concentration of 25 µM. Fluorescence was 
monitored for 15 minutes at room temperature in a Lab systems Fluoroskan Ascent 
spectrofluorometer. IC50 values were determined from plots of percent activity over compound 
concentration using GraphPad Prism software
204
. 
The assays for selected human cysteine proteases, cathepsin B, K and L were conducted in a 
similar way as described above for FP-2. The assay concentration used for cathepsin B, K and L 
were 7.94 nM, 3.40 nM and, 5.38 nM, respectively. The appropriate substrates (Z-Phe-Arg-AMC 
for cathepsin K and L, and Z-Arg-Arg-MCA for cathepsin B) were added to a final concentration 
of 25 µM. 
Activity against malaria parasites was tested against the chloroquine-resistant (W2) strain of P. 
falciparum, which was cultured at 2% hematocrit of human erythrocytes in RPMI 1640 medium 
supplemented with 0.5% Albumax (Gibco), 2% heat inactivated human serum and 100 µM 
hypoxanthine in 96-well culture plates. Parasites were synchronized with 5% sorbitol
205
. All 
tested compounds were prepared as 10 mM stock solutions in DMSO and diluted in medium at 
least 1:1000, resulting in ≤0.1% final concentrations of DMSO. Parasites at 1% parasitemia were 
incubated with compounds at 37 °C under 3% O2, 5% CO2, 92% N2. After 48 hours, the medium 
was removed, and cells were fixed with 2% formaldehyde in PBS for 24 hours. After fixation, 5 
µl aliquots were incubated for 15 min in the dark in 150 µl of 100 mM NH4Cl, 0.1% Triton X-
100 in PBS, and 10 nM YOYO-1 (Molecular Probes). Parasitemia was determined based on 
counts from a FACSort flow cytometer (Beckton Dickinson) using CellQuest software (Beckton 
Dickinson).  IC50 values for growth inhibition were determined from plots of percent control 
parasitemia over inhibitor concentration using Prism
®
 software (GraphPad). Compounds were 
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also evaluated for cytotoxicity on VERO (monkey kidney fibroblast) cells by the neutral red 
assay
206
. IC50 values for each compound were computed from the growth inhibition curve. 
2.2.7. Calculation of electrophilicity of soft-electrophiles in identified hits 
Atomic Fukui indices, derived from Mulliken population of the Highest Occupied Molecular 
Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO), were used to quantify 
electrophilicity of a molecule at a particular atomic site. Two different set of Fukui indices 
calculated include the HOMO and the LUMO. Each index has two subscripts: N stands for the 
electron density and, S stands for the spin density. Thus, a total of four indices were calculated 
for both, the HOMO and the LUMO: F_NN, F_NS, F_SN, and F_SS. The first index shows 
which property responds to a change in the property indicated by the second index, hence, F_NN 
indicates the change in the electron density when only the electron density that is changing, and 
the spin density is constant. Similarly, F_NS represents the change in the electron density when 
only the spin density is changing etc. F_NN_LUMO was considered for measuring 
electrophilicity of electrophilic center in the target compounds. Structures were subjected to the 
geometry optimization using the hybrid density functional B3LYP
207, 208
 and a basis set 6-31G* 
in a gas phase using Jaguar. The default convergence criterion implemented in Jaguar were used 
for SCF calculations (accuracy level= Quick, convergence criteria: maximum iteration=48 and, 
energy change= 5 × 10
-5
 hartree), and, optimization (Maximum steps=100, convergence 
criteria=default, initial hessian=Schlegel guess
209
). The fully optimized geometry of compounds 
were subjected to the calculation of Atomic Fukui indices implemented in the property section of 
the Jaguar optimization panel, according to formalism presented elsewhere
210, 211
. Fukui function 
for the electron density integrates to one, so the predicted reactivity here are scaled from zero to 
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one, one being the most reactive. It is worthwhile mentioning that in all cases, the SH group of 
the active site cysteine has been assumed as a nucleophile or HOMO component of a 
nucleophilic-electrophilic addition reaction. 
2.3. Result and Discussions 
Out of 50 compounds submitted for biological testing, a total of 21 diverse non-peptidic hits 
were identified. The IC50 values of hits for FP-2 inhibition ranged from 1.4 µM to 49 µM (shown 
in Table 2.3.1). Four compounds 2, 5, 8 and 11 were found to be dual inhibitors of FP-2 and -3. 
The structures of identified inhibitors are depicted in Figure 2.3.1.  
Table 2.3.1. Biological evaluation of compounds selected hits from SBVS against FP-2 and 
cultured parasites. 
 
Compound 
Code
c
 
FP-2
a 
IC50 
(μM) 
FP-3
a1 
IC50 
(μM) 
W2
b
IC50 
(μM) 
Compound 
Code
c
 
FP-2
a 
IC50 
(μM) 
FP-3
a1 
IC50 
(μM) 
W2
b
 
IC50 
(μM) 
1 1.39 >50 NA 12 23.81 >50 NA 
2 2.18 4.95 NA 13 25.25 >50 NA 
3 3.26 >50 NA 14 25.96 >50 NA 
4 4.59 >50 NA 15 25.99 >50 NA 
5 7.51 30.27 1.90 16 28.66 >50 NA 
6 7.85 >50 4.34 17 32.85 >50 NA 
7 10.32 >50 NA 18 37.34 >50 1.92 
8 11.58 45.64 NA 19 44.94 >50 NA 
9 11.86 >50 NA 20 46.97 >50 NA 
10 15.11 >50 1.57 21 49.18 >50 5.83 
11 20.87 36.05 NA 22 >50 >50 7.21 
E-64 0.08 0.15 - E-64 0.08 0.15 - 
Artemisinin -  0.01 Artemisinin -  0.01 
Chloroquine -  0.05 Chloroquine -  0.05 
NA= not active up to 50 μM; afalcipain-2, a1falcipain-3, bAntimalarial activity against 
chloroquine resistant (W2) strain of P. falciparum. 
c
all compounds were non-cytotoxic at least up 
to 50 μM in VERO (monkey kidney fibroblast) cells. E-64, artemisinin and chloroquine were 
used as positive controls. 
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A major bottleneck in SBVS is finding a suitable scoring function for the target of interest to 
enable the identification of potential active compounds prior to the screening of large chemical 
databases. Novel approaches to address this problem include the use of a target-biased scoring 
function which takes into consideration the nature of the target (polar vs apolar binding site) as 
well as the nature (pharmacophoric patterns and similarity considerations) and key interaction of 
known ligands with the target
212
. In the present study, two scoring functions implemented in the 
Glide module of Schrodinger, Gscore and Emodel were evaluated for their abilities to retrieve 
known FP-2 inhibitors from decoys downloaded from the DUD database. The recovery rates 
(Figure 2.2.4.2c) showed that among the scoring functions evaluated, Emodel performed better 
than Gscore in 5%, 10% and 30% database screens. At the 5% database screened mark, the 
percentage of actives recovered was 50% for Emodel while at the 10% and 30% database 
screened marks, the percentage of actives recovered was 66% and 84% by the Emodel scoring 
function as compared to 28% and 50%, respectively, for the Gscore. These results were quite 
encouraging considering the diversity of the actives used in this study and enhanced our 
confidence in using Emodel as a scoring function for the SBVS study. The higher enrichment 
rate associated with Emodel might be because of significant weighting of force field components 
such as the Coulomb and van der Waals energy in Emodel as compared to Gscore
213
. These 
interactions may be a major driving factor for the ligand binding for the apolar FP-2 binding site, 
and, as a result, Emodel performed better with the FP-2 active site than Gscore. A similar 
observation was made by Li et al. in their virtual screening study, suggesting the importance of 
Dock energy score (GAsDock) over a Chemscore-based (GScore) scoring function more suitable 
for the apolar FP-2 binding site
186
. The success ratio for the present study in finding novel 
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chemotypes was 42%, which suggest the score-based active/inactive separation ability of current 
docking protocol against this target. The higher hit ratio also implied the importance of scoring 
function based enrichment studies prior to SBVS. 
 
Figure 2.3.1. Structures of the FP-2 inhibitors identified through SBVS of FCPI library. 
Substructure containing electrophiles of interest are highlighted in blue. 
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Prior to virtual screening of FCPI library, the database was curtailed with a docking pose based 
pharmacophore query. Key interactions of vinyl sulfone inhibitor with residues of FP-2 active 
site such as Gly83, Cys42, Gln36, along with the hydrophobic residues of S2 and S3 pocket 
(shown in Figure 3d) were used to build the pharmacophore query, consisting of four descriptors: 
HBD, HBA, HY1, and, HY2. The selection of pharmacophoric descriptors were based on a 
thoughtful consideration of crucial interactions of cysteine protease inhibitors with the conserved 
residues of the papain-family cysteine proteases. For example, Gly83 is highly conserved in the 
S3 subsite of clan CA cysteine proteases
34, 214
 (Figure 2.3.2), and, the lack of potency was 
reported for the cysteine protease inhibitors particularly binding to the non-prime (S1-S4) site 
lacking hydrogen bond with the carbonyl oxygen of glycine
11, 215
. Similarly, inhibitors of the 
papain-family of enzymes, are commonly shown to form hydrogen bonding interactions with 
residues forming oxyanion hole such as Gln36 and backbone amine of catalytic cysteine Cys42 
in FP-2 
11, 216, 217
. Moreover, as with the most other papain-family of proteases, analysis of the 
specificity of FP-2 indicated that the amino acid at the P2 position plays a key role in mediating 
substrate specificity, at least with peptide substrates
34
. In addition, substrate mapping and 
inhibitor profiling study against FP-2 revealed strong preference for hydrophobic residue at P2 
(Leu>Phe>Val) in the S2 Pocket
34, 185
. Finally, the recently published X-ray structure of FP-2 
bound to a covalent irreversible epoxysuccinate inhibitor (E-64)
50
 gives an additional validity to 
our selection of docking-pose based pharmacophoric descriptors (Figure 1.2, Chapter 1). The 
carboxyl group of E-64 occupies the oxyanion hole formed by Gln36 and Cys42, resembling 
HBA feature of our pharmacophore query. Similarly, peptidyl backbone amine of E-64 forms 
hydrogen bond with a backbone carbonyl of Gly83, similar to assigned HBD descriptor of 
78 
 
pharmacophore query. The P2-leucine of E-64 exhibits hydrophobic interactions in the S2 pocket 
with Ile85, L172 and Ala175, whereas P3 side chain of E-64 exhibited hydrophobic interaction 
with Gly83, Leu84, and, cation-pi interactions with the Tyr78 in S3 pocket, relating to the HY1 
and HY2 descriptors of docking pose-based pharmacophore query.  
                                                                                                                                 * 
FP-2    --------QMNYEEVIKKYR-GEENFDHAAYDWRLHS----GVTPVKDQK 37 
FP-3    TLSPPVSYEANYEDVIKKYKPADAKLDRIAYDWRLHG----GVTPVKDQA 46 
CAT_K   -------------------------RAPDSVDYRKKG----YVTPVKNQG 21 
CAT_L1  ----------------------------FSVDWREKG----YVTPVKNQG 18 
CAT_B   YLKRLCGTFLGGPKPPQRVMFTEDLKLPASFDAREQWPQCPTIKEIRDQG 50 
                    * 
FP-2    NCGSCWAFSSIGSVESQYAIRK--NKLITLSEQELVDCSFK--NYGCNGG 83 
FP-3    LCGSCWAFSSVGSVESQYAIRK--KALFLFSEQELVDCSVK--NNGCYGG 92 
CAT_K   QCGSCWAFSSVGALEGQLKKKT--GKLLNLSPQNLVDCVSE--NDGCGGG 67 
CAT_L1  QCGSCWAFSATGALEGQMFRKT--GRLISLSEQNLVDCSGPQGNEGCNGG 66 
CAT_B   SCGSCWAFGAVEAISDRICIHTNAHVSVEVSAEDLLTCCGSMCGDGCNGG 100 
 
FP-2    LINNAFEDMIELGGICP---DGDYPYVSDAPNLCNIDRCTEKYGIKNYLS 130 
FP-3    YITNAFDDMIDLGGLCS---QDDYPYVSNLPETCNLKRCNERYTIKSYVS 139 
CAT_K   YMTNAFQYVQKNRGIDS---EDAYPYVGQE-ESCMYNPTGKAAKCRGYRE 113 
CAT_L1  LMDYAFQYVQDNGGLDS---EESYPYEATE-ESCKYNPKYSVANDTGFVD 112 
CAT_B   YPAEAWNFWTRKGLVSGGLYESHVGCRPYSIPPCEHHVNGSRPPCTGEGD 150 
 
FP-2    VPD------------------------------NKLKEALRFLGPISISV 150 
FP-3    IPD------------------------------DKFKEALRYLGPISISI 159 
CAT_K   IPEG---------------------------NEKALKRAVARVGPVSVAI 136 
CAT_L1  IPK----------------------------QEKALMKAVATVGPISVAI 134 
CAT_B   TPKCSKICEPGYSPTYKQDKHYGYNSYSVSNSEKDIMAEIYKNGPVEGAF 200 
 
FP-2    AVS-DDFAFYKEG-IFDGECG-DELNHAVMLVGFGMKEIVNPLTKKGEKH 197 
FP-3    AAS-DDFAFYRGG-FYDGECG-AAPNHAVILVGYGMKDIYNEDTGRMEKF 206 
CAT_K   DASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQ----------KGN 176 
CAT_L1  DAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTE------SDNN 178 
CAT_B   SVY-SDFLLYKSG-VYQHVTGEMMGGHAIRILGWGVEN----------GT 238 
 
                      * 
FP-2    YYYIIKNSWGQQWGERGFINIETDESGLMRKCGLGTDAFIPLIE------ 241 
FP-3    YYYIIKNSWGSDWGEGGYINLETDENGYKKTCSIGTEAYVPLLE------ 250 
CAT_K   KHWIIKNSWGENWGNKGYILMARNKN---NACGIANLASFPKM------- 216 
CAT_L1  KYWLVKNSWGEEWGMGGYVKMAKDRR---NHCGIASAASYPTV------- 218 
CAT_B   PYWLVANSWNTDWGDNGFFKILRGQD----HCGIESEVVAGIPRTDQYWE 284  
Figure 2.3.2. Multiple sequence alignment of FP-2 with homologous cysteine proteases 
performed using Clustal 2.0.12 
1
. Sequence information is from SWISS-PROT (accession 
numbers: Q9NAW2, Q9NB39, P43235, P07711 and P07858). The conserved residues among all 
papain-family cysteine proteases are shown in green. The amino acid residues of the S2 pocket 
differing between FPs and mammalian cysteine proteases are highlighted in red. Catalytic 
residues are highlighted in *. 
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As mentioned before, the main drawback of covalent modifiers (for example, compounds 
bearing electrophiles such as α, β-unsaturated ketones, α-halo ketones, cynamide) is lack of 
target specificity. In addition, non-specific binding of covalent modifiers to protein, DNA or 
glutathione (GSH) may lead to unfavorable toxicological events such as immunogenic response 
or life-threatening idiosyncratic adverse drug reactions (ADRs)
218, 219
. Soft-electrophiles 
attenuate the reactive nature of hard electrophiles and might reduce the risk of toxicity associated 
with covalent modifiers. Thus, use of the soft-electrophiles based FCPI library for SBVS 
provides a strategic approach to discover novel, selective inhibitors, preferably modulating the 
enzyme through non-covalent interactions. The soft-electrophiles selected here had previously 
shown to form tetrahedral intermediates with cysteine proteases, for example, α-heteroatom 
substituted ketones
217, 220-222, α-keto amide56, 223, α-keto acid56, α-keto ester56 and azetidinones215. 
To assess the soft-nature of electrophiles present in target compounds, we performed calculations 
of the Atomic Fukui indices on a few selected compounds (1, 3-5, 7, 11, 12, 14, and 15) 
containing diverse soft-electrophiles. Fukui indices are partial second derivatives of the electron 
or spin density with respect to a change in the electron count or the unpaired spin count. They are 
regional descriptor of site reactivity predicting which atoms in a molecule are most reactive 
towards electrophilic or nucleophilic attack based on the analysis of Frontier Molecular Orbitals 
(FMOs) in a molecule
210
. The greater the magnitude of an index, the greater change in electron 
or spin density near the atoms of interest, and thus, higher reactivity of a molecule at that atomic 
site for an electrophilic or a nucleophilic reaction
224
. Generally, a nucleophilic reaction takes 
place preferably in the substrate sites with the largest values for the LUMO density. Likewise, an 
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electrophilic reaction is most likely to occur at the largest HOMO electron density in the 
molecular site
211, 225
. Since our goal was to probe the most electrophilic center in identified FP-2 
hits and predict its electrophilicity, we considered calculation of Fukui indices, F_NN_LUMO at 
a constant spin density in selected compounds. The electrophilicity of electrophilic centers 
present in identified FP-2 hits were compared with the known cysteine protease inhibitors with 
an irreversible covalent (α-halo ketone, R1; vinyl sulfone, R2) and a reversible covalent (α-
ketoamide, R3) warhead groups. The values of Fukui index F_NN_LUMO, of the most 
electrophilic atoms of the FP-2 inhibitors, and, reference compounds (R1-R3) are shown in 
Figure 2.3.3.  
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Figure 2.3.3. An evaluation of regional Fukui functions to predict the electrophilicity of atomic 
site of reference compounds (R1-R3) and selected FP-2 inhibitors is shown here. The most 
electrophilic center in the compounds is shown by the arrows. The corresponding value of the 
Fukui index, F_NN_LUMO, for the reactive atoms (scaled from zero to one) is shown in blue. 
 
The result from the calculation (Figure 2.3.3) demonstrates that the site specific reactivity of 
the identified FP-2 inhibitors is less than the irreversible covalent inhibitors: R1 with an α-halo 
ketone (LUMO = 0.518) and R2 with a vinyl sulfone warhead group (LUMO = 0.428) and, are 
comparable to the known reversible covalent inhibitor, R3 with an α-keto amide (LUMO = 
0.395) moiety. These calculations suggest the soft-nature of the electrophilic atoms in the 
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identified FP-2 hits. However, one exception here is compound 14 with a higher than expected 
electrophilicity value, presumably because of the ring strain of an azetidin-3-ones moiety, which 
is reflected in the calculated LUMO value (0.417). On the basis of the predicted site reactivity of 
soft-electrophiles, compounds with an α-hetero ester (5, LUMO = 0.322) were found to be more 
electrophilic than those with an α-hetero ketone (7, 11, LUMO = 0.251; 15, LUMO = 0.253), 
which in turn had a higher electrophilicity than hits with an α-hetero amide functionality (1, 
LUMO = 0.115; 4, LUMO = 0.020). One point worth mentioning here is that the calculated 
electrophilicity is influenced by the complex interplay of factors such as a neighboring group 
effects, the internal geometry of the compound, intermolecular hydrogen-bonding and the 
solvation effects. For example, the predicted electrophilicity of the α-keto amide 12 (LUMO = 
0.223) was found to be lower than the R3 LUMO (0.395). This difference may be due to the 
presence of an adjacent heteroaromatic system leading to extensive conjugation as well as 
intramolecular hydrogen bonding between the nitro group and the enolic OH forming a six 
membered chelate. Similarly, in case of hits with α-heteroatom substituted ketones, a slightly 
higher predicted electrophilicity of 15 than 7 or 11 might be due to the presence of the electron 
withdrawing p-chloro group, increasing the electrophilicity of the carbonyl carbon. However, a 
comparison of predicted site-specific reactivity of identified hits with FP-2 inhibition data 
suggests a lack of correlation of electrophilicity with the enzymatic inhibition. For instance, 
compound 14 with an azetidine-3-one, had the highest predicted LUMO based electrophilicity 
among the identified hits, however, it was only moderately active in the FP-2 inhibition assay 
(IC50 =25.9 μM). By comparison, compounds with an α-hetero amide (compounds 1, 4) were 
predicted to have a negligible electrophilicity but showed relatively higher experimental 
83 
 
Q 36 W 206
C 42
L 84
I 85
S 149
D 234
L 172
S2
S1
S3
S1′
A 175
G 83
N 173
V 152
H 174
Y 78
C 39
C 80
S 41
N 171
G 82
F 236
A 235
Q 36 W 206
C 42
L 84
I 85
S 149
D 234
L 172
S2
S1
S3
S1′
A 175
G 83
N 173
V 152
H 174
Y 78
C 39
C 80
S 41
N 171
G 82
F 236 A 235
Q 36
W 206
C 42
L 84
I 85
S 149
D 234
L 172
S2
S1
S3
S1′
A 175
G 83
N 173
V 152
H 174
Y 78
C 39
C 80
S 41
N 171
G 82
F 236
A 235
inhibition of FP-2 (IC50 = 1-5 μM). This observation emphasizes the obvious involvement of 
other factors in enzyme inhibition, such as the overall geometry and interaction patterns of the 
compounds in the FP-2 binding site.  
 
 
 
 
 
 
 
Figure 2.3.4. Predicted binding mode of virtual screening hits (a) 1 (b) 2 (c) 6 in the FP-2 
binding site. 
 
Figure 2.3.4 shows predicted interaction profiles of representative compounds 1, 2 and 6 in FP-
2 active site. The 4-oxo-phthalazine core in molecule 1 appears to protrude into the S1‟ pocket 
with the carboxylic acid group interacting with the residues of an active site-forming oxyanion 
hole such as the backbone –NH of Cys 42 and the amide side chain of Gln 36 (see Figure 2.3.4a). 
Also, Trp206 and Val152 of the S1‟ pocket are involved in the van der Waals interactions with 
the pthalazine moiety wherein the indole –NH of Trp206 participates in hydrogen bonding with 
the carboxylate moiety of 1. The α-ketoamide soft-electrophile exhibits hydrogen bonding 
interaction with the backbone –NH of Gly82 and the backbone carbonyl of Asn173. The phenyl 
ring at the terminus of the amide linker can undergo hydrophobic interaction with the side chains 
of Ala175. The terminal 2, 4 dimethyl phenyl moiety is involved in hydrophobic interactions 
with the side chains of Leu84, Ile85 at the entrance of the S3 pocket as well as with the Phe236 
a. c. b. 
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buried deeper in the S2 pocket. 
In case of compound 2, the 5-methyl-isooxazole moiety was well placed in the S1‟ pocket of 
FP-2, exhibiting hydrophobic interactions with the side chains of Tyr206 and Val152 (Figure 
2.3.4b). Also, the isoxazoyl moiety of 2 was involved in multiple hydrogen bonding interactions 
with the side chain amide proton of Gln36 as well as the indole -NH of Trp206. The carbonyl 
group of the α-keto amide electrophile located over the catalytic Cys42 formed a critical 
hydrogen bonding interaction with the backbone amine of Cys42, whereas the –NH of the α-keto 
amide electrophile acts as a hydrogen bond donor for the backbone carbonyl of Asn 173. In 
addition, the α-keto amide linker was involved in hydrophobic interactions with Gly82. The 
nitrogen of the tetrazole moiety acted as a hydrogen bond acceptor with the backbone amine of 
Gly83. The phenyl ring attached to the tetrazole moiety of 2 vectors into the critical S2 pocket, 
forming hydrophobic interactions with Leu172 at the entrance of the S2 pocket as well as with 
the Leu84 side chain lining the S3 pocket. The anilinic -NH of 2 donated a hydrogen bond to the 
side chain carboxylic group of Asp234 buried in the hydrophobic environment of the S2 pocket. 
The terminal phenyl ring was found to exhibit van der Waals interactions with the side chain of 
Leu172, exposing the para fluoro group to the solvent.  
A similar observation was made for compound 6 near the S1‟ pocket, especially for the 5-
methyl-isooxazole moiety (Figure 2.3.4c). The thioacetamide electrophile is placed over the 
catalytic cysteine sulfur, and its carboxamide group participates in the hydrogen bonding 
interactions with Cys42 and Asn173 in a similar manner as observed for 2. The quinazoline core 
of 6 is placed aptly in the S2 pocket, forming van der Waals interactions with Ala175 and 
Leu172. In addition, nitrogen on the quinazoline ring of 6 accepts a hydrogen bond from the 
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backbone of Gly83. Moreover, the admantyl moiety of 6 protrudes into the S3 pocket and 
participates in the van der Waals interactions with the Tyr78 of the S3 pocket.  
 
Figure 2.3.5. Comparison of similarity of hits identified in the current study with previously 
identified hits (structure shown in Figure 2.2.4.3) using dbcmpr utility of Sybyl 8.1. The median 
Tanimoto coefficient is about 0.33 (where the graph crosses the 50% threshold), and all of 
compounds in the current dataset have a Tanimoto of 0.5 or less with their nearest neighbour in 
the reference database suggesting identified hits are structurally novel. 
 
The average pair-wise Tanimoto similarity index of the 21 FP-2 inhibitors was 0.24, which 
point towards the diverse nature of the identified hits (see similarity matrix, Table 2.3.2). The 
diversity of hits obtained in the present study with previously identified FP-2 inhibitors was 
analyzed using the dbcmpr module of Sybyl. dbcmpr utility calculates the Tanimoto similarities 
using UNITY 2D fingerprints between all compounds identified in current study (test set) with 
their nearest neighbors in the previous study (reference set). The result of this comparison 
showed that 95% of compounds from the test set has the Tanimoto similarity of less than or 
equal to 0.5 to its nearest neighbor in the reference set (see database comparison, Figure S3 in 
the supporting information). The results clearly suggest novelty of the hits identified in the 
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present study. 
Table 2.3.2. The pair-wise Tanimoto similarity matrix table generated using Canvas, version 1.2 
(Schrödinger, LLC, New York, NY, 2009) for 21 identified hits. The maximum similarity was 
0.5 between compound pairs 4 and 21 which share same core. 
 
Comp 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20 21 19 
1 1.00 0.32 0.25 0.29 0.22 0.19 0.33 0.20 0.33 0.36 0.17 0.26 0.27 0.19 0.22 0.23 0.38 0.29 0.20 0.28 0.17 
2 0.32 1.00 0.24 0.27 0.21 0.26 0.32 0.20 0.25 0.31 0.13 0.24 0.20 0.19 0.17 0.23 0.30 0.24 0.20 0.26 0.15 
3 0.25 0.24 1.00 0.30 0.36 0.24 0.31 0.20 0.29 0.26 0.19 0.32 0.25 0.29 0.23 0.27 0.31 0.23 0.29 0.28 0.19 
4 0.29 0.27 0.30 1.00 0.21 0.26 0.32 0.31 0.33 0.23 0.16 0.23 0.25 0.26 0.21 0.41 0.42 0.46 0.26 0.50 0.29 
5 0.22 0.21 0.36 0.21 1.00 0.21 0.26 0.14 0.24 0.37 0.17 0.24 0.23 0.32 0.21 0.25 0.23 0.17 0.26 0.19 0.18 
6 0.19 0.26 0.24 0.26 0.21 1.00 0.25 0.20 0.24 0.19 0.15 0.24 0.21 0.23 0.18 0.27 0.25 0.26 0.28 0.24 0.19 
7 0.33 0.32 0.31 0.32 0.26 0.25 1.00 0.32 0.27 0.38 0.15 0.32 0.36 0.27 0.36 0.40 0.38 0.33 0.32 0.32 0.21 
8 0.20 0.20 0.20 0.31 0.14 0.20 0.32 1.00 0.21 0.18 0.21 0.19 0.33 0.18 0.24 0.31 0.27 0.28 0.42 0.28 0.17 
9 0.33 0.25 0.29 0.33 0.24 0.24 0.27 0.21 1.00 0.27 0.17 0.24 0.33 0.20 0.27 0.26 0.31 0.28 0.23 0.33 0.22 
10 0.36 0.31 0.26 0.23 0.37 0.19 0.38 0.18 0.27 1.00 0.14 0.28 0.27 0.34 0.30 0.29 0.35 0.28 0.25 0.21 0.18 
11 0.17 0.13 0.19 0.16 0.17 0.15 0.15 0.21 0.17 0.14 1.00 0.14 0.24 0.21 0.15 0.16 0.13 0.17 0.18 0.18 0.15 
12 0.26 0.24 0.32 0.23 0.24 0.24 0.32 0.19 0.24 0.28 0.14 1.00 0.26 0.27 0.22 0.30 0.28 0.23 0.20 0.20 0.16 
13 0.27 0.20 0.25 0.25 0.23 0.21 0.36 0.33 0.33 0.27 0.24 0.26 1.00 0.25 0.29 0.34 0.29 0.27 0.31 0.24 0.19 
14 0.19 0.19 0.29 0.26 0.32 0.23 0.27 0.18 0.20 0.34 0.21 0.27 0.25 1.00 0.25 0.34 0.24 0.22 0.22 0.17 0.27 
15 0.22 0.17 0.23 0.21 0.21 0.18 0.36 0.24 0.27 0.30 0.15 0.22 0.29 0.25 1.00 0.26 0.25 0.23 0.25 0.21 0.20 
16 0.23 0.23 0.27 0.41 0.25 0.27 0.40 0.31 0.26 0.29 0.16 0.30 0.34 0.34 0.26 1.00 0.38 0.35 0.25 0.31 0.22 
17 0.38 0.30 0.31 0.42 0.23 0.25 0.38 0.27 0.31 0.35 0.13 0.28 0.29 0.24 0.25 0.38 1.00 0.49 0.26 0.34 0.21 
18 0.29 0.24 0.23 0.46 0.17 0.26 0.33 0.28 0.28 0.28 0.17 0.23 0.27 0.22 0.23 0.35 0.49 1.00 0.22 0.31 0.24 
20 0.20 0.20 0.29 0.26 0.26 0.28 0.32 0.42 0.23 0.25 0.18 0.20 0.31 0.22 0.25 0.25 0.26 0.22 1.00 0.28 0.17 
21 0.28 0.26 0.28 0.50 0.19 0.24 0.32 0.28 0.33 0.21 0.18 0.20 0.24 0.17 0.21 0.31 0.34 0.31 0.28 1.00 0.27 
19 0.17 0.15 0.19 0.29 0.18 0.19 0.21 0.17 0.22 0.18 0.15 0.16 0.19 0.27 0.20 0.22 0.21 0.24 0.17 0.27 1.00 
  
In addition to inhibition of FP-2, compounds 5, 6, 10, 18, 21 and 22 exhibited in vitro anti-
malarial activity. Compounds 5 and 6 showed the same log order IC50 values in whole-cell 
assays as in the enzyme assay. Other compounds (10, 18, 21 and 22) displayed greater activity 
against cultured parasites than FP-2. These observations might be explained in a number of 
ways: First, the compounds might be acting both against FP-2 and non-protease targets, as 
suggested by results with phenothiazines
226
. For example, compound 10 contains napthoquinone 
scaffold conferring its redox potential
227
 and may exert its activity via protein crosslink in the 
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cultured parasites in addition to inhibition of FP-2. Second, the compounds may be acting against 
targets other than FP-2. This possibility is suggested by the fact that compounds 18, 21 and 22 
did not form a swollen, hemoglobin-filled food vacuole, as seen with highly potent covalent 
falcipain inhibitors
64, 183
. Third, the compounds might concentrate in the food vacuole, allowing 
activity at culture concentrations below those that inhibit the protease. In any event, our screens 
identified a number of compounds with low micromolar antimalarial activity. Of note, all the 
compounds shown in Figure 2.3.1 were non-toxic in cytotoxicity assay, suggesting potential for 
development of related compounds as drugs.  
Next, we screened identified FP-2 hits (compound 1-7, FP-2 IC50 ≤ 10 μM) against selected 
human papain-family cysteine proteases (cathepsin B, cathepsin K and cathepsin L), for possible 
off-target activity (Table 2.3.3). As expected, the evaluated hits (1-7) were found to inhibit 
selected cathepsins that are closely related to the parasitic cysteine proteases. Although, 
homology exists between the parasitic cysteine protease and its human orthologues, there are 
significant differences in the binding site residues, especially near the S2 pocket of these 
enzymes. For instance, sequence comparison (Figure 2.3.2) suggested Ser149 in the S2 pocket of 
FPs is replaced by Ala in human orthologues. Ser149A mutation in FP-2 was reported to 
decrease the proteolytic activity by 91% 
48
 and, can be targeted for design of selective protozoal 
cysteine protease inhibitors. In addition, Ile85 of the S2 pocket of FP-2 and FP-3 is replaced by 
methionine in cathepsin K and L and, proline in cathepsin B. Moreover, the polar residues such 
as Asp234 and Glu243 in the S2 pocket of the FP-2 and FP-3 binding sites, respectively are 
replaced by hydrophobic residues such as Leu and Ala in cathepsin K and L
228
. These differences 
between the proteases can be utilized for the design of selective inhibitors of FPs. To our 
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surprise, compound 4 did not show any inhibition up to 50 μM against the evaluated mammalian 
cysteine proteases. Further docking studies of 4 in the selected mammalian cysteine protease 
panel might provide valuable insights for the binding mode and selectivity of this compound in 
FP-2. 
Table 2.3.3. The IC50 values of FP-2 hits against selected human cathepsin peptidases 
Comp No. 
Cathepsin K 
IC50 (μM) 
Cathepsin L 
IC50 (μM) 
Cathepsin B 
IC50 (μM) 
1 
20.00 9.30 10.72 
2 
3.83 24.39 37.14 
3 
25.60 41.57 14.74 
4 
>50 >50 >50 
5 
26.70 5.86 49.08 
6 
29.66 16.52 21.44 
7 
6.12 31.63 17.66 
E-64 
0.004 0.016 0.007 
 
 
2.4.  Conclusions 
The focused cysteine protease inhibitor library consisting of ~65,000 compounds was screened 
against the X-ray crystal structure of FP-2. The attractive components of the virtual screening 
approach were the FCPI library based on soft-electrophiles of interest, the enrichment study to 
select the best scoring function, the docking pose-based pharmacophore query as a filter in the 
SBVS protocol, and, consideration of binding energy of the receptor-ligand complex for the 
selection of putative hits. The study reported a high success ratio with novel antimalarial 
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scaffolds. Twenty one compounds were active against FP-2 and four were also active against FP-
3. Two FP-2 hits, compound 5 and 6, showed corresponding inhibition of the cultured parasites, 
showing promise for further structural optimization. Moreover, the predicted site-specific 
electrophilicity, as measured by calculating the LUMO electron density of each atom in the form 
of the atomic Fukui Indices, suggested a soft-nature of the electrophiles present in identified hits. 
Thus, any potential risk of toxicity associated with the irreversible inhibition of the cysteine 
protease is attenuated. Assessment of the selectivity of identified hits against related mammalian 
cysteine proteases (cathepsin B, K and L) revealed compound 4 as a selective inhibitor of FP-2 
(IC50 > 50 μM against tested mammalian proteases). The hits obtained through the present 
screening efforts can be optimized via substructure/similarity search approaches to identify 
structural analogs of the active hits taking into consideration the key residues of the S2 pocket 
for the biochemical selectivity as discussed above. In addition, combinatorial library synthesis 
for selected hits (for example, compounds 2, 4, 6, 7) using commercially available building 
blocks can be pursued taking insights from the recently published co-crystallized structure of FP-
2
50
, for enhanced binding site occupancy and interaction profiles, to establish an SAR, and, will 
be addressed in follow up work.  
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Chapter 3 
 
 
 
 
 
Design, Synthesis and Biological Evaluation 
of Benzothiazole Analogs as Falcipain-2 
Inhibitors 
 
 
 
 
 
 
 
 
 
 
 
The content of this chapter is published in: Shah, F., Wu, Y., Jiri G., Pedurri, Y., Rosenthal, 
P., Avery M. A. Design, synthesis and biological evaluation of novel benzthiazole and triazole 
analogs as inhibitors of falcipain, cysteine protease of malaria parasite Plasmodium falciparum, 
MedChemComm, 2011 DOI: 10.1039/C1MD00129A 
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3.1. Introduction 
As discussed in previous chapters, most of the potent FP-2 inhibitors described in the 
literature were peptide analogs, displaying a covalent irreversible binding mode with the active 
site cysteine, and were relatively non-selective. It is highly desirable to develop non-peptidic, 
non-covalent inhibitors of FPs to minimize toxicity risk while retaining in vivo activity and 
selectivity.  In our previous study, we carried out the structure-based virtual screening (SBVS) of 
the FCPI library built based on soft-electrophiles against the X-ray structure of FP-2
229
. The 
study identified 21 diverse micromolar inhibitors of FP-2. In the present work, we initiated 
efforts to optimize the potency of lower micromolar FP-2 hit 1 with a benzothiazole core (Figure 
1). Compound 1 was selected for further optimization based on a) ease to synthesize 
combinatorial library around commercially available benzthiazole core and to establish an SAR 
and b) to test selectivity hypothesis of these series of compounds to FPs over other homologous 
mammalian cysteine proteases of the papain-family. The optimization of benzothiazole series 
was carried out with mutation of the benzothiazole core with other complementary groups 
followed by combinatorial library design and synthesis around the benzothiazole core. A total of 
23 analogs were made in this series and evaluated against the enzyme FP-2, FP-3 and for the 
activity against cultured P. falciparum parasites. Twelve compounds from the benzothiazole 
series showed moderate activity against FP-2. Two compounds from the benzothiazole series 
showed dual inhibition of FP-2 and FP-3. One particular compound from benzothiazole series 
showed corresponding inhibition of the cultured parasites. Docking of these inhibitors in the FP-
2 active site provided insights about SAR and interactions of the inhibitors with the active site of 
FP-2.  
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3.2. Optimization strategies: Core hopping, Structure-based design 
Core or scaffold hopping is a technique frequently used by medicinal chemists to discover 
novel compounds by mutating the molecule core or scaffold starting from known active 
molecules
230
. Core hopping gives medicinal chemists an opportunity to pursue drug design in a 
different chemical space to improve potency, to improve ADMET liabilities of a given scaffold, 
to circumvent intellectual property rights associated with a parent scaffold or to speed up the lead 
optimization process
230
.  
Our primary goal was to improve the potency of virtual screening hits 1. For the initial 
optimization of 1 with core-hoping strategy, we selected analogs which were commercially 
available, affordable and had an α-thioketone to act as a soft-electrophile prior to initiating 
extensive synthetic efforts. From the docking studies of 1, we envisioned that the replacement of 
the benzothiazole core with benzimidazole and thioacetamide moieties may improve the overall 
affinity of 1 by forming strong H-bond networks with the backbone Gly83 and Asn173. 
Therefore, our selection was limited to commercially available compounds (3-10) containing 
these cores with the goal of improving potency. While selecting compounds in these series, 
compounds with electron withdrawing groups para to the phenyl ring (for example, 3, 4, 7) were 
preferred to enhance the reactivity of the carbonyl carbon with the catalytic Cys42 of the FP-2 
active site.  It is worthwhile to mention that compounds 9 and 10 can be reasonably enolic and 
Figure 3.1.  Structures and biological 
activity of 1 against the cysteine 
proteases: FP-2 and FP-3, the 
chloroquine-resistant (W2) strain of P. 
falciparum, and the mammalian 
cysteine proteases cathepsins (Cat) K, 
L, and B are shown. 
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may predominantly behave as α, β-unsaturated ketones in the FP-2 active site. This enolic 
behavior is in equilibrium, thus availability of the carbonyl tautomer should not be 
problematical. Selected compounds were docked in the crystal structure of FP-2 using Glide 
extra precision (XP) mode and a previously validated docking protocol
229
. Although 
thioacetamide and benzimidazole compounds showed improved interaction profiles in the 
binding site (Figure 3.2.1), they were inactive against FP-2 at concentration up to 50 µM. These 
findings, although surprising, suggested the importance of the benzothiazole core for FP-2 
inhibition and prompted us to design a library around this core. 
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Figure 3.2.1. Docking pose of representative compounds from benzimidazole (3, Left) and 
thioacetamide (7, Right) series. 
 
From the docking pose of compound 1 shown in Figure 3.2.2, it was evident that 1 could be 
modified to better occupy the S1‟ and, S2 pockets of FP-2. For example, hydrophobic 
substituents can be placed on the 6-aminobenzothiazole scaffold to interact with hydrophobic 
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residues such as Ala235, Ile85 and Leu172 lining the border of the S2 pocket. Also, the flat S1‟ 
pocket of FP-2 is composed of hydrophobic residues such as Trp206 and Val152. Therefore, two 
regions of the benzothiazole core spanning the S1‟ and S2 sites were selected to perform 
chemical transformations and, thereby to develop SAR information. In addition, α-thioketones of 
1 were modified to α-thioesters and α-thioacetamide electrophiles to investigate the chemical 
reactivity of these electrophiles with the active site cysteine sulfur and determine its effects on 
FP-2 inhibition. Thus, two series were designed (Table 3.5.1). 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 3.2.2. (top) docking pose of compounds 1 in the FP-2 binding site; (bottom) core hopping 
of compound 1 and 2 with tetrazole and benzothiazole cores (highlighted in blue), respectively 
are shown. The tetrazole core of 1 was modified to triazole core to take an advantage of click 
chemistry. The benzothiazole core of 2 was modified to commercially available benzimidazole 
and thioacetamide core containing compounds (3-10) with anticipated gain in potency.  
 
The deep hydrophobic S2 pocket in FPs harbors polar residues such as Asp234 and, Ser149 
in FP-2 and Glu243 and, Ser158 in FP-3. Electrostatic interactions of compounds with the polar 
residues of the S2 pocket might lead to an overall boost in potency. In addition, sequence 
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alignments of FPs with homologous mammalian protease of papain family (Figure 2.3.2) 
suggested that polar residues of the S2 pocket are replaced by hydrophobic residues in cathepsin 
K, and L and can be targeted to design selective inhibitors of FPs. Therefore, in the α-thioketones 
and α-thioacetamide series, compounds with protonated amino groups were designed 
(compounds 39-42) to exhibit ionic interactions with Asp234 of the S2 subsite. The preliminary 
docking studies suggested a preference for R over S isomers of designed compounds, and, hence, 
Boc-(D) phenyl glycine or Boc-(D) valine were used in the synthesis of 39-42.  
3.3. Synthetic Schemes. The synthetic strategies adopted to obtain various benzothiazole 
derivatives are highlighted in Schemes 1 and 2. Scheme 1 depicts condensation of appropriate α-
haloketones (12, 13), α-haloacetate (14), and α-haloamides (15) with the commercially available 
6-aminobenzothiazole-2-thione (11) in the presence of triethylamine to give respective S-
alkylated α-thioketones (16, 17), α-thioesters (18) or α-thioacetamide (19). In the next step of N-
acylation, intermediate 16-19 provided corresponding N-acylated derivatives 20-34 by treatment 
with various acid chlorides. Synthesis of designed analogs targeting polar residues of the S2 
pocket was accomplished as depicted in Scheme 2. Accordingly, compounds 17 and 19 were 
coupled with (D)-N-Boc phenyl glycine and (D)-N-Boc valine using standard 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide/ hydroxybenzotriazole (EDCI/HOBT) peptide coupling 
conditions and triethylamine as a base to yield Boc-protected compounds 35-38. Deprotection of 
Boc with 4 M HCl in 1, 4-dioxane provided the target compounds 39- 42 as HCl salts.  
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Scheme 3.1 
 
 
Scheme 3.2 
 
 
3.4. Biological Evaluation. The synthesized compounds were evaluated for inhibition of 
recombinant FP-2 and, FP-3 and, the in vitro growth of the chloroquine resistant W2 strain of P. 
falciparum according to previously described procedures
229
. The epoxysuccinate E-64 was used 
as a positive control for the enzyme assays whereas artemisinin and chloroquine were used as 
positive controls for testing against W2 strain of P. falciparum.  
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3.5. Results and Discussion 
The structure and biological evaluations of benzthiazole analogs are shown in Table 3.5.1. 
The SAR of compounds in this series is discussed below. 
In the benzothiazole series, compounds lacking R2 substituents (for example, compounds 16-
19) were devoid of activity against FP-2 (Table 3.5.1). A few analogs showed similar log order 
activity as that of parent compound 2, whereas others were inactive. Interestingly, no direct 
correlation was observed between the chemical reactivity of electrophiles such as α-thioketones 
(20-25, and 41, 42), α-thioesters (26-29) and α-thioacetamide (30-34, and 39, 40) towards Cys-
42 and inhibition of FP-2. Overall, the compounds with α-thioacetamide and α-thioketones 
electrophiles showed moderate activity against FP-2 compared to those possessing α-thioesters 
electrophiles. Moreover, compounds 41 and 42 with protonated amino groups were the only 
compounds from the benzothiazole series displaying dual inhibition of FP-2 and FP-3.  
Table 3.5. 1. Biological activity of benzothiazole analogs. 
 
 
 
 
 
 
Sr. 
No. 
R1 R2 
FP-2 
IC50 
(µM) 
Sr. 
No. 
R1 R2 
FP-2 
IC50 
(µM) 
16 
 
H >50 27 
 
 
>50 
17 
 
H >50 28 
 
 
>50 
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18 
 
H >50 29 
 
 
31.34 
19 
 
H >50 30 
  
24.33 
20 
 
 
11.14 31 
  
13.89 
21 
  
35.70 32 
  
13.96 
22 
  
>50 33 
  
16.48 
23 
  
13.18 34 
  
16.87 
24 
  
>50 39 
  
>50 
25 
  
43.25 40 
  
>50 
26 
 
 
>50 
≠
41 
 
 
12.22 
E-
64 
- - 0.05 
≠
42 
  
12.75 
≠ 
IC50 of compound 41 and 42 against FP-3 were 13.77 µM and 14.94 µM, respectively; 
compound 24 & 41 also inhibited the growth of W2 strain of P. falciparum with IC50 = 2.08 µM 
and 4.65 µM, respectively. IC50 of positive controls, artemisinin and chloroquine, against W2 
strain were 0.012 µM and 0.062 µM, respectively. 
Among the evaluated compounds, compound 24 and 41 showed activity against the W2 
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strain of P. falciparum. However, compound 24 was inactive against FP-2, suggesting action 
against targets other than FP-2. The majority of identified compounds specifically inhibited FP-2 
but not FP-3, which may account for their inability to block parasite development, as deletion of 
only FP-2 by gene knockout was not lethal to parasites
231
. Activity of compound 41 can be 
attributed to its dual inhibition against FP-2 and FP-3. However, compound 42 was not active up 
to 10 µM concentration in culture parasites, despite of having same log order of activity against 
FPs as 41. This suggests the obvious involvement of other physicochemical properties for 
inactivity of 42 in cultured parasites development such as the solubility, lipophilicity, polar-
surface area etc. 
To gain insight into the binding mode of test compounds, docking of compounds into the FP-
2 binding site using the Glide docking program was performed. Previously, we compared 
abilities of two scoring functions implemented in Glide: Gscore and Emodel, to enrich known 
FP-2 actives from decoys downloaded from the DUD database
229
. In our study, Emodel 
outperformed Gscore in retrieving actives from decoys and proved more appropriate for the 
apolar FP-2 binding site
229
. Thus, we applied our validated Glide XP protocol with an Emodel 
scoring function to rank order the analogs from both series. Here, the distance of the electrophilic 
carbonyl carbon present in the putative hits to the cysteine sulfur (typically <3.5 Å) was used as a 
measure of covalent adduct formation. Docking studies revealed some important trends which 
are discussed below.  
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Among the benzothiazole series, compounds with α-thioacetamide and α-thioketones 
electrophiles were ranked higher (Emodel scores from -61 to -84), whereas compounds with α-
thioesters showed Emodel scores of greater than -56, except compound 29 (Emodel score -61). 
This trend was consistent with the experimental affinity of compounds from the benzothiazole 
series. For example, most of the compounds from the α-thioesters were inactive up to 50 µM 
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Figure 3.5.1. Docking pose of 42 (a), 31 
(c) in FP-2 and 42 in FP-3 (b). 
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concentration, and, thus, ranked lower, except 29, which showed moderate activity (IC50 = 31.34 
µM) against FP-2. In addition, in α-thioesters containing compounds, the distance of reactive 
carbonyl carbon from the catalytic Cys 42 of the FP-2 active site was always >4.0Å. On the other 
hand, the majority of compounds in the α-thioacetamide series showed a similar log order of 
activity against FP-2, and they were always more active than corresponding α-thioesters. These 
observations suggest the predictive nature of the scoring scheme used here to separate actives 
from inactives in congeneric series of compounds. However, correlation of docking scores with 
activity was poor, perhaps due to similar log orders of activity for identified hits and the parent 
compound 2. In the benzothiazole series, bulkier R1 and R2 substituents affected the placement 
of the reactive carbonyl carbon in the vicinity of the catalytic Cys42 of the FP-2 active site. For 
example, compounds 24 and 25 with naphthalene in the S1‟ pocket and quinoline or substituted 
phenyl in the S2 pocket, showed modest or no activity against FP-2.  
The compounds with the α-thioacetamide electrophile (30-39) formed an additional H-bond 
with the Asn173 of FP-2, placing the reactive carbonyl carbon in an appropriate position for 
nucleophilic attack by Cys42. The docking pose of representative compound 31 from 
thioacetamide series is shown in Figure 3. The p-toluene moiety of 31 showed hydrophobic 
interactions with Tyr 206 of the S1‟ pocket. The thioacetamide linker exhibited interactions with 
key catalytic residues such as Cys 42 and Gln36 in addition to H-bond formation with Asn173. 
The anilinic –NH of 31 formed an H-bond with Asp234 of the S2 site.  
FP-2 and FP-3 share 65% sequence identity
50
. Both of these enzymes have a preference for 
substrate with a hydrophobic residue at the P2 position
203
. The major difference between these 
two enzymes is in their S2 pockets. The Asp234, Leu84 and Leu172 of the S2 pocket in FP-2 is 
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replaced by the bulkier Glu243, Tyr93 and Pro181 in FP-3, making the S2 pocket more narrow 
in FP-3
50
. These differences are likely major contributing factors for distinct biochemical 
specificity and ligand recognition among these two homologous hemoglobinases. In the present 
study, compounds 41 and 42 showed inhibition of FP-2 and FP-3. The binding modes of 41 in 
FP-2 and FP-3 explain their inhibition, as follows (Figure 3.5.1). First, as expected, the 
protonated amino functionality of 41 forms charge-charge interactions with Asp234 and Glu243 
in the S2 pockets of FP-2 and FP-3, respectively. Second, the isopropyl side chain of 41 forms 
van der Waals interactions with Leu172 in FP-2 and Pro181 in FP-3. Third, the thiazole nitrogen 
of 41 interacts with the main chains of glycine residue (Gly83 in FP-2 and Gly92 in FP-3) that is 
highly conserved in papain-like family of cysteine proteases and considered important for 
inhibition of these enzymes. Fourth, the carbonyl carbon of α-thioketone linker interacts with the 
residues of an oxyanion hole formed by the backbone of Cys42 and side chain of Gln36. Finally, 
the naphthalene moiety exhibits van der Waals interactions with Tyr206 and Val152 in S1‟ 
pocket of FP-2 and Tyr215 and Ala161 in S1‟ pocket of FP-3. Collectively, the above interaction 
profiles of 41 contribute to its activity against both parasitic cysteine proteases. 
Next, we screened compound 41 and 42 with protonated amino group against selected human 
papain-family of cysteine proteases, cathepsins K, L1 and B (Table 3.5.2). Although, cathepsins 
K and L1 lack corresponding polar residues in the S2 pocket (Leu in Cat K and Ala in Cat L1, 
see Figure 2.3.2 in Chapter 2) as present in FPs (Asp in FP-2, Glu in FP-3), compound 41 and 42 
also inhibited these enzymes, whereas both compounds were inactive against cathepsin B having 
polar glutamate residue at the same position. These suggest the polar residues of S2 pocket, 
although important for improving potency, may not be crucial for design of selective inhibitors 
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against falcipains.  
 
Table 3.5.2. The IC50 values of FP-2 hits against selected human cathepsin (Cat) peptidases, K, 
L1 and B. 
 
Compound  
No. 
Cat K 
IC50 (µM) 
Cat L1 
IC50 (µM) 
Cat B 
IC50 (µM) 
41 14.52 5.87 >50 
42 5.62 4.39 >50 
E-64 0.004 0.016 0.005 
 
The compounds reported in this study are ketone-based inhibitors and are likely to bind in a 
covalent but reversible fashion with the active site cysteine. However, extensive efforts would be 
required to actually prove that these compounds undergo covalent adduct formation with the 
catalytic cysteine moiety. The proposed mechanism of action of these compounds (shown in 
Figure 4) which involves formation of a tetrahedral intermediate (hemithioacetal) after 
nucleophilic attack by the catalytic cysteine (stabilized by the Gln 36, Cys42 residues of the 
oxyanion hole) is supported by SAR and recent studies by Ellman and co-workers
232, 233
. 
 
Figure 3.5.2. The proposed mechanisms of action for the α-thioketone soft-electrophiles 
containing compounds.  
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3.6. Conclusions 
The present study reports novel, non-peptidic active analogs of the benzothiazole and triazole 
series. Fifteen compounds showed moderate activity against FP-2 and, three were also active 
against FP-3. In the benzothiazole series, compounds 41 and 42, with protonated amines 
inhibited both hemoglobinases. However, these compounds also displayed activity against 
homologous mammalian cysteine proteases lacking corresponding polar residues (Asp 234 in 
FP-2 and Glu243 in FP-3), suggesting less significance of these residues in the design of 
selective inhibitors against FPs. The relative inactivity of synthesized analogs against FP-3 and 
cultured P. falciparum needs to be addressed in the subsequent lead optimization process. 
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Chapter 4 
 
 
 
 
 
 
 
 
Analogs of FP-2 Hits: Virtual Screening, 
Structure-Activity Relationships, Solvent 
Thermodynamics and Reactivity Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Content of this chapter is submitted for publication: Shah
 
F., Jiri G., Legac, J., Shivakumar, 
D., Sherman W., Rosenthal, P., Avery M. A. Computer-Aided Drug Design of Falcipain 
Inhibitors: Virtual Screening, Structure-Activity Relationships, Solvent Thermodynamics and 
Reactivity Analysis.  
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4.1. Introduction 
Previously, we reported 21 diverse low-micromolar non-peptidic hits against FP-2, originating 
from novel scaffolds
229
. Compound 2 with a tetrazole scaffold was identified as a selective 
inhibitor of FP-2. In the first part of our current study, we describe efforts to explore the chemical 
space around the core group of virtual screening hits 1-3 with low-micromolar affinity to FP-2 
(Figure 4.1). A combined ligand- and structure-based virtual screening approach was adopted 
that involved mining of compounds bearing substructures of 1-3 from the Asinex and 
Chembridge databases, followed by docking of putative hits into the active site of FP-2. A 
number of active analogs were identified, some of which also showed activity against FP-3 and 
against development of cultured P. falciparum. Most of the active analogs showed the same order 
of potency as the parent compounds. However, the resulting SAR in these congeneric series of 
compounds was complex and could not be deciphered by only considering the steric, 
electrostatic, or van der Waals interactions of inhibitors in the protein active site. Therefore, the 
second part of this work considers additional factors involved in the binding process, such as the 
displacement of explicit water molecules and changes in the reactivity of electrophiles based on 
different chemical substitutions.  
The solvent thermodynamics of FP-2 and FP-3 ligand binding domain were computed using the 
recently published method referred to as WaterMap
234, 235
. WaterMap predicts the location and 
thermodynamic properties of the active site solvent using a combination of explicit solvent 
molecular dynamics, spatial clustering, and inhomogeneous solvation theory. The result of this 
procedure is a map containing water locations, occupancy, and determinations of whether the 
water clusters (referred to as “hydration sites”) are favorable or unfavorable in the binding site 
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relative to bulk solvent. WaterMap has been successfully applied to number of targets in a variety 
of contexts, such as assessing binding affinity of potent inhibitors
236, 237
, understanding the SAR 
in congeneric series of compounds,
238, 239
 and investigating selectivity of compounds within gene 
family targets such as kinases
240
. Recently, the method was used to rationalize accurate 
isothermal titration calorimetry data showing that the addition of lipophilic groups to a ligand 
resulted in increased potency that was gained via enthalpy from released water molecules, rather 
than the more traditional view that entropy gain from released water is the only driver of the 
hydrophobic effect.
241
  
The water displacement patterns of FP-2 and FP-3 inhibitors aided in our understanding of key 
experimental observations of known FP-2 inhibitors, perplexing trends in the SAR of identified 
hits. However, the relatively modest affinity of some inhibitors (also displacing unstable 
hydration sites from FP-2 LBD in a few cases) was not evident from the WaterMap analysis 
alone. We hypothesized that poor reactivity of soft-electrophiles were responsible for the low 
affinity of some inhibitors towards FP-2. To further support our hypothesis, virtual screening of a 
small compound library enriched in diverse aryl and aliphatic nitriles with a moderate reactivity 
profile (based on the reactivity index of nitrile-containing compounds proposed by Obella et 
al.
242
) was carried out against FP-2. The biological results showed good agreement between 
chemical reactivity and the inhibitory potency of these compounds against FP-2.  
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Figure 4.1. FP-2 inhibitors identified by structure-based virtual screening of the Focused 
Cysteine Protease Inhibitor library (IC50<10 µM). W2 stands for the chloroquine resistant strain 
of P. falciparum parasites. Cathepsin (Cat) K, L and B are human cysteine proteases of the 
papain-family. α-heteroacetamide soft-electrophile is highlighted in blue. 
 
4.2. METHODS 
 
4.2.1. Virtual Screening. The protocol used for virtual screening is shown in Figure 4.2. The 
substructure search on the highlighted query atoms for compounds 1-3 was conducted in the 
Chembridge (http://www.hit2lead.com) and Asinex (http://www. asinex.com) 2009 collections 
using the built-in substructure search utilities of these databases. The substructure hits were 
prepared for docking using the LigPrep program (Schrodinger LLC, NY). Approximately 1500 
compounds matching sub-graphs of 1-3 were subjected to docking using our previously validated 
Glide XP protocol
229
. The top 20% (~300) compounds were selected based on the top Emodel 
score. Docking poses were visually inspected for the following criteria prior to submitting them 
for biological evaluation: (a) placement of a soft-electrophile within 3.5 Å of the sulfur atom of 
the catalytic cysteine; (b) formation of key hydrogen bonds and hydrophobic interactions by 
ligand atoms with the key residues of the FP-2 active site such as Gly82, Gly83, Cys42, and 
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Gln36; (c) energetically reasonable ligand geometry without obvious strain; and (d) commercial 
availability and diversity of putative hits. Based on these criteria, 65 analogs with diverse R1-R3 
groups were purchased for analysis.  
Virtual Screening Workflow
Chembridge, Asinex
2009 collection
~1500
Docking:3BPF
Glide XP, Emodel, 
Top 20%
69
Visual 
Inspection
~300
28  FP-2 hits
Biological 
Evaluation
Substructure Queries
 
Figure 4.2. Virtual screening workflow to find hits related to compounds 1-3. Substructure 
queries for 1-3 are shown in blue. 
 
An additional substructure search was performed for compounds with aliphatic or aromatic 
nitriles, followed by a similar virtual screening protocol to that shown in Figure 2. Compounds 
with a match to the query “CC#N” (i.e. carbon connected to carbon connected to nitrogen via a 
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triple bond) were retrieved from the Chembridge database (2009 collection). The matching set of 
~5000 compounds was then docked into the FP-2 binding site. The top 10% (~500) of 
compounds was visually inspected for the criteria described in the preceding paragraph. Finally, 
a total of 14 compounds with aliphatic or aromatic nitriles were prioritized for biological 
evaluation based on two criteria a) compound should have similar interactions in the binding site 
as predicted for pyrimidine nitrile compounds, a potent class of FP inhibitors
183
 and b) they 
should displace the key unstable hydration sites from the FP-2 LBD  
4.2.2. Biological Evaluation. The prioritized hits were evaluated against FP-2, FP-3, and 
cultured W2 strain (chloroquine-resistant) P. falciparum. A selected set of compounds was also 
evaluated against mammalian cysteine proteases cathepsin K (Cat K), cathepsin B (Cat B), and 
cathepsin L1 (Cat L1). These biological assays were conducted using the same protocols as 
described previously
229
. 
4.3.3. Thermodynamic Characterization of Waters in the Binding Site. WaterMap predicts 
the location of water molecules around a protein and provides a quantitative estimation of 
enthalpy (∆H), entropy (-T∆S), and free energy (∆G) associated with the waters234, 235. The 
approach combines explicit solvent molecular dynamics, solvent clustering, and statistical 
thermodynamics. In short, a grand canonical Monte Carlo simulation is run to obtain the initial 
placement of the waters, followed by a series of equilibration stages and a 2.0 ns production run 
of explicit solvent molecular dynamics. The protein is constrained in the simulations, allowing 
for convergence in the sampling of water configurations around the protein conformation of 
interest. The waters from approximately 2000 equally spaced frames are clustered to determine 
regions of high solvent density, termed “hydration sites”234. The entropy for each hydration site is 
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computed using inhomogeneous solvation theory.
243, 244
 The enthalpy of each hydration site is 
calculated using the non-bonded molecular mechanics interaction energy with the OPLS_2005 
force field.
245
 These energy terms are calculated relative to a hydration site in bulk water. 
WaterMap profiles were generated for FP-2 in complex with an epoxy succinate  (E-64) 
inhibitor (3BPF, PDB code)
50
 and for FP-3 in complex with a vinyl sulfone (VS) inhibitor 
(3BWK, PDB code)
216
. Proteins were prepared using the Protein Preparation Wizard in Maestro 
(Schrodinger, LLC, Portland, OR). The protonation states of the catalytic His174 in FP-2 and 
His183 in FP-3 were adjusted to HIE (histidine with hydrogen on the epsilon nitrogen). Finally, 
the proteins were minimized with a harmonic potential restraint as implemented in the Impref 
module from Impact to prepare the final systems for the WaterMap calculations. All waters 
within 5 Å of the co-crystallized inhibitor were considered for the WaterMap calculations.  
4.3. Result and Discussion 
 
The work presented here was initiated to establish structure-activity relationships (SAR) 
around the active core of compounds 1-3 (Figure 4.1). The combined sub-structure search and 
rigid-receptor docking identified 28 active analogs of 1-3. The activity of these compounds 
against FP-2, FP-3, and cultured parasites is shown in Table 1. The SAR in each series is 
discussed below.  
4.3.1. SAR in 1, 2, 3, 4-tetrazole series. In the tetrazole series, linear compounds showed greater 
inhibitory activity against FP-2 as compared to the branched compounds. For example, 
compounds with R3 substitutions showed either a decrease (8, 9, and 11) in activity or no activity 
(12), whereas compounds with R2 substitutions (4-6) showed moderate inhibition of FP-2 (Figure 
3 and Table 1). In addition, compounds lacking R2 substitutions (13) or containing smaller R2 
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groups (14) were inactive. This trend was consistent with the SAR of compounds in this series 
recently reported by us using the combinatorial library synthesis approach
246
. Compounds 1, 4 
and 9, with heteroaromatic moieties at R1, seem to be well tolerated in the S1-S1‟ pocket, 
possibly because of additional interactions with residues of an oxyanion hole, such as Gln36 and 
Cys 42 in FP-2 (Figure 4.3.8). Although linear compounds such as 1 and 4 showed decent 
potency against both falcipains, they also appeared to inhibit the mammalian cysteine proteases 
cathepsin B, K, and L1, and were non-selective (Table 4.3.4). In addition, none of the compounds 
in this series showed activity against cultured parasites at concentrations up to 10 µM (Table 
4.3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.1. Chemical structures of compounds with 1, 2, 3, 4-tetrazole core. Original subgraph 
is highlighted in blue. 
 
 
 
Table 4.3.1. Biological evaluation of analogs of virtual screening hit 1 with 1, 2, 3, 4-tetrazole 
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core 
Compound 
Code  
FP-2 
IC50 
(μM) 
FP-3 
IC50 
(μM) 
W2 
IC50 
(μM) 
Compound 
Code 
FP-2 
IC50 
(μM) 
FP-3 
IC50 
(μM) 
W2 
IC50 
(μM) 
4 6.67 19.4 >10 11 38.13 >50 >10 
5 11.35 43.9 >10 12 38.13 >50 >10 
6 19.15 >50 >10 13 38.13 >50 >10 
7 31.46 >50 >10 14 38.13 >50 >10 
8 33.04 >50 >10 E-64 0.03 0.16 NT 
9 35.92 >50 >10 Artemisinin - - 0.092 
10 37.81 >50 >10     
              NT= not tested, W2= chloroquine-resistant strain of P. falciparum 
4.3.2. SAR in 1, 2, 4-triazole series. Substituents at R1 and R2 had greater impact on the activity 
in the 1, 2, 4-triazole series. For example, compounds lacking R2 substituents (27-34) or with 
shorter R2 substituents (35-38) were inactive (Figure 4.3.3). The majority of the active analogs 
had phenyl at the R2 position. Compounds 43-48, with substitutions on the R2-phenyl moiety, 
were not tolerated either (Figure 4.3.3). At the R1 position, the amino-substituted compounds 
(forming thioacetamide) were well tolerated (Figure 4.3.2 & Table 4.3.2). Analogs with the fused 
nitrogen heterocycles (40-45) or lacking polar -NH (49, 50) at that position were inactive. This 
could be due to lack of ability of these compounds to form an H-bond with Asn173 (Figure 
4.3.9c). 
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Figure 4.3.2. Chemical structures of compounds with 1, 2, 4-triazole core. Original subgraph is 
highlighted in blue. 
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Figure 4.3.3. Inactive compounds in 1, 2, 4-triazole series 
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Table 4.3.2. Biological evaluation of analogs of virtual screening hit 2 with 1, 2, 4-triazole core 
 
Compound 
Code  
FP-2 
IC50 
(μM) 
FP-3 
IC50 
(μM) 
W2 
IC50 
(μM) 
Compound 
Code 
FP-2 
IC50 
(μM) 
FP-3 
IC50 
(μM) 
W2 
IC50 
(μM) 
15 15.32 >50 1.61   34 >50 >50 NT 
16 18.61 >50 5.91  35 >50 >50 NT 
 17  20.66 >50 NT  36 >50 >50 NT 
18 23.21 >50 6.42  37 >50 >50 NT 
19 26.45 >50 1.91 38 >50 >50 NT 
20 27.43 >50 4.65 39 >50 >50 NT 
  21 28.61 31.33 NT 40 >50 >50 NT 
22 29.40 >50 8.91 41 >50 >50 NT 
  23 36.95 >50 NT 42 >50 >50 NT 
  24 >50 >50 NT 43 >50 >50 NT 
  25 >50 >50 NT 44 >50 >50 NT 
  26 >50 >50 NT 45 >50 >50 NT 
  27 >50 >50 NT 46 >50 >50 NT 
  28 >50 >50 NT 47 >50 >50 NT 
  29 >50 >50 NT 48 >50 >50 NT 
  30 >50 >50 NT 49 >50 >50 NT 
  31 >50 >50 NT 50 >50 >50 NT 
  32 >50 >50 NT E-64 0.03 0.16 NT 
  33 >50 >50 NT Artemisinin NT NT 0.092 
             NT= not tested, W2= chloroquine-resistant strain of P. falciparum 
Substitution at R3 seemed to be crucial for modulating selectivity against FP-2 for this 
series of compounds. From the multiple sequence alignment of falcipains and other homologous 
mammalian cysteine proteases of the papain family (cathepsin B, K, and L) it was evident that 
the composition of the S2 and S3 pocket differs critically in these cysteine proteases
229, 246
. More 
importantly, the gate-keeper Leu at the entrance of the S3 pocket in FP-2 and in cathepsin L is 
substituted by the bulkier Tyr in FP-3, Cat K, and Cat B. To further understand the selectivity of 
2 against FP-2, preliminary docking studies were carried out in FP-2 and the cathepsins (Figure 
4.3.4). As anticipated, the R3 methyl phenyl group of 2 was aptly placed in the S3 pocket of FP-2 
and Cat L, whereas this moiety was directed into the S2 pocket in FP-3, Cat K, and Cat B, 
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leading to unfavorable placement of 2 (Figure 4.3.5). This might explain the exclusive selectivity 
of 2 for FP-2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.4. The proposed binding mode of 2 in a) FP-2; b) FP-3; c) Cat K; d) Cat L1 and e) Cat 
B. 
 
To further analyze the effects of R3 substituents on FP-3 selectivity, we evaluated selected 
active compounds from this series against FP-3 and cathepsins B, K, and L1 (Figure 4.3.5). As 
expected, compounds with smaller R3 substituents (e.g. pyridine in compound 21) tended to be 
non-selective, showing activity against all the cysteine proteases (except Cat B). As the length of 
R3 substituents increased, activity against FP-3, Cat K, and Cat B decreased, probably due to 
steric clash with Tyr at the entrance of the S3 pocket (for example, compounds 17, 19, and 2). 
Interestingly, compounds with more flexible R3 substituents (16 and 18) showed activity against 
FP-2 as well as cathepsins, probably due to the abilities of flexible R3 substituents to enter into 
a. b. c. 
d. e. 
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the S3 pocket. Most of the active compounds from this series were also active against cultured 
parasites, with an IC50 of <10 μM. Moreover, a few compounds from this series, although 
inactive against FP-2, were active against the cultured parasites, suggesting involvement of other 
targets in addition to FP-2 for the mode of action of these compounds (Table 4.3.4). 
 
 
 
Figure 4.3.5. Effect of R3 substituents of 1, 2, 4-triazole series on selectivity to FPs and 
homologous mammalian cysteine proteases of the papain family: Cat K, Cat L1, and Cat B. 
 
4.3.3. SAR in quinazoline series 
 
In the quinazoline series, activity was retained when aliphatic (t-butyl, isopropyl) or aryl 
(phenyl) substituents at the R3 position were directly attached to the quinazoline core (e.g. 
compounds 52-54). Alicyclic substitutions such as alkyl cyclopentane resulted in diminished 
activity (for example, compound 59) or no activity (compounds 60, 61, Figure 4.3.6, Table 4.3.3) 
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against FP-2. Substitutions on the quinazoline core at the R2 position resulted in decreased 
activity (compound 58) or inactive analogs (compound 62), probably due to the steric clash in the 
narrow S2 pocket of FP-2. At the R1 position, there was preference for ampiphilic aryl groups 
such as 1, 2, 5-oxadiazole (3), thiazole (52, 55), 1, 3, 4-thiadiazole (53), isoxzaole (56, 59), and 
furan (57). Also, the heterocyclic moiety with three heteroatoms (3, 53) at R1 was more potent 
than a two (52, 55, 56) or single (57) heteroatom containing ring. Substitutions at R1 either with 
only hydrophobic groups, such as compounds 63 and 64 or polar groups at R1 (such as compound 
65), were found to be inactive. From the docking studies, it was suggested that these heterocycles 
exhibit hydrogen bonding interactions with the side chains of Gln 36 and Trp 206 in addition to 
hydrophobic interactions with Tyr206 (Figure 4.3.10a). The inactivity of 66 versus 54 might be 
explained by unfavorable placement of carboxylic acid in the S1‟ pocket, which is composed 
predominantly of hydrophobic residues, whereas the inactivity of 67-69 is not clearly understood 
based on visual inspection of the interactions.  
Among the active analogs, compound 54 showed an IC50 value of 8.5 μM against FP-2 
and was also active against cultured parasites (W2 IC50 = 6 µM). Compound 54 moderately 
inhibited Cat K (IC50 = 39.2 µM) and Cat L (IC50 = 14.6 µM) and was inactive against Cat B at 
concentration up to 50 µM. In addition, as reported previously by our laboratory
19
, compound 54 
was a low-micromolar inhibitor of SARS severe acute respiratory syndrome 3CL
pro
 (IC50 of 5.8 
μM), which is the main protease of SARS, playing an important role in viral replication 247. To 
the best of our knowledge, 54 is the first common inhibitor of malarial (protozoal) and SARS 
(viral) cysteine proteases reported to date. The discovery of 54 holds merit as these two cysteine 
proteases are quite different from each other, in terms of their protease family (FP-2 is a member 
of the papain-like family whereas SARS-3CL
pro
 is a chymotrypsin-like cysteine protease), and in 
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their active site geometry. 
 
Figure 4.3.6. Chemical structures of compounds from quinazoline core. Original subgraph is 
highlighted in blue. 
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Table 4.3.3. Biological evaluation of analogs of virtual screening hit 3 with quinazoline core 
 
Compound 
Code  
FP-2 
IC50 
(μM) 
FP-3 
IC50 
(μM) 
W2 
IC50 
(μM) 
Compound 
Code 
FP-2 
IC50 
(μM) 
FP-3 
IC50 
(μM) 
W2 
IC50 
(μM) 
52 4.64 >50 NT  62 >50 >50 NT 
53 5.93 >50 NT  63 >50 >50 NT 
54 8.57 >50 6.0  64 >50 >50 NT 
55 9.19 >50 NT  65 >50 >50 NT 
56 14.00 49.50 NT 66 >50 >50 NT 
57 15.81 >50 NT 67 >50 >50 NT 
58 18.82 >50 NT 68 >50 >50 NT 
59 >50 >50 NT 69 >50 >50 NT 
60 >50 >50 NT E-64 0.03 0.16 - 
61 >50 >50 NT Artemisinin - - 0.092 
 
Table 4.3.4. Evaluation of selected FP-2 hits against the mammalian cysteine proteases, 
cathepsins K, L1, and B  
 
 
Compound  
No. 
Cat K 
IC50 (µM) 
Cat L1 
IC50 (µM) 
Cat B 
IC50 (µM) 
4 4.22 3.12 10.07 
17 >50 12.80 >50 
18 40.74 49.05 >50 
19 >50 40.3 >50 
21 34.02 20.59 >50 
54 39.21 14.55 >50 
E-64 3.99 16.15 5.01 
  
Several trends in the SAR could not be understood from the molecular docking studies with 
FP-2. For example, the experimental SAR of identified hits was very sensitive for compounds 
with R2 substituents pointing towards the S2 pocket of FP-2, although no specific interactions in 
this pocket suggested such a significant change in potency. Also, there was a general preference 
for ampiphilic substituents in the S1-S1‟ pocket that could not be explained based on molecular 
interactions. Moreover, the identified analogs showed the same log order of activity, in spite of 
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enhanced interaction profiles, compared to the parent compounds 1-3 in the ligand binding 
domain of FPs. The steric and electrostatic interactions alone in addition to other terms of the 
Emodel scoring function (e.g. van der Waals, H-bond, lipophilic, ligand strain) were not 
sufficient to understand the steep SAR or moderate affinities of these compounds. Therefore, we 
anticipated a potentially important role of explicit solvent in the binding site and/or reactivity of 
the electrophiles in these compounds, both of which are generally not estimated by typical 
scoring functions.  
Water molecules in protein binding sites have unfavorable entropy compared with those in bulk 
solvent due to their restrained movement in the active site, with the amount of entropy loss 
related to the degree of translational and rotational restrition
234, 235
. They may have favorable or 
unfavorable enthalpy relative to bulk water, depending on the exact nature of the binding pocket 
and interaction with neighboring waters. Therefore, the thermodynamic properties of waters 
cannot be estimated by simple visual inspection. Accurately assessing the thermodynamics of 
water molecules is important for drug design, since displacement of high-energy water molecules 
from the protein binding site by complementary groups of ligands is considered to be a principle 
source of binding affinity
236
. A number of methods can account for solvation effects in the 
protein binding site, although many methods, such as MM-GBSA
248
 and MM-PBSA
249
, are 
based on continuum electrostatics and do not account for the explicit nature of water. One 
method that accounts for waters explicitly, WaterMap, uses a combination of explicit solvent MD 
simulation and statistical mechanics calculations to provide a quantitative description of 
enthalpy, entropy, and free energies of water molecules at the surface of proteins (see methods). 
From the design perspective, water molecules with positive values of ∆G should be displaced by 
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complementary groups of the ligand, with expected gains in binding affinity resulting from an 
increase in entropy when water is released into bulk solvent. Conversely, water molecules with 
negative enthalpy (∆H) should be considered carefully, as displacement will result in a loss of 
enthalpy. Therefore, such waters should be avoided, bridged, or judiciously displaced with polar 
groups to replace polar interactions of water molecules
236
. 
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Figure 4.3.7. The WaterMap profile of (a) FP-2, (b) FP-3, (c) FP-2 in complex with E-64, and 
(d) vinyl sulfone in complex with FP-3. The thermodynamically interesting hydration sites 
important for the SAR are shown in spheres. Stable hydration sites (ΔG < 0 kcal mol-1) are 
colored in green, whereas significantly unstable hydration sites (ΔG > 1 kcal mol-1) are shown in 
purple. The water sites are labeled based on decreasing values of predicted ΔG. Key hydrogen 
bonding interactions of inhibitors (shown in yellow) with the residues of FP binding sites (shown 
in grey) are displayed as dotted lines. 
The WaterMap profiles of FP-2 and FP-3 with and without co-crystallized inhibitors (E-64 in 
FP-2 and a vinyl sulfone inhibitor k11017 in FP-3) are shown in Figure 4.3.7a-d. The 
thermodynamic breakdown of predicted hydration sites are shown in Tables 4.3.5. and 4.3.6. The 
location and energetics values of waters in these homologous proteases are consistent. The 
solvent analysis identifies the triangle of enthalpically unstable waters (W1, W5, W12 in FP-2 
and W1, W5, W6 in FP-3), solvating the hydrophobic S2 pocket in both FPs. The hydration sites 
in the narrow hydrophobically enclosed region of the S2 pocket are enthalpically unfavorable 
126 
 
(positive ΔH), as they are unable to form a full complement of hydrogen bonds with protein 
residues (ΔG = >2.3 kcal mol-1 for all three in FP-2 and ΔG = >3.4 kcal mol-1 for all three in FP-
3).  
WaterMap predicts two unfavorable waters (W10 = 2.6 kcal mol
-1
 and W19 = 1.7 kcal mol
-1 
in 
FP-2; W2 = 4.22 kcal mol
-1
and W6 = 3.45 kcal mol
-1 
in FP-3) near Gly83 in FP-2 and Gly92 in 
FP-3. The interaction of a ligand with the conserved glycine near the entrance of the S3 pocket is 
considered essential for inhibitors of papain-family cysteine proteases binding to non-prime sites 
(S1-S3)
11, 50, 215
. Compounds lacking these predicted interactions were void of activity. When co-
crystallized inhibitors were mapped onto the generated WaterMap profile, they can be seen to 
selectively displace these unfavorable hydration sites.  For example, the shape of the P2-Leu of 
E-64 in FP-2 and of VS k11017 in FP-3 complements the arrangement of the unstable waters of 
the S2 pocket, expelling them to the solvent (Figure 4.3.7c and 4.3.7d). This result is consistent 
with the observation that FP-2 and FP-3 prefer substrates with leucine in the P2 position 
203, 250
 
and is consistent with previous findings with other targets that show strong preference for 
specific amino acids being driven by water displacement
251
. The amide carbonyl near the P2 side 
chain displaces the unfavorable water (W10 in FP-2, ΔG = 2.6 kcal mol-1; W2 in FP-3, ΔG = 4.2 
kcal mol
-1
) and replaces the H-bond with Gly83 in FP-2 and Gly92 in FP-3, thereby presumably 
imparting the observed gain in binding affinity.  
 
 
 
127 
 
 
 
 Water Site Occupancy ΔH -TΔS ΔG 
W1 0.68 2.55 2.01 4.56 
W2 0.51 2.73 1.78 4.51 
W3 0.79 0.63 3.03 3.66 
W4 0.59 1.67 1.86 3.53 
W5 0.40 2.22 1.27 3.49 
W6 0.86 0.42 2.8 3.22 
W7 0.81 0.13 2.83 2.96 
W8 0.46 1.32 1.55 2.87 
W9 0.97 -1.63 4.35 2.72 
W10 0.46 1.28 1.33 2.61 
W11 0.35 1.3 1.03 2.33 
W12 0.43 0.98 1.33 2.31 
W13 0.38 1.18 1.06 2.23 
W14 0.33 1.32 0.9 2.22 
W15 0.63 0.28 1.78 2.06 
W16 0.52 0.56 1.46 2.02 
W17 0.54 0.47 1.51 1.98 
W18 0.61 0.15 1.73 1.88 
W19 0.37 0.67 1.03 1.70 
W20 0.50 -0.09 1.43 1.34 
W21 0.47 -0.3 1.46 1.16 
W22 0.95 -2.25 3.36 1.11 
W23 0.50 -0.52 1.55 1.03 
W24 0.58 -3.88 1.94 -1.94 
W25 0.58 -4.10 1.97 -2.13 
W26 0.36 -3.95 1.19 -2.76 
Water Site Occupancy ΔH -TΔS ΔG 
W1 0.43 3.00 1.25 4.25 
W2 0.86 1.45 2.77 4.22 
W3 0.71 1.62 2.32 3.94 
W4 0.96 -0.09 3.91 3.82 
W5 0.91 2.50 1.10 3.60 
W6 0.45 2.21 1.24 3.45 
W7 0.42 2.30 1.15 3.45 
W8 0.37 2.27 1.14 3.41 
W9 0.84 -0.79 3.28 2.49 
W10 0.57 0.62 1.71 2.33 
W11 0.51 0.80 1.45 2.25 
W12 0.40 1.09 1.09 2.18 
W13 0.88 -0.93 2.98 2.05 
W14 0.29 0.98 0.84 1.82 
W15 0.39 0.45 1.13 1.58 
W16 0.43 0.15 1.29 1.44 
W17 0.44 0.19 1.24 1.43 
W18 0.40 0.28 1.14 1.42 
W19 0.31 0.47 0.83 1.30 
W20 0.52 -0.36 1.6 1.24 
W21 0.61 -2.55 1.89 -0.66 
W22 0.48 -2.28 1.37 -0.91 
  
WaterMap identifies unfavorable waters (W7, ΔG = 3.0 kcal mol-1 and W22, ΔG = 1.1 kcal 
mol
-1
 in FP-2; W4, ΔG = 3.8 kcal mol-1 and W16, ΔG = 1.4 kcal mol-1 in FP-3) in the S1 pocket 
near the residues of an oxyanion hole (Cys42/51 and Gln36/45). W7 in FP-2 and both unstable 
waters (W4 and W16) in FP-3 are displaced by corresponding atoms of the co-crystallized 
inhibitors. In addition, the guanidine moiety of E-64 and morpholine side chain of the vinyl 
sulfone inhibitor displaces several unfavorable hydration sites from the S3 pocket of FP-2 and 
FP-3, respectively. In addition, WaterMap predicts other unfavorable hydration sites near the S3 
Table 4.3.5. Predicted occupancy and thermodynamic 
properties of selected WaterMap waters in FP-2 
Table 4.3.6. Predicted occupancy and thermodynamic 
properties of selected WaterMap waters in FP-3 
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pocket (W2, W3 in FP-2 and W9, W11 in FP-3) and in the S1‟ pocket (W6, W8, W9, W11, W15, 
and W21 in FP-2; W3, W12, W15, and W20 in FP-3) that are out of the plane of these peptidic 
inhibitors. These sites could potentially be targeted, with anticipated gain in binding affinity, with 
a different ligand scaffold that is able to place functional groups to displace these waters. Finally, 
WaterMap predicts stable clusters of waters (W24-W26 in FP-2; and W21, W22 in FP-3, ΔG and 
ΔH < 0 kcal mol-1) in the vicinity of Asp234 and Ser149 of FP-2 and Glu243 and Ser158 of FP-3 
of the S2 pocket that can potentially be bridged for water-mediated hydrogen bonding to gain 
binding affinity. 
Mapping of the newly identified hits in this work on the WaterMap-generated thermodynamic 
hydration site profiles of FPs elucidated salient features of the SAR. For example, compound 4, a 
linear analog from the tetrazole series, has a complementary shape to the binding site of FPs and 
it displaces six unfavorable water molecules with ΔG > 2.0 kcal mol-1 of unfavorable hydration 
sites (Figure 4.3.8a and b). In particular, it displaces the unfavorable water W3 bound to Ile 85 in 
FP-2 (ΔG = 3.7 kcal mol-1) and W18 (ΔG = 1.9 kcal mol-1). Interestingly, compound 4 binds in a 
similar fashion to FP-3 and FP-2, but it did not displace the unfavorable water W9 (ΔG = 2.5 kcal 
mol
-1
) near Ile 95 of FP-3, potentially explaining the log difference in potency of 4 to FP-3 over 
FP-2. This difference in hydration site displacement is possibly due to the narrow S2 pocket of 
FP-3 (Glu243 in FP-3 versus Asp234 in FP-2, respectively), directing the methoxy phenyl moiety 
of 4 close to Pro181.  
Likewise, compounds 9 and 14 are unable to displace W3 and W18 from FP-2, and as a result, 
these compounds display either diminished activity or inactivity against FP-2 (Figure 4.3.8c and 
d). In FP-3 these compounds also miss key unfavorable hydration sites and hence are devoid of 
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activity. This may explain why linear compounds in the tetrazole series were more active than the 
branched compounds. The oxazole moiety of 4 and 9 displaces the unfavorable water (W22 in 
FP-2, ΔG= 1.1 kcal mol-1, W4 in FP-3, ΔG= 3.8 kcal mol-1) from the S1 pocket and forms an 
additional H-bond with Tyr 206, potentially explaining why heteroaromatic substituents were 
preferred in the S1‟ pocket. These interactions and water displacements profiles together likely 
contribute to the higher affinity of 1 and 4 for both falcipains compared to other analogs in the 
series. 
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Figure 4.3.8. The predicted binding poses and thermodynamic hydration site profile of 4 in 
complex with (a) FP-2 and (b) FP-3; the predicted binding poses and thermodynamic profile of 
(c) 9 and (d) 14 in complex with FP-2. Water site labeling and color codes are the same as shown 
in Figure 4.3.7. 
 
In the triazole series, compounds lacking R2 substituents (29) or with shorter R2 substituents 
(36) were unable to displace the hydrophobically enclosed unstable waters from the S2 pocket, 
and hence they are inactive (Figured 4.3.9c and 4.3.9d). Moreover, R2 substituents of this series 
projected differently than the P2-Leu of E-64. For example, compounds with a phenyl (16) or 
substituted phenyl (17) at R2 could not displace the least favorable hydration sites from the S2 
pocket, and hence they showed reduced affinity for FP-2 (Figures 4.3.9a and 4.3.99b).  
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Figure 4.3.9. The predicted binding poses and thermodynamic hydration site profile of (a) 16 (b) 
17; (c) 29 and (d) 36 in complex with FP-2. Water site labeling and color codes are the same as 
shown in Figure 4.3.7. 
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Compounds 3 and 57 from the quinazoline series with an oxazole moiety are predicted to 
displace the unfavorable waters (W7 and W22) from the S1-S1‟ pocket as well as form an H-
bond with the residues of the oxyanion hole such as Gln36, Cys42 and Tyr206 (Figure 4.3.10b). 
Compounds such as 32 and 38, lacking corresponding heteroaromatic substitutions or unable to 
displace the unfavorable waters of the S1‟ pocket, were inactive (Figure 4.3.10c). Compound 54 
additionally displaces the unfavorable waters (W8, ΔG = 2.9 kcal mol-1, W21, ΔG = 1.2 kcal mol-
1) from the S1‟ pocket. The quinazoline moiety of 54 displaces the unstable waters from the S2 
pocket (except the least favorable W1) as well as from the S3 pocket (W14, ΔG = 2.2 kcal mol-1 
and W16, ΔG = 2.0 kcal mol-1), which likely accounts for moderate affinity of this compound for 
FP-2.  
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Figure 4.3.10. The predicted binding poses and thermodynamic profiles of (a) 54 (b) 57 (c) 67 
and (d) 68 in complex with FP-2. Water site labeling and color codes are the same as shown in 
Figure 4.3.7. 
 
A few analogs with the ability to displace the high-energy waters of the S2 pocket, such as 
compound 68 from the quinazoline series (Figure 4.3.10d) or compound 30 (Figure 4.3.13d) 
from the triazole series, did not show additional gains in binding affinity. Also, none of the 
analogs of this series were more potent than compounds 1-3, suggesting that there was an 
additional factor reducing the binding affinity of these compounds. Based on prior work in our 
group, we reasoned that the soft-nature of electrophiles present in these hits could account for 
their moderate affinity against FPs. In our previous study
229
, we utilized the LUMO density 
variant of atomic Fukui indices to locate the most electrophilic center and to estimate the 
reactivity of electrophiles present in the virtual screening hits. The predicted LUMO density of α-
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hetero amide electrophiles were in the range of 0.02-0.32 (on the scale of zero to one, one being 
the most electrophilic), lower than the LUMO density of compounds containing hard 
electrophiles, such as α-fluoro ketone (0.52) or vinyl sulfone (0.43). In a similar reactivity 
analysis, Obella and co-workers assessed the reactivity of diverse nitrile containing compounds 
using DFT calculations
242
. Their method involved approximating the free energy of formation of 
thioimidate by calculating the difference between the energy of thioimidate adduct [E(Adduct)], 
the nitrile molecule [E(Nitrile compound)], and the precursor methanethiol [E(Methanethiol)]. 
The generated reactivity index was scaled from 0 to -10 kcal/mol. As anticipated, the 
heteroaromatic nitriles, in particular triazine and pyrimidine nitriles, were excellent electrophiles 
(predicted reactivity of -10 kcal mol
-1
), whereas the aliphatic and the aryl nitriles were predicted 
as poor electrophiles (0 to -2 kcal mol
-1
). Furthermore, the authors validated their findings by 
measuring the ability of representative aliphatic, aromatic, and heteroaromatic nitriles to form 
irreversible thiazoline adducts upon incubation with cysteine. The calculations showed that 
poorly electrophilic aryl nitriles (such as naphthalene or pyridine nitrile) have a reduced ability to 
form cysteine adducts, whereas more electrophilic pyrimidine nitriles or cyanamide have 
enhanced cysteine adduct formation. Their results showed excellent correlation between 
predicted reactivity and the ability to form irreversible cysteine adducts
242
.   
Recently, Coteron et al. published data for a 2-pyrimidinecarbonitrile series, showing sub-
nanomolar activity against FPs as well as cultured parasites.
183
 The representative compounds 
from this series are shown in Figure 4.3.11. As discussed above, the strong electrophile 
pyrimidine nitrile could be a major contributor in the high affinity of these compounds against 
FPs. This motivated us to further assess the importance of reactivity of electrophiles in the 
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inhibition of cysteine proteases by evaluating a subset of aliphatic or aryl nitriles (purchased from 
Chembridge Corporation) with moderate electrophilicity (as proposed by Obella et al.) against 
FP-2 (Figure 4.3.12). If reactivity of electrophiles plays an important role in the affinity of FP 
inhibitors, then these compounds were expected to show moderate or less binding affinity as 
compared to CN-1 to 3. 
 
 
Figure 4.3.11.  Potent inhibitors of FP-2, FP-3, and W2 from the 2-pyrimidinecarbonitrile series 
reported by Obella et al.
183
  
 
The identified hits 70-73, although having similar binding modes and water displacement 
profiles as CN-1 (Figure 4.3.13a-c), displayed moderate affinity towards FP-2 (IC50 = 10-20 
μM). In addition, out of fourteen compounds evaluated, only four compounds (70-73) were 
active against FP-2 (Figure 4.3.12). Our data clearly demonstrates that it can be difficult to 
achieve potent inhibition of FPs with compounds lacking reactive electrophilic centers. 
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Figure 4.3.12. Aryl- or aliphatic nitrile-containing compounds discovered by substructure search 
in the Chembridge database. Alkyl nitrile electrophiles are highlighted in blue. 
 
Table 4.3.5. Biological evaluation of analogs of virtual screening hit 3 with quinazoline core 
 
Compound 
Code 
FP-2 IC50 
(μM) 
FP-3 
IC50 
(μM) 
W2 
IC50 
(μM) 
Compound 
Code 
FP-2 
IC50 
(μM) 
FP-3 
IC50 
(μM) 
W2 
IC50 
(μM) 
 70  18.96 >50 7.89   78 >50 NT >10 
71 10.33 >50 5.92 79 >50 NT >10 
72 18.39 >50 >10 80 >50 NT >10 
73 11.21 >50 6.75 81 >50 NT >10 
 74 >50 NT >10   82 >50 NT >10 
75 >50 NT >10 83 >50 NT >10 
76 >50 NT 8.53 E-64 0.03 0.16 - 
77 >50 NT >10 Artemisinin - - 0.092 
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Figure 4.3.13. The predicted binding poses and thermodynamic hydration site profiles of (a) CN-
1 (b) CN-2; (c) CN-3, and (d) 30 in complex with FP-2. Water site labeling and color codes are 
identical to those shown in Figure 3. 
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4.4. Conclusions 
A combined ligand- and structure-based virtual screening was performed against the Asinex 
and Chembridge databases to discover non-peptidic inhibitors of FP-2. The core structures of 
previously discovered virtual screenings hits were used as a query to mine commercial databases 
for structural analogs. A total of 69 putative hits with diverse R-groups, prioritized based on 
docking calculations, were evaluated against FP-2. As a result, 28 compounds inhibited FP-2, 
with IC50s of 5-48 μM. Some of these compounds were also active against cultured malaria 
parasites, with IC50s <10 μM. 
The complex SAR of these congeneric series of compounds was difficult to explain using 
traditional computational descriptors like hydrogen bonds, van der Waals energy, electrostatic 
interactions, and ligand strain. However, we found that accounting for the thermodynamic 
characteristics of explicit solvent in the ligand binding domain of FP-2 and FP-3 provided an 
explanation for most of the SAR. The hydration site thermodynamics revealed multiple 
unfavorable hydration sites, most notably in the S2 pocket of FP-2 and FP-3. Modeling predicted 
that the leucine moiety at the P2 position of the co-crystallized inhibitors E-64 and vinyl sulfone 
k11017 in the S2 pockets of FP-2 and FP-3 complemented the arrangement of these 
hydrophobically enclosed waters and, as a result, displaced them from the S2 pocket of both FPs 
for increased binding affinity. This also reflected the preference for a P2-Leu as a recognition 
element for FP inhibition. The most potent hits generally displaced the least favorable hydration 
sites; however, a majority of the identified hits were unable to displace the least favorable water 
of the S2 pocket (in a similar pattern to leucine), which accounts for the moderate affinity 
observed for most of these compounds.  
In a few cases, displacement of the least favorable hydration sites did not correlate with the 
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binding affinity. This could be explained based on the poor reactivity of soft electrophiles toward 
the catalytic cysteine in these weak hits. We evaluated moderately electrophilic alkyl and aryl 
nitrile inhibitors against FP-2 to further highlight the effect of the reactivity on cysteine protease 
inhibition. The aryl and alkyl nitriles only showed moderate affinity (10-20 μM) towards FP-2 as 
opposed to compounds with strong electrophiles such as pyrimidine nitriles, which have sub-
nanomolar affinity.  
The present study highlights three important factors that appear to maximize inhibition of FP: 
a) strong hydrogen bond networks with the key residues of the FP-2 active site such as Gly83, 
Cys42, Gln36 and Asn173; b) displacement of unfavorable hydration sites (in particularly the 
triangle of unstable waters from the S2 pocket) by complementary groups of the ligands, and c) 
chemical reactivity of electrophiles to the catalytic cysteine of the active site. In general, 
computing binding energies is a complex process with many factors involved. The work 
presented here shows that terms that are often neglected from scoring functions (i.e. explicit 
water energies and chemical reactivity) can play an important role in binding. While the chemical 
reactivity of a ligand is likely to be most important in cases of covalent bond formation, as was 
the case for the FPs studied here, the hydration site thermodynamics are expected to be important 
in most ligand binding processes. More work is needed to develop a unified scoring function that 
can simultaneously account for all of these terms. 
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Chapter 5 
 
 
 
 
 
 
 
 
 
 
Understanding Binding Affinity of α-Keto 
Substituted Peptidomimetics for the Inhibition 
of Plasmodium falciparum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this chapter will be submitted for publication: Weldon, D., Shah
 
F., Chittiboyina, A., 
Jiri, G., Rosenthal, P., Shivakumar, D., Sherman W., Desai, P., Jung J. C., Avery M. A. Design, 
Synthesis, and Biological Results of α-Keto Substituted Peptidomimetics for the Inhibition of 
Plasmodium falciparum. 
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5.1. Introduction 
In our parallel efforts for drug discovery against FP-2, several peptidomimetics were designed 
and synthesized taking an advantage of a published crystal structure for cruzain, a related 
cysteine protease from Trypanosoma cruzi. Docking of compound 1 into a homology model of 
falcipain-2 developed in our laboratory
252
 
revealed that inhibitors of cruzain would be 
good templates for the design of inhibitors 
against falcipains. Therefore, a congeneric 
series of compounds utilizing 1 as a template 
were designed. The initial design 2 and its 
overlap with 1 are shown in blue in Figure 5.1.1. Of particular note, one of the phenylalanine 
residues in 1 has been replaced with a homophenylalanine in 2.  In addition, the other Cbz-
protected phenylalanine has been replaced with a Cbz-protected proline. These changes from 
natural to unnatural amino acids were incorporated to prevent peptidases from cleaving the 
compound, thereby increasing the compound half-life, and also to increase the rigidity of the 
falcipain inhibitor in order to improve its cell permeability. Docking studies of these compounds 
in a homology model of falcipain-2 suggested that they could closely mimic the binding modes 
of non-covalent inhibitor 1 and might form important hydrogen bonds, similar to those seen in 
the co-crystal structures of 1-like compounds in complex with cruzain
10
. Thirty-six 
peptidomimetics were designed and synthesized (Figure 5.1.2, compounds 15-50) in our 
laboratory considering the prime and non-prime substrate sites of falcipain-2 to elucidate the 
Figure 5.1.1. Overlap of cruzain inhibitor    
1 with design template 2. 
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SAR and evaluated for activity against falcipain-2, falcipain-3, and cultured malaria parasites 
(Table 5.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.1.2. Chemical structures of synthesized peptidomimetics 15-50. 
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Table 5.1. Activity of compounds 15-50 against Falcipain-2 (FP-2), Falcipain -3 (FP-3) and 
cultured malaria parasites. All values shown are IC50s in μM. 
 
Series
s 
Compoun
d 
FP-2 FP-3 
 
W2 
1 
15 112.22 357.06 >50 
16 48.13 149.01 13.77 
17 154.23 36.36 18.12 
18 >250 >250 >50 
19 72.81 5.43 21.57 
2 
20 235 >250 >50 
21 170 >250 >50 
22 192 >250 >50 
23 168 47.46 >50 
24 5.52 0.54 >50 
25 7.32 1.86 32 
26 4.42 0.91 47.6 
3 
27 33.74 5.88 >50 
28 61.64 20.18 >50 
29 80.71 23.90 >50 
30 >250 >250 
 
 
 
 
>50 
31 >250 >250 >50 
32 36.63 37.47 27.5 
33 >250,000 >250000 >50 
34 69.17 47.23 23.29 
35 33.86 73.98 >50 
36 3.25 8.22 28.16 
37 16.54 11.53 >50 
38 29.67 131.13 >50 
39 30.08 11.91 37.21 
40 87.23 >250 >50 
41 33.64 25.44 47.21 
4 
42 0.08 0.06 7.70 
43 1.10 0.52 19.64 
44 65.3 3.56 18.64 
45 232 223 10.16 
46 >250 >250 41.51 
47 >250 >250 19.48 
48 >250 >250 >50 
49 >250 >250 >50 
50 >250 >250 19.92 
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From the analysis of experimental SAR, it was evident that hydroxyl proline in the S2 pocket, 
an α-hydroxy ketone electrophile in the S1-S1‟ pocket, and homophenylalanine (hPhe) in the S1 
pocket were suitable substituents for high binding affinity peptidomimetics. Efforts to understand 
the SAR of this series by means of steric and electrostatic interactions derived from the docking 
calculations in falcipains did not provide useful insights. Van der Waals energy, electrostatics, 
hydrogen bonds, or DockingScore from Glide SP 
253, 254
 docking calculations did not reveal any 
correlation with experimental affinity. Furthermore, implicit solvent binding energy estimations 
from MM-GBSA (as implemented in the program Prime
255, 256
) did not show a significant 
correlation with experimental affinity. In light of the above findings, we anticipated the 
involvement of explicit water molecules in the binding of these inhibitors and therefore 
generated thermodynamic profiles of waters present in the LBD of falcipain-2 and falcipain-3 
using WaterMap. 
5.2. Methods 
5.2.1. WaterMap Calculations: Thermodynamic characterization of water molecules in the 
falcipain ligand binding domain were carried out with WaterMap, which computes the location 
and energetics of water molecules around protein using explicit solvent MD simulation, solvent 
clustering, and statistical thermodynamics.
234, 235
 In short, the simulation consists of an initial 
equilibration followed by 2 ns of production molecular dynamics. Water molecules from a 
collection of snapshots taken every 1.2 ps were clustered into “hydration sites”. The enthalpy of 
the waters within each hydration site was computed using the non-bonded interaction energy 
with the OPLS_2005 force field.
245
 The entropy was computed using a local expansion of the 
spatial and orientational correlation functions as described in inhomogeneous solvation theory
243, 
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244
. WaterMap has been effectively applied to a broad range of pharmaceutically relevant targets, 
including PDZ domains
251
, kinases
240
, G-protein coupled receptors (GPRCs)
239
, protein-protein 
interaction interfaces
257
, and serine proteases
238
. 
WaterMap analysis was carried out for falcipain-2 in complex with the epoxy succinate 
inhibitor E-64 (3BPF, PDB code)
50
 and with falcipain -3 in complex with the vinyl sulfone 
inhibitor k11017 (3BWK, PDB code)
216
. Structures were prepared using Protein Preparation 
Wizard of Maestro (Schrodinger, LLC, Portland, OR). Protonation states of catalytic His 174 in 
falcipain -2 and His 183 in falcipain -3 were adjusted to HIE (proton on the epsilon nitrogen). 
Finally, proteins were minimized with a harmonic positional restraint using the Impref module 
from Impact to prepare the final systems for the explicit MD simulation. All waters within 5 Å of 
the co-crystallized inhibitor were considered for the WaterMap calculations.   
5.2.2. Calculation of LUMO density using Atomic Fukui Indices. Quantum mechanics 
calculations were run to determine the effect of electronegative substituents on the reactivity of a 
series of compounds, with the aim of correlating the activation of a bond with the potential to 
gain binding potency through enhanced interactions. Atomic Fukui indices are regional 
descriptors of site-specific reactivity and can be used to predict which atoms in a molecule are 
most reactive toward electrophilic or nucleophilic attack by analyzing frontier molecular orbitals 
(FMOs).
210
  We used the program Jaguar
198
 to compute Atomic Fukui indices for several 
compounds in a similar manner as described in Chapter 2. The values were normalized on a scale 
from 0-1, with 1 being the most reactive.  
5.3. Results and Discussion 
WaterMap computes the location and thermodynamic properties (enthalpy, entropy, and free 
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energy) of water clusters (“hydration sites”) using explicit solvent simulations.234, 235 WaterMap 
analysis was performed on the recently published crystal structures of falcipain-2 (3BPF, PDB 
code) and falcipain -3 (3BWK, PDB code) using default settings. The WaterMap calculations 
revealed several highly unstable water molecules in the binding domain of falcipains. The 
thermodynamic values of selected hydration sites in falcipain -2 and falcipain-3 as calculated by 
WaterMap are shown in Tables 5.3.1 and 5.3.2. 
Typically, water molecules with unfavorable free energy (ΔG > 1 kcal mol-1) should be 
displaced by ligand functional groups complementary to the protein active site to gain in the 
overall binding free energy through release of the water molecule into bulk solvent. Conversely, 
water molecules with negative free energy values should be considered as structural water 
molecules that can either be bridged or judiciously displaced with the polar atoms of ligands.
258
 
Waters with negative ΔG also have negative enthalpy (ΔH), because the entropy contribution (-
TΔS) is, by definition, always unfavorable for waters in the binding site relative to bulk solution. 
Given the above considerations, the emerging SAR trends of peptidomimetics from series 1-4 are 
explained here in the context of the most active compound 42.  
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Figure 5.3.1.The WaterMap profile of (a) FP-2 and (b) FP-3 LBD in complex with 42 is shown. 
The thermodynamically interesting hydration sites important for the SAR are shown in spheres. 
Stable hydration sites (ΔG <0 kcal mol-1) are colored in green, whereas significantly unstable 
hydration sites (ΔG >1 kcal mol-1) are shown in purple. The water sites are labeled based on 
decreasing values of predicted ΔG.  
 
The full thermodynamic profile of falcipain -2 and falcipain-3 LBD in complex with 42 are 
shown in Figure 5.3.1. The WaterMap hydration sites in falcipain -2 and falcipain-3 binding sites 
along with compound 42 are shown in Figure 5.3.2. The proline hydroxy group of 42 
successfully displaces the most unstable hydration site (W1, ΔG = 4.6 kcal mol-1 in falcipain -2; 
W1, ΔG = 4.3 kcal mol-1 in falcipain-3) in the S2 pocket of both falcipains and forms an 
additional H-bond with the backbone of His174/183 in the active site of the proteases. 
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Furthermore, the hydroxy proline moiety displaces two other unfavorable hydration sites (W5 
and W12 in falcipain -2; W5 and W6 in falcipain -3) with ΔG ≥ 2.3 kcal mol-1 from the S2 
pockets of both enzymes. The boost in the potency of 42, as compared to other analogs in this 
series, is mainly attributed to its proline hydroxyl substituent displacing highly unstable water 
sites of the S2 pocket. The inactivity of 15 and 23 (Figures 5.3.3a and 5.3.3b) from series 1 and 
2, respectively, can be explained by their inability to displace the unfavorable water sites of the 
S2 pocket.  Compound 42 also displaces W10 in falcipain -2 (ΔG = 2.6 kcal mol-1) and W2 in 
falcipain -3 (ΔG = 4.2 kcal mol-1), with the replacement of a critical hydrogen bond with Gly83, 
which is considered important for inhibitors of papain family cysteine proteases binding to the 
non-prime site
229
. Moderate activities of compound 24 (Figure 5.3.3c), 36  37, 39, and 41(not 
shown) are due to the formation of a strong H-bond network with Gly83 in addition to the 
displacement of a few unfavorable water sites (ΔG ≥ 2.3 kcal mol-1) of the S2 pocket of 
falcipain-2. The Cbz moiety of 42 also displaces several unfavorable water sites from the S3 
pocket of falcipains (W4, W14, W16 and W20 in falcipain -2; W7, W8, W17 and W18 in 
falcipain -3) into the solvent, and is a suitable substituent for the S3 subsite. 
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 Water Site Occupancy ΔH -TΔS ΔG 
W1 0.68 2.55 2.01 4.56 
W2 0.51 2.73 1.78 4.51 
W3 0.79 0.63 3.03 3.66 
W4 0.59 1.67 1.86 3.53 
W5 0.40 2.22 1.27 3.49 
W6 0.86 0.42 2.8 3.22 
W7 0.81 0.13 2.83 2.96 
W8 0.46 1.32 1.55 2.87 
W9 0.97 -1.63 4.35 2.72 
W10 0.46 1.28 1.33 2.61 
W11 0.35 1.3 1.03 2.33 
W12 0.43 0.98 1.33 2.31 
W13 0.38 1.18 1.06 2.23 
W14 0.33 1.32 0.9 2.22 
W15 0.63 0.28 1.78 2.06 
W16 0.52 0.56 1.46 2.02 
W17 0.54 0.47 1.51 1.98 
W18 0.61 0.15 1.73 1.88 
W19 0.37 0.67 1.03 1.70 
W20 0.50 -0.09 1.43 1.34 
W21 0.47 -0.3 1.46 1.16 
W22 0.95 -2.25 3.36 1.11 
W23 0.50 -0.52 1.55 1.03 
W24 0.58 -3.88 1.94 -1.94 
W25 0.58 -4.10 1.97 -2.13 
W26 0.36 -3.95 1.19 -2.76 
Water Site Occupancy ΔH -TΔS ΔG 
W1 0.43 3.00 1.25 4.25 
W2 0.86 1.45 2.77 4.22 
W3 0.71 1.62 2.32 3.94 
W4 0.96 -0.09 3.91 3.82 
W5 0.91 2.50 1.10 3.60 
W6 0.45 2.21 1.24 3.45 
W7 0.42 2.30 1.15 3.45 
W8 0.37 2.27 1.14 3.41 
W9 0.84 -0.79 3.28 2.49 
W10 0.57 0.62 1.71 2.33 
W11 0.51 0.80 1.45 2.25 
W12 0.40 1.09 1.09 2.18 
W13 0.88 -0.93 2.98 2.05 
W14 0.29 0.98 0.84 1.82 
W15 0.39 0.45 1.13 1.58 
W16 0.43 0.15 1.29 1.44 
W17 0.44 0.19 1.24 1.43 
W18 0.40 0.28 1.14 1.42 
W19 0.31 0.47 0.83 1.30 
W20 0.52 -0.36 1.6 1.24 
W21 0.61 -2.55 1.89 -0.66 
W22 0.48 -2.28 1.37 -0.91 
 
 
Table 5.3.1. Predicted occupancy and thermodynamic 
properties of selected WaterMap waters in FP-2 
 Table 5.3.2.. Predicted occupancy and 
thermodynamic properties of selected WaterMap 
waters in FP-3 
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Figure 5.3.2. The WaterMap profile of 42 in (a) falcipain -2 and (b) falcipain -3 is shown. The 
thermodynamically interesting hydration sites important for SAR are shown in spheres. The 
unstable hydration sites (ΔG >1 kcal mol-1) are shown in purple. The water sites are labeled 
based on decreasing value of predicted ΔG. Key hydrogen bonding interactions of 42 (shown in 
yellow) with the residues of falcipain binding (shown in cyan) sites are displayed as dotted blue 
lines.    
 
The carbonyl moiety of the α-hydroxy ketone in 42 displaces the proximal unstable water (W7 in 
FP-2, ΔG = 3.0 kcal mol-1, W16 in FP-3, ΔG = 1.4 kcal mol-1) from the S1 pocket and replaces 
its H-bond interaction with the side chain of Gln36/45 and backbone of Cys42/51 in FP-2/3, 
respectively. The hydroxy group of the α-hydroxy ketone forms an H-bond with His 174/283 in 
FP-2/3. Additionally, the hydroxy ketone also stabilizes the unfavorable water molecule of the 
S1‟ pocket (W22 in FP-2 with ΔG = 1.1 kcal mol-1, W4 in FP-3, ΔG = 3.6 kcal mol-1) by forming 
a water-mediated H-bond with Trp (206/215) in both enzymes. However, WaterMap did not 
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provide any additional insights about the preference of α-hydroxy ketone in the S1-S1‟ pocket 
over other electrophiles. This might be expected, given that WaterMap only accounts for solvent 
displacement and not direct interactions made with the receptor. We anticipate that the reactivity 
of the carbonyl carbon in the vicinity of catalytic cysteine (42/51) with different α-substituents 
might play an important role in the activity of these compounds (discussed below).  
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Figure 5.3.3. The predicted binding poses and interesting hydration sites for (a) 15 (b) 23 (c) 24 
and (d) 49 in FP-2 are shown. Hydration sites labeling and color codes are same as shown in 
Figure 5.3.2. 
 
The HPhe in the S1 pocket displaces unfavorable water sites (W19 and W23 in FP-2; W14 and 
W19 in FP-3) in both enzymes. The replacement of HPhe with a phenyl moiety, a modification 
that was expected to reduce the flexibility of these peptidomimetics, resulted in the inactive 
analogs 47-50. As shown in Figure 5.3.3d, compound 49 is not able to displace unfavorable 
waters (W19 and W23 in FP-2) into the bulk of the solvent, as observed with HPhe in 42. In 
addition, the increased rigidity resulted in unfavorable placement of the α-hydroxy ketone 
electrophile near the catalytic cysteine in the S1-S1‟ pocket (Figure 5.3.3d). This observation is 
further supported by the inactivity of compound 47, with an α-chloro ketone electrophile, 
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anticipated to show higher reactivity with the catalytic cysteine.  
In addition, WaterMap predicts other unfavorable waters in the LBD of FPs that were not 
assessed in this work. For example, WaterMap predicts unstable water (W3 in FP-2 with ∆G = 
3.66 kcal mol
-1
; W9 in FP-3 with ∆G = 2.5 kcal mol-1) interacting with the backbone carbonyl of 
ILE 85/87 lining the S2 pocket of the proteases. W9 is also present in the X-ray structure of FP-
3
216
. Moreover, WaterMap shows a stable water (W24-W26 in FP-2 with ∆G = <-2 kcal mol-1; 
W21, W22 in FP-3 with ∆G = <-0.7 kcal mol-1) at the bottom of the S2 pocket forming an H-
bond with Asp234 in FP-2 and Glu243 in FP-3. These water sites can be either targeted 
(displacing unstable waters) or interacted with (water-mediated H-bonds) in future work to gain 
additional binding affinity.  
 To understand the reactivity of electrophiles with the catalytic cysteine residue and its effect 
on the inhibitory activity of 42-45, we calculated the LUMO variant of Atomic Fukui indices at 
constant spin density using the quantum mechanics package Jaguar, as described previously.
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The congeneric series of compounds 42-45 with different electrophilic groups were considered 
for these calculations. The LUMO variant of Fukui indices was considered for predicting 
electrophilicity of the carbonyl carbon. The predicted LUMO values were scaled from zero to 
one, one being the most reactive, and are shown in Table 2. 
The predicted reactivity of electrophiles was significantly higher for the compound with an α-
hydroxy ketone (42, LUMO = 0.52), than the compound with an α-thio ketone (43, LUMO = 
0.46; 44, LUMO = 0.26), which in turn had a higher electrophilicity than the α-amino ketone (45, 
LUMO = 0.01). The activity of 43 with the α-thio ketone might be due to its elongated alkyl 
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phenyl chain displacing unfavorable waters from the S1‟ pocket in FP-2 over 42. The calculated 
LUMO density values predict correct ordering of the inhibition of FPs for compounds 42-45.  
Table 5.3.3. Predicted LUMO density of the most electrophilic center (shown by asterisk *) in 
compound 42-45. 
 
Compound No. Electrophiles F_NN_LUMO values 
42 
 
0.52 
43 
 
0.46 
44 
 
0.26 
45 
 
0.01 
 
5.4. Conclusions 
WaterMap highlighted the putative role played by water molecules in the binding of 
peptidomimetics in falcipains and provided important insights about the SAR. In particular, 
WaterMap analysis explained the role played by the hydroxyproline moiety in the potency of 42 
based on the displacement of the most unstable predicted waters in the falcipain binding site and 
the reason a homophenylalanine (HPhe) binds significantly tighter than phenylalanine. 
Furthermore, the quantum mechanics calculations of Atomic Fukui indices correctly predicted 
the trend in electronegative substitution effects on potency. The information gained from 
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WaterMap analysis and Atomic Fukui indices can be used to design the next generation of 
inhibitors of falcipains. Specifically, we plan to synthesize compounds that are able to displace 
unstable hydration sites that were not displaced by the compounds presented in this work. This 
may require developing new chemical scaffolds, as some of the unstable hydration sites are not 
accessible with the R-group positions in the chemotypes studied here. Further design efforts 
against FPs will consider the reactivity of electrophiles in addition to the displacement of 
unfavorable waters, in particular from the S2 pocket of falcipain-2 and falcipain-3. 
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Chapter 6 
 
 
 
Understanding the Binding Affinity of 
Inhibitors of SARS-3CL
pro
 by Explicit 
Molecular Dynamic Simulation 
 
 
 
 
 
 
 
 
 
 
Content of this chapter is partly adapted from: Mukherjee, P., Shah, F., Desai, P., Avery M. 
A. SARS-3CLpro: Virtual Screening, Biological Evaluation and Molecular Dynamics 
Simulation Studies, Journal of Chemical Information and Modeling, 2011, 51 (6), 1376. 
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6.1. Introduction 
SARS-CoV (Severe acute respiratory syndrome-coronavirus) is a previously unidentified 
virus belonging to the coronaviridae family which has been recognized as the etiological agent 
for SARS, a highly infective upper respiratory tract disease. The disease was first diagnosed in 
the winter of 2002 amongst patients in the remote Guangdong province of southern China. This 
highly infectious disease with ~10% mortality rate, quickly reached pandemic status, spreading 
to over 37 countries worldwide and causing over ~9000 infections
96, 97, 260-262
. Although the 
initial outbreak of the virus was stymied about an year from its first discovery, recent findings on 
the isolation of the virus from animals including the Chinese horse shoe bats
263-265
 which act as 
natural reservoirs for this virus are suggestive of the possibility of a future animal to human 
transmission of the SARS-CoV or other closely related corona viruses in the near future. The 
imminent threat from this disease led to the discovery of a number of viral proteins
266
 which 
could be utilized as possible targets for the development of antiviral therapy. Among these 
targets, SARS-3CL
pro
, a cysteine protease indispensible to the viral life cycle, has been identified 
as one of the key therapeutic target against SARS.  Chapter 1 describes the detailed overview of 
SARS-3CL
pro
 functions and various classes of inhibitors developed so far. As a part of our 
efforts to discover inhibitors against SARS-3CL
pro
, we previously reported a cascading virtual 
screening study, involving similarity/substructure searching, docking and ranking based on 
docking pose based descriptors was carried out against the Asinex Platinum collection in our 
laboratory
19, 267
. As a result, numbers of lower micromolar inhibitors of SARS-3CL
pro
 were 
identified (Table 6.1), the structures of which are shown in Figure 7.1.1 and their docking pose in 
the binding site of SARS-3CLpro are shown in Figure 6.1. 2. 
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Figure 6.1.1. SARS-3CL
pro
 inhibitors identified by combined structure/ligand-based drug design 
approach. 
 
Table 6.1. Results from the SARS-3CL
pro
 enzyme inhibition assay 
 
 
The present efforts were initiated to understand the binding affinity of the identified hits 
and to highlight trends in the SAR of these compounds. Our aim was to incorporate the 
information gained from binding affinity analysis into future structure-based design of SARS-
3CL
pro
 inhibitors. Therefore, we carried out multi nanosecond explicit MD simulation of SARS-
3CL
pro
 in complex with PJ207, PJ224, PJ225, PJ316 to study the overall stability of the 
interaction profiles predicted from rigid docking studies as well as novel interactions that were 
not observed during the docking study. The studies revealed several novel interactions that can 
be considered for future structure-based drug design of SARS-3CL
pro
 inhibitors.  
 
ID %Inh (10 μM) 
SARS-3CL
pro
 IC50 
(μM) 
PJ207 25.03 39.4 
PJ224 44.93 15 
PJ225 61.26 5.8 
PJ316 55.69 10.3 
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  c)                                                                                            d) 
            a)                                                                                            b) 
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Figure 6.1.2. Interaction profile and surface representation of the poses of the identified hits 
(a)(b) PJ207, (c)(d) PJ224, (e)(f) PJ225 and (g)(h) PJ316. 
 
      g)                                                                                       h) 
                e)                                                                                        f) 
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6.2. Methods 
The docked ligand/SARS-3CL
pro
 complexes of the biological hits (Figure 6.1.2) were 
used to perform MD simulations with the parallelized Desmond Molecular Dynamics System 
v2.2 (D. E. Shaw Research, New York, NY) within the maestro environment. The model system 
for simulation was prepared using the „system builder‟, a graphics tool in maestro. The OPLS-
AA/2005 force field parameters were assigned for all the simulation systems. Each inhibitor-
enzyme complex was placed in the center of a cubic box with a dimension of 94.4 Å ensuring 10 
Å solvent buffers (~23,400 water molecules) between the solute and the boundary of simulation 
box in each direction. The SPC model was used to describe the water molecules. Na
+
 and Cl
-
 
ions were added at physiological concentration of 0.15 M to ensure the overall neutrality of the 
systems. Any solvent molecules that overlapped with the solute structures were removed. The 
final size of the solvated system was close to ~33,000 atoms. The crystallographic waters were 
retained as part of the simulation system. 
The model systems were relaxed using a six step default protocol implemented in 
Maestro, utilized to prepare systems for production-quality simulation. The relaxation protocol 
implemented in Maestro involved a series of minimizations followed by a series of short MD 
runs to relax the model systems. The solvated systems were first minimized for 10 steps of 
steepest-descent followed by the limited-memory Broyden-Fletcher-Goldfarb-Shanno (LBFGS) 
minimization over a maximum of 2000 steps, keeping all the protein and ligand atoms fixed. The 
convergence criterion and force constant on the solute was set to 50.0 kcal mol
-1
 Å
-1
. In the 
second step all positional restraints were removed and the system was minimized to a 
convergence criterion of 5 kcal mol
-1
 Å
-1 
using the same sequence as the last step. In the third 
169 
 
step, a 12 ps simulation was performed using the NVT ensemble using a Berendsen 
thermostat
268
, a temperature of 10K, a fast temperature relaxation constant of 0.1 ps, velocity 
rescaling at every 1 ps and restraints on all non-hydrogen solute atoms with a force constant of 
50.0 kcal mol
-1
 Å
-1
. Following these, two short simulations of 12 and 24 ps were performed 
using the NPT ensemble using a Berendsen barostat
268
, maintaining pressure at 1 atm and a slow 
pressure relaxation constant of 50 ps with all other parameters preserved from the previous NVT 
simulation. The restraint set from the third step was preserved through the fourth and fifth steps. 
Temperature was maintained at 10k for the fourth step and then elevated to 300k for the fifth 
step. In the final stage of the relaxation protocol, all atoms were set free and the simulation was 
performed using the NPT ensemble for a simulation time of 24 ps using a pressure relaxation 
constant of 2.0 ps. This final step resembled the conditions of the actual production runs.  
 The relaxed systems were subjected to a production phase, using the NPT ensemble and 
periodic boundary conditions for a period of 5 ns. The Martyna-Tobias-Klein
269
 pressure control 
method was used to maintain the pressure of the cell at 1.013 bar using the isotropic coupling 
method. The Nose-Hoover thermostat method was used to control the temperature at 300K. 
Heavy atom-hydrogen covalent bonds were constrained using the SHAKE algorithm
270
 which 
allowed a 2-fs integration step to be used. The integration of the equation of motion as 
implemented according to the RESPA
271
 multiple time step scheme was used in the simulations. 
Long-range electrostatic forces were computed using the smooth Particle-Mesh Ewald (PME) 
method
272
. The cutoff distance for calculating short-range electrostatics and Lennard-Jones 
interaction was set to 9.0 Å. The trajectories and the energies were recorded at every 25 and 6 ps 
respectively. The glue option was turned on for proper display of recorded trajectories and 
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convenience in structure analysis. The simulation quality analysis tool was used for the analysis 
of the energetics of the simulations whereas the simulation event analysis tool provided the 
graphical interface for calculating the root mean square deviations (RMSDs), as well as the H-
bond distance, angles and Van der Waals interaction monitors. 
6.3 Result and Discussions 
 Molecular Dynamics simulations were carried out to investigate the overall stability of the 
predicted docking poses as well as conformational changes of the inhibitors relative to the active 
site resulting in altered interaction profiles as well as movements of amino acid side chains lining 
the binding site. The overall stability of the individual simulations was evaluated by plotting the 
total energy of the system as a function of time (Figure 6.3.1) and was suggestive of 
energetically stable complexes with maximum fluctuations at < 1% of the total energy of the 
system.  
 
Figure 6.3.1. Potential energy plot for the production phase of dynamic simulation of 
ligand/SARS-3CL
pro
 complex.  
 
 The superposition of the trajectories onto the system conformations at the start of the 
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production phase helped in the analysis of the RMSD progression over the time of the 
simulation. The average heavy atom RMSD of the binding site (BS) side chain residues (Thr25, 
Leu27, His41, Met49, Phe140, Leu141, Asn142, Cys145, His 163, Met 165, Glu166, His172, 
Asp187, Gln189 and Gln 192) of SARS-3CL
pro
 in complex with PJ207, PJ224, PJ225 and 
PJ316 were found to be 1.14 Å, 1.41 Å, 1.44 Å and 1.49Å respectively for 5 ns of simulation 
time and were suggestive of a stable binding site. The average RMSD of the ligands PJ207, 
PJ224, PJ225 and PJ316 were 0.72 Å, 1.05 Å, 1.0 Å, and 1.48 Å respectively (Figure 7b, 8b, 
9b, and 10b) and were suggestive of stable binding poses. The average RMSD of the inhibitors 
were at the same level (PJ316) or lower (PJ207, PJ224, PJ225) than the corresponding average 
heavy atom RMSD of the binding site (BS) side chain residues, suggesting that the movement of 
inhibitors in the active site should be relatively smaller as compared to the overall 
conformational changes of the SARS-3CL
pro
 binding site. The most noticeable side chain 
movements were shown by Gln189. This residue are solvent exposed and are located in the 
opening of the catalytic cleft located between domain I and II
273
  might explain their positional 
variability due to inter domain movements.  
 In addition, the MD trajectories of the representative inhibitors were analyzed for the 
presence of H-bonds as well as hydrophobic interactions between the inhibitors and important 
residues of the enzyme binding site predicted by the docking studies. Analysis of the MD 
trajectories indicated the presence of several H-bonds and hydrophobic interactions with 
moderate to high frequency of occurrence. MD studies also helped to identify new interactions 
formed over the period of the simulation and suggested the possibility of considering these 
interactions for the rational designing of the inhibitors against SARS-3CL
pro
. A D-A (Donor-
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Acceptor) distance cut-off of ≤3.5 Å and angle (D-H-A) of ≥ 120° was used for the identification 
of H-bonds. For hydrophobic interactions, a cut-off distance of ≤4.5 Å between corresponding 
hydrophobic heavy atoms from the protein and ligand was considered. The interactions of each 
inhibitor with the active site residues of SARS-3CL
pro
 are discussed below in detail. The plots of 
the MD simulation of all inhibitors are graphically shown in Figure 6.3.2.-6.3.5. The distance 
monitors (Figure 6.3.2a, 6.3.3a, 6.3.4a and 6.3.5a) used for H-bonds and hydrophobic 
interactions are shown using red and green dotted lines respectively. 
a)  
L 27
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M 165
M 49 E 166
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b)                                                                                c) 
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Figure 6.3.2. (a) Docking pose of PJ207 showing the H-bond (red) and hydrophobic (green) 
monitors used during the simulation; (b) Heavy atom RMSD of the side chain residues of 
enzyme‟s binding site (BS), PJ207 and side chain of four residues of BS that showed maximum 
fluctuations during the simulation; (c) H-bond (H-A) distances and (d) D-H-A angle of His163[-
NH]-[O]PJ207 and Glu166[-NH]-[O]PJ207; (e) Hydrophobic [CH-CH] interactions of PJ207 
with Thr25, Leu27, Met49 and M165 and a cation(pi)-pi interaction with His172. 
 
 The results from the simulation of the PJ207/SARS-3CL
pro
 complex are shown in Figure. 
6.3.2. All the H-bonds (Figure 6.3.2 c, d) formed between PJ207 and residues of the BS were 
transient in nature. A very interesting observation was made in respect to the critical H-bonding 
interaction in the S1 sub pocket. In the 0-3ns of the simulation the H-bond interaction between 
the NE2 of His 163 from the S1 subsite of the enzyme and the amide side chain carbonyl of 
PJ207 was retained an average D-A distance of 2.69Å and D-H-A angle of 120.1°. Following 
this the H-bond is lost and was compensated by the formation of a new H-bond between the 
carbonyl side chain of PJ207 and backbone –NH of Glu 166 located close to the S1 pocket with 
an average D-A distance of 2.85 Å and D-H-A angle of 135° for 4-5 ns of the simulation time 
(Figure 6.3.2 c, d). The hydrophobic interaction profile (Figure 6.3.2e) showed interactions of 
d)                                                                                e) 
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PJ207 with Thr25, Leu27 of the S1‟ site as well as Met49 from S2 and Met165 where the 
corresponding heavy atom distances were  retained at ≤ 4.5 Å for 42%, 70.5%, 50%, and 64.5% 
of the simulation time respectively. A cation(pi)-pi interaction could also be observed between 
the thiazole group and the His172 in the 0-3ns of the simulation. It‟s likely, that the relatively 
polar nature of the aromatic group (compared to the other active analogues) at the end of the S1 
substitution could also contribute to the observed higher movement of the amide side chain. It is 
also interesting to note that the RMSD fluctuation of Met165 shows a biphasic behavior between 
0-3 and 3-5 ns of the simulation showing larger fluctuations in the second phase which 
corresponds with the H-bond compensation phenomenon observed between the ligand‟s amide 
side chain carbonyl and the His163 and Glu166 residues (discussed above). Overall, the more 
transient nature of the interactions in case of PJ207 (compared to the other hits) may be 
indicative of its relatively weaker affinity. 
a) 
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Figure 6.3.3. (a) Docking pose of PJ224 showing the H-bond (red) and hydrophobic (green) 
monitors used during the simulation; (b) Heavy atom RMSD of the side chain residues of 
enzyme‟s binding site (BS), PJ224 and side chain of four residues of BS that showed maximum 
fluctuations during the simulation; (c) H-bond (H-A) distances and (d) D-H-A angle of 
Asn142[O]-PJ224[NH], His163[-NH]-[O]PJ224 and Gly-1[NH]-PJ224[O]; (e) Hydrophobic 
[CH-CH] interactions of PJ224 with Thr25, Met49, and Met165 and a cation(pi)-pi interaction 
with His172. 
 
b)                                                                                           c) 
d)                                                                                e) 
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 The results from the simulation of the PJ224/SARS-3CL
pro
 complex are shown in Figure. 
6.3.3. As predicted from the docking studies, the amide carbonyl side chain of PJ224 appeared 
to form a strong H-bond with the NE2 of His163 with an average D-A distance of 2.61 Å and 
average D-H-A angle of 124.2° (Figure 6.3.3 c, d). Another H-bond was observed between the 
side chain -NH of Asn142 and the side chain carbonyl oxygen of PJ224 with an average D-A 
distance of 2.9 Å and average D-H-A angle of 120.9° for 0.55-5.0 ns of the simulation time. This 
interaction was not observed in the static docking pose and pointed towards the importance of 
the MD simulation in detecting a possible additional interaction. MD simulation also revealed a 
new H-bond between the carboxylate moiety of PJ224 and N-terminal Gly-1 (of subunit B) with 
an average D-A distance of 2.69 Å for the first 2.2 ns of the simulation time which was not 
observed in the docking pose. The additional H-bond interactions in PJ224 vis-a-vis PJ207 may 
contribute to its higher affinity. Thr25 from the S1‟ sub site exhibited strong hydrophobic 
interactions with the benzpyrimidine scaffold of PJ224 with the corresponding hydrophobic 
heavy atom distance at ≤4.5 Å for 88% of the simulation time with an average distance of 4.03 
Å. Also, Met165 and Met49 from the S2 sub site were found to interact with the phenyl side 
chain of PJ224 with the corresponding hydrophobic heavy atom distance at ≤4.5 Å for 87% and 
71% of the simulation time respectively (Figure 6.3.3 e). A transient cation (pi)-pi interaction 
was observed between the phenyl group and His172 in the S1 pocket. 
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Figure 6.3.4. (a) Docking pose of PJ225 showing the H-bond (red) and hydrophobic (green) 
monitors used during the simulation; (b) Heavy atom RMSD of the side chain residues of 
enzyme‟s binding site (BS), PJ225 and side chain of four residues of BS that showed maximum 
fluctuations during the simulation; (c) H-bond (H-A) distances and (d) D-H-A angle of 
Asn142[NH]-PJ225[O], Ser144[OH]-PJ225[O] and His163[NH]-[O]PJ225; (e) Hydrophobic 
[CH-CH] interactions of PJ225 with Thr25, Met49, Phe140, Leu141 and Met165 and a 
cation(pi)-pi interaction with His172. 
 
 The results of the MD studies for SARS-3CL
pro
 in complex with PJ225 are shown in Figure 
7.3.4. Similar to PJ224, a stable H-bond was observed between the side chain amide carbonyl 
oxygen of PJ225 with the NE2 of His 163 with an average D-A distance of 2.69 Å and average 
D-H-A angle of 125.6° (Figure 9 c, d). Also, a transient H-bond was observed between the side 
chain OH of Ser144 and amide carbonyl oxygen of PJ225 (D-A distance ≤3.5 43.5% of the 
simulation time). This residue is located on the loop (residues 140-146) involved in the oxyanion 
hole formation and stabilization of the covalent tetrahedral intermediate generated during 
substrate hydrolysis by the enzyme. Coincidentally, this interaction was not observed in the 
d)                                                                                e) 
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docking pose of PJ225. However, the Gly-1 H-bond is not possible in case of PJ225 and the 
Asn142 interaction had a lower residence time in comparison to PJ224. During the course of the 
simulation, several strong hydrophobic interactions were observed. These included interactions 
of PJ225 with the side chains of Thr25, Leu141, Phe140, Met165 and Met49 where the 
corresponding hydrophobic heavy atoms were retained at ≤ 4.5 Å for 82.5%, 30.5%, 85.5%, 72% 
and 59% of the simulation time respectively. As predicted from the docking study, PJ225 in 
comparison to PJ224 and PJ207 demonstrated additional hydrophobic interactions (Figure 7.3.4 
e) between the ethyl moiety of the ligand with Phe140 and Leu141. A highly stable cation(pi)-pi 
interaction was observed between the phenyl ring and His 172 with the distance ≤ 4.5 Å 100% of 
the time. These additional and/or stronger interactions in the S1 pocket observed for PJ225 could 
account for its higher inhibitory activity (IC50=5.8 μM) against SARS-3CL
pro
 in comparison to 
PJ224 (IC50=15μM) and PJ207 (IC50=39.4 μM).  
a) 
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Figure 6.3.5. (a) Docking pose of PJ316 showing the H-bond (red) and hydrophobic (green) 
monitors used during the simulation; (b) Heavy atom RMSD of the side chain residues of 
enzyme‟s binding site (BS), PJ316 and side chain of four residues of BS that showed maximum 
fluctuations during the simulation; (c) H-bond (H-A) distances and (d) D-H-A angle of Phe140 
[O]-[NH]PJ316, G143[-NH]-[CO]PJ316, Ser144 [NH]-[O]PJ316 and H163[-NH]-[O]PJ316; (e) 
Hydrophobic [CH-CH] interactions of PJ316 with Thr25, Met49, Leu141 and  Met165 and a 
cation(pi)-pi interaction with His172. 
 
b)                                                                                c) 
d)                                                                                e) 
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The simulation plots for the PJ316/SARS-3CL
pro
 complex are shown in Figure 7.3.5. 
Multiple H-bonds were predicted for PJ316 based on the docking simulations (Figure 7.3.5 c, d). 
The amide carbonyl oxygen of the benzpyridone moiety of PJ316 appeared to form a stable H-
bond with NE2 of His 163 (Avg. D-A distance= 2.47Å and Avg. D-H-A angle=125°) of the S1 
pocket. The amide nitrogen of the bicyclic ring of PJ316 also formed a H-bond with the 
backbone carbonyl oxygen of Phe140 with an average D-A distance of 2.22 Å and D-H-A angle 
of 139°. In addition, the amide side chain of PJ316 formed a bifurcated H-bond with the 
backbone amide of Gly143 (Avg. D-A distance= 1.83Å and Avg. D-H-A angle=164°) and 
Ser144 which forms the oxyanion hole to stabilize the covalent tetrahedral intermediate resulting 
from substrate hydrolysis by the enzyme. The hydrophobic interactions profile for PJ316-
enzyme complex is shown in Figure 7.3.5e. Also, Thr25 exhibited a strong interaction with the 
benzyl side chain of PJ316 with a distance ≤ 4.5 Å for 91.5% of the simulation time and an 
average distance of 4.48 Å. Met49 exhibited hydrophobic interaction with PJ316 for 57.5% of 
the simulation time.  In addition, the hydrophobic interactions between the side chain of Met165 
with the phenyl side chain of PJ316, and Leu141 with the benzpyridone moiety of the ligand 
falling within the cutoff distance of ≤4.5 Å for 40% and 51% of the simulation time respectively. 
Amongst the current hits only PJ316 may explore the S4 pocket through the chlorine substitution 
on the phenyl ring. Also of interest is the RMSD fluctuation of the Met49 and Met165 residues 
which show a biphasic behavior. The residues appear to undergo induced-fit in the 0-2 ns of the 
simulation following which they preserve their conformational states for the remainder of the 
simulation. The hydrophobic distance progression (Figure 7.3.5e) for Leu141 also showed a 
biphasic behavior (0-1.5ns and 1.5-5ns) suggesting the possible stabilization of the interaction 
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with the dimethyl moiety of the ligand in the second phase which would also stabilize the two H-
bonds in the S1 pocket.  
6.4 Guidelines for future structure-based drug design of SARS-3CL
pro
 inhibitors.  
Based on the analysis of SAR trends as well as MD simulation, certain guidelines could be 
formed for structure-based modification schemes that could be used for the synthesis of 
analogues. First, the S2 sub site appears to be highly specific to the hydrophobic groups that may 
be utilized to occupy this subsite. While the smaller/bulkier aliphatic groups didn‟t provide 
adequate hydrophobic interaction/caused steric clash, longer groups would require a 
corresponding S1 group of compatible size for proper fit. A phenyl group at the S2 position  is 
advantageous because it allows a vector into the S4 packet which could be occupied with a 
hydrophobic group potentially leading to an increase in overall affinity. In case of PJ316, we 
observed the hydrophobic chlorine group vectored into the S4 cavity adds to the overall stability 
of the binding pose and suggest that such structure-based modifications in both active 
chemotypes could be beneficial towards potency gain. Furthermore, additional smaller 
hydrophobic substituents may be useful in probing the depths of the S2 pocket. The S1 interaction 
with His163 was found to be highly stable in all the simulations except PJ207 and is one of the 
most critical binding site requirements. The alternate H-bonding demonstrated by PJ207 with the 
backbone of Glu166 in lieu of His163 and the Ser144 (from the oxyanion hole ) interaction 
observed in case of PJ225 suggests that possible modifications vectoring two hydrogen 
acceptors (e.g. sulfonamide for Ser144) could be utilized to harness additional binding affinity. 
Also, of interest would be the interaction with Asn142 as observed in the MD simulations of 
PJ224 and PJ225. It would also appear that, the interaction with Leu141 (observed in the 
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docking pose and MD simulations of the two more potent hits PJ225 and PJ316) through 
aliphatic hydrophobic groups may add to the overall stability by forming additional hydrophobic 
interactions which in turn helps in the stabilization of the H-bonds formed in the S1 pocket. 
Additionally, as shown in case of PJ316 the H-bonding interactions with the backbone of 
Gly143 and Ser144 residue forming the oxyanion hole could form a strong anchor point for 
ligand stability. The Gly-1 residue from the second monomer was found to participate in a 
transient H-bonding interaction during the MD simulation and may be pursued as part of the 
structure-based design strategy. The binding site appears to prefer an amphiphilic group 
extending into the S1 pocket and is critical towards the stability of the interactions formed in this 
region.   
6.5. Conclusions 
A multi nanosecond explicit solvent simulation were carried out using the docking poses of the 
identified hits to study the overall stability of the binding site interactions as well as identify 
important changes in the interaction profile that may not be apparent from a docking study. 
Additionally, the docking poses from the identified hits were utilized for a series of multi 
nanosecond simulations to study the overall stability of the interaction profiles and well as novel 
interactions not observed during the docking study. The information from these analyses would 
be utilized for further structure guided synthesis of analogues that might help in the identification 
of potent antiviral leads targeted against SARS-CoV. Cumulative analysis of the evaluated 
compounds and the simulation studies led to the identification of certain SAR traits which would 
be useful in further structure based design efforts. 
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1
H and 
13
C spectra of intermediates and final compounds 16-41 (Chapter 3) were recorded on 
Bruker ][500MHz, 400MHz, or Bruker 400MHz Ultra Shield and the analyses conducted in 
CDCl3, MeOD, or DMSO-d6.  
 
2-((6-aminobenzo[d]thiazol-2-yl)thio)-1-phenylethanone (16) 
1
H NMR (500 MHz, DMSO-d6) δ 8.06 (d, J = 6.84 Hz, 2H), 7.64 - 7.78 (m, 1H), 7.58 (d, J = 
6.41 Hz, 2H), 7.43 (d, J = 8.55 Hz, 1H), 6.99 (br. s., 1H), 6.69 (d, J = 7.27 Hz, 1H), 5.34 (br. s., 
2H), 5.03 (br. s., 2H); 
13
C NMR (126 MHz, DMSO-d6) δ 193.2, 157.4, 146.6, 144.1, 136.6, 
135.4, 133.7, 128.8, 128.4, 121.5, 114.4, 103.9, 40.9; HRMS (m/z): [M +H] calcd for 
C15H13N2OS2 301.0469, found 301.0448 
 
2-((6-aminobenzo[d]thiazol-2-yl)thio)-1-(naphthalen-2-yl)ethanone (17) 
1
H NMR (500 MHz, DMSO-d6) d 8.83 (br. s., 1H), 8.11 - 8.42 (m, 2H), 8.04 (br. s., 2H), 7.58 - 
7.78 (m, 2H), 7.44 (br. s., 1H), 7.01 (br. s., 1H), 6.70 (br. s., 1H), 5.27 - 5.47 (m, 2H), 5.17 (br. 
s., 2H); 13C NMR (126 MHz, DMSO-d6) d 193.0, 157.3, 146.5, 144.0, 136.5, 135.1, 132.5, 
131.9, 130.5, 129.5, 128.8, 128.3, 127.6, 126.9, 123.6, 121.3, 114.2, 103.7 
HRMS (m/z): [M + H] calcd for C19H15N2OS2 351.0626, found 351.0626 
 
ethyl 2-((6-aminobenzo[d]thiazol-2-yl)thio)acetate (18) 
1
H NMR (400 MHz, DMSO-d6) δ 7.48 (dd, J = 3.14, 8.41 Hz, 1H), 7.00 (br. s., 1H), 6.66 - 6.86 
(m, 1H), 5.36 (br. s., 2H), 4.16 - 4.29 (m, 2H), 4.13 (dd, J = 3.01, 7.03 Hz, 2H), 1.09 - 1.30 (m, 
3H)
 
; 
13
C NMR (101 MHz, DMSO-d6) δ 168.2, 146.7, 144.1, 136.6, 135.9, 121.6, 114.4, 103.9, 
61.2, 34.8, 14.0; HRMS (m/z): [M + H] calcd for C11H13N2O2S2 269.0418, found 269.0389 
 
2-((6-aminobenzo[d]thiazol-2-yl)thio)-N-(p-tolyl)acetamide (19) 
1
H NMR (400 MHz, DMSO-d6) δ 10.27 (br. s., 1H), 7.42 - 7.66 (m, 2H), 7.10 (br. s., 2H), 6.74 
(br. s., 1H), 5.34 (br. s., 2H), 4.24 (br. s., 2H), 2.14 - 2.39 (m, 3H); 
 13
C NMR (101 MHz, DMSO-
d6) δ 165.3, 157.8, 146.7, 144.3, 136.7, 136.3, 132.6, 129.2, 121.6, 119.3, 114.5, 104.0, 37.9, 
20.5; HRMS (m/z): [M + H] calcd for C16H16N3OS2 330.0735, found 330.0700  
 
2-nitro-N-(2-((2-oxo-2-phenylethyl)thio)benzo[d]thiazol-6-yl)benzenesulfonamide (20) 
1
H NMR (400 MHz, CHLOROFORM-d) δ 8.07 (d, J = 7.28 Hz, 2H), 7.87 (d, J = 7.78 Hz, 1H), 
7.76 - 7.80 (m, 1H), 7.67 - 7.72 (m, 2H), 7.62 - 7.67 (m, 2H), 7.55 - 7.59 (m, 1H), 7.50 - 7.55 (m, 
2H), 7.35 (s, 1H), 7.17 (dd, J = 2.13, 8.66 Hz, 1H), 4.93 (s, 2H); 
13
C NMR (126 MHz, 
CHLOROFORM-d) δ 193.8, 166.9, 150.6, 148.4, 136.3, 135.8, 135.5, 134.7, 133.6, 133.3, 
131.6, 130.8, 129.7, 129.1, 125.2, 122.1, 121.6, 115.2, 41.3; HRMS (m/z): [M - H] calcd for 
C21H14N3O5 S3 484.0095, found 484.0066 
 
N-(2-((2-oxo-2-phenylethyl)thio)benzo[d]thiazol-6-yl)-4-(trifluoromethoxy)benzene 
sulfonamide (21) 
1
H NMR (400 MHz, CHLOROFORM-d) δ 8.06 - 8.12 (m, 2H), 7.77 (d, J = 8.78 Hz, 2H), 7.62 - 
7.67 (m, 2H), 7.58 (d, J = 2.01 Hz, 1H), 7.50 - 7.56 (m, 2H), 7.25 (s, 1H), 6.99 (dd, J = 2.26, 
8.53 Hz, 1H), 6.64 (br. s., 1H), 4.94 (s, 2H); 
13
C NMR (101 MHz, DMSO-d6) δ 192.8, 179.1, 
165.4, 151.1, 149.7, 138.1, 135.7, 135.3, 133.9, 133.8, 129.3, 128.9, 128.4, 121.5, 121.4, 120.2, 
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113.8, 40.9; HRMS (m/z): [M-H] calcd for C22H13 F3N2O4 S3 523.0067, found 523.9977 
 
N-(2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)-4-
(trifluoromethoxy)benzenesulfonamide (22) 
1
H NMR (400 MHz, DMSO-d6) d 8.86 (br. s., 1H), 8.16 (br. s., 2H), 7.99 - 8.12 (m, 2H), 7.86 
(br. s., 1H), 7.60 - 7.81 (m, 3H), 7.27 (br. s., 1H), 5.29 (br. s., 2H), 4.56 (d, J = 9.54 Hz, 2H), 
4.13 (br. s., 1H), 1.27 (br. s., 3H), 0.86 (br. s., 2H); 
13
C NMR (126 MHz, CHLOROFORM-d) δ 
192.7, 165.2, 149.7, 135.8, 135.3, 133.7, 132.7, 132.1, 130.7, 129.7, 129.0, 128.5, 127.7, 127.1, 
123.7, 121.5, 120.2, 113.3, 41.0; HRMS (m/z): calcd for C21H14F3 N2O3S3 495.0041, found 
495.0118 
 
N-(2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)acetamide (23) 
1
H NMR (500 MHz, CHLOROFORM-d) δ 8.65 (s, 1H), 8.27 (br. s., 1H), 8.10 (dd, J = 1.71, 
8.55 Hz, 1H), 7.99 (d, J = 7.69 Hz, 1H), 7.93 (dd, J = 8.33, 17.31 Hz, 2H), 7.72 (d, J = 8.55 Hz, 
1H), 7.65 (t, J = 7.05 Hz, 1H), 7.59 (t, J = 7.05 Hz, 1H), 7.34 (br. s., 1H), 7.20 - 7.26 (m, 1H), 
5.07 (s, 2H), 2.21 (s, 3H); 
13
C NMR (126 MHz, DMSO-d6) δ 192.9, 181.9, 168.4, 163.8, 136.2, 
135.4, 135.3, 132.7, 132.1, 130.7, 129.7, 129.0, 128.5, 127.7, 127.1, 123.7, 121.0, 118.4, 111.1, 
79.2, 41.0, 24.0; HRMS (m/z): [M + Na] calcd for C21H16 N2 NaO2S2 415.0550, found 415.0566 
 
N-(2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)quinoline-8-sulfonamide 
(24) 
1
H NMR (400 MHz, CHLOROFORM-d) δ 9.15 - 9.22 (m, 1H), 8.58 (s, 1H), 8.55 (br. s., 1H), 
8.32 (br. s., 1H), 8.30 (d, J = 2.35 Hz, 1H), 8.00 - 8.07 (m, 2H), 7.96 (d, J = 8.02 Hz, 1H), 7.86 - 
7.94 (m, 2H), 7.64 (dt, J = 4.18, 8.27 Hz, 2H), 7.53 - 7.60 (m, 2H), 7.50 - 7.53 (m, 1H), 7.48 (d, 
J = 8.80 Hz, 1H), 6.92 (dd, J = 1.96, 8.61 Hz, 1H), 4.99 (s, 2H); 
13
C NMR (126 MHz, DMSO-d6) 
δ 192.7, 164.6, 151.5, 149.1, 142.7, 137.0, 135.4, 135.2, 135.0, 134.6, 134.3, 132.6, 132.2, 132.1, 
130.7, 129.6, 129.0, 128.4, 128.4, 127.7, 127.1, 125.6, 123.7, 122.6, 121.1, 119.6, 112.5, 41.0; 
HRMS (m/z): [M + Na] calcd for C28H19N3O3S3Na, 564.0486; found, 564.0499 
 
4-fluoro-N-(2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)benzene 
sulfonamide (25) 
1
H NMR (500 MHz, CHLOROFORM-d) δ 8.63 (s, 1H), 8.08 (s, 1H), 7.99 (d, J = 8.12 Hz, 1H), 
7.92 (dd, J = 8.33, 16.03 Hz, 2H), 7.75 (dd, J = 4.92, 8.76 Hz, 2H), 7.58 - 7.69 (m, 3H), 7.55 (d, 
J = 1.71 Hz, 1H), 7.09 (t, J = 8.55 Hz, 1H), 6.98 - 7.04 (m, 1H), 5.05 (s, 3H); 
13
C NMR (126 
MHz, DMSO-d6) δ 192.7, 165.3, 149.6, 135.7, 135.2, 134.1, 132.6, 132.1, 130.7, 129.7, 129.7, 
129.0, 128.5, 128.4, 127.7, 127.1, 127.0, 123.7, 121.4, 120.2, 116.5, 116.3, 113.6, 40.9; 
HRMS (m/z): [M + Na] calcd for C25H17FN2O3S3Na, 531.0283; found, 531.0308 
 
ethyl 2-((6-(2,2,2-trifluoroethylsulfonamido)benzo[d]thiazol-2-yl)thio)acetate (26) 
1
H NMR (500 MHz, CHLOROFORM-d) δ 7.74 (d, J = 8.55 Hz, 1H), 7.69 (s, 1H), 7.40 (br. s., 
1H), 7.22 (dd, J = 2.14, 8.55 Hz, 1H), 4.28 (d, J = 7.27 Hz, 4H), 4.16 (s, 2H), 3.80 (d, J = 8.98 
Hz, 2H), 1.32 (t, J = 7.05 Hz, 3H); 
13
C NMR (126 MHz, DMSO-d6) δ 168.0, 164.8, 149.7, 135.9, 
133.7, 123.4, 121.7, 120.3, 113.4, 61.4, 52.5, 34.7, 14.0; HRMS (m/z): [M + H] calcd for C13H14 
F3N2O4S3 415.0068, found 415.0059 
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ethyl 2-((6-(4-fluorophenylsulfonamido)benzo[d]thiazol-2-yl)thio)acetate (27) 
1
H NMR (400 MHz, CHLOROFORM-d) δ 7.72 - 7.81 (m, 2H), 7.63 (d, J = 8.61 Hz, 1H), 7.56 
(s, 1H), 7.17 (br. s., 1H), 7.10 (t, J = 8.51 Hz, 2H), 7.01 (dd, J = 1.96, 8.61 Hz, 1H), 4.26 (q, J = 
7.17 Hz, 2H), 1.30 (t, J = 7.14 Hz, 3H); 
13
C NMR (126 MHz, DMSO-d6) δ 168.0, 165.3, 164.8, 
163.3, 149.5, 135.8, 135.6, 134.2, 129.8, 129.7, 121.5, 120.2, 116.5, 116.3, 113.6, 61.3, 34.7, 
13.9; HRMS (m/z): [M +H] calcd for C17H16FN2O4S3 427.0256 found 427.02562 
 
ethyl 2-((6-(2-nitrophenylsulfonamido)benzo[d]thiazol-2-yl)thio)acetate (28) 
1
H NMR (500 MHz, CHLOROFORM-d) δ 7.85 - 7.93 (m, J = 7.69 Hz, 1H), 7.80 (d, J = 7.69 
Hz, 1H), 7.71 (br. s., 2H), 7.54 - 7.61 (m, 1H), 7.38 (br. s., 1H), 7.29 (s, 1H), 7.16 - 7.23 (m, J = 
8.12 Hz, 1H), 4.23 - 4.31 (m, 2H), 4.16 (s, 2H), 1.31 (t, J = 6.84 Hz, 3H); 
13
C NMR (101 MHz, 
DMSO-d6) δ 168.0, 165.3, 149.8, 147.9, 135.8, 134.7, 133.3, 132.6, 131.2, 130.1, 124.6, 121.6, 
120.6, 114.2, 61.4, 34.7, 14.0; HRMS (m/z): [M + Na] calcd for C17H15N3NaO6S3 476.0021, 
found 476.0068 
 
ethyl 2-((6-(quinoline-7-sulfonamido)benzo[d]thiazol-2-yl)thio)acetate (29) 
1
H NMR (500 MHz, CHLOROFORM-d) δ 9.20 (d, J = 4.27 Hz, 1H), 8.58 (br. s., 1H), 8.33 (t, J 
= 6.62 Hz, 2H), 8.04 (d, J = 8.12 Hz, 1H), 7.65 (dd, J = 4.27, 8.55 Hz, 1H), 7.55 - 7.61 (m, 2H), 
7.53 (d, J = 8.55 Hz, 1H), 6.93 (dd, J = 1.92, 8.76 Hz, 1H), 4.21 (q, J = 7.12 Hz, 2H), 4.09 (s, 
2H), 1.26 (t, J = 7.05 Hz, 3H); 
13
C NMR (126 MHz, DMSO-d6) δ 167.9, 164.1, 151.5, 149.0, 
142.7, 136.9, 135.4, 135.0, 134.7, 134.3, 132.2, 128.3, 125.6, 122.6, 121.2, 119.6, 112.6, 61.3, 
34.6, 13.9; HRMS (m/z): [M+H] calcd for C20H18N3O4S3 460.0459, found 460.0483 
 
N-(p-tolyl)-2-((6-(2,2,2-trifluoroethylsulfonamido)benzo[d]thiazol-2-yl)thio) acetamide (30) 
1
H NMR (500 MHz, DMSO-d6) δ 10.29 - 10.34 (m, 1H), 9.77 (br. s., 1H), 7.69 - 7.75 (m, 1H), 
7.40 - 7.46 (m, 1H), 7.32 - 7.37 (m, 2H), 7.31 (br. s., 1H), 7.01 (d, J = 8.12 Hz, 2H), 4.09 (br. s., 
2H), 3.72 - 3.89 (m, 2H), 2.21 (s, 3H); 
13
C NMR (101 MHz, DMSO-d6) δ 165.2, 164.6, 149.7, 
143.7, 135.7, 133.3, 132.4, 128.8, 121.2, 119.8, 119.1, 112.9, 37.5, 20.3; HRMS (m/z): [M - H] 
calcd for C18H15 F3N3 O3 S3 474.0306, found 474.0145 
 
2-((6-acetamidobenzo[d]thiazol-2-yl)thio)-N-(p-tolyl)acetamide (31) 
1
H NMR (500 MHz, DMSO-d6) δ 9.88 (br. s., 1H), 9.67 (br. s., 1H), 8.28 (s, 1H), 7.66 (d, J = 
8.98 Hz, 1H), 7.48 - 7.54 (m, 1H), 7.39 - 7.44 (m, 1H), 7.35 (d, J = 8.12 Hz, 2H), 7.00 (d, J = 
8.12 Hz, 2H), 4.08 (br. s., 2H), 2.21 (s, 3H), 2.08 (s, 3H); 
13
C NMR (101 MHz, DMSO-d6) δ 
168.5, 165.0, 164.1, 148.5, 136.3, 135.4, 132.6, 129.2, 121.0, 119.2, 118.5, 111.2, 37.8, 24.0, 
20.4; HRMS (m/z): [M + H] calcd for C18H18 N3 O2 S2 372.0840, found 372.0797 
 
2-((6-(quinoline-7-sulfonamido)benzo[d]thiazol-2-yl)thio)-N-(p-tolyl)acetamide (32) 
1
H NMR (500 MHz, CHLOROFORM-d) δ 9.59 (br. s., 1H), 9.22 (d, J = 2.99 Hz, 1H), 8.69 (br. 
s., 1H), 8.35 (dd, J = 8.12, 9.83 Hz, 2H), 8.06 (d, J = 7.69 Hz, 1H), 7.68 (dd, J = 4.06, 8.33 Hz, 
1H), 7.64 (d, J = 8.55 Hz, 1H), 7.60 (d, J = 7.69 Hz, 1H), 7.56 - 7.59 (m, 1H), 7.33 (d, J = 8.12 
Hz, 2H), 7.29 (s, 1H), 7.07 (d, J = 8.12 Hz, 2H), 3.99 (s, 2H), 2.26 - 2.36 (m, 3H); 
13
C NMR 
(101 MHz, DMSO-d6) δ 164.8, 151.5, 149.2, 142.7, 137.0, 136.2, 135.4, 135.0, 134.6, 134.3, 
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132.5, 132.2, 129.2, 128.4, 125.6, 122.6, 121.1, 119.6, 119.2, 112.6, 52.9, 37.7, 20.4; 
HRMS (m/z): [M + Na] calcd for C25H20N4O3S3Na, 543.0595; found 543.0584 
 
2-((6-(4-fluorophenylsulfonamido)benzo[d]thiazol-2-yl)thio)-N-(p-tolyl)acetamide (33) 
1
H NMR (500 MHz, CHLOROFORM-d) δ 9.55 (br. s., 1H), 7.78 (dd, J = 5.77, 8.33 Hz, 3H), 
7.62 (d, J = 1.71 Hz, 1H), 7.36 (d, J = 8.55 Hz, 2H), 7.08 - 7.17 (m, 4H), 6.78 (br. s., 1H), 4.06 
(s, 2H), 2.30 (s, 3H); 
13
C NMR (101 MHz, DMSO-d6) δ 166.0, 165.4, 163.5, 150.1, 136.7, 136.2, 
136.0, 134.6, 133.0, 130.2, 129.6, 121.9, 120.7, 119.7, 117.0, 116.8, 114.1, 63.8, 38.2, 20.8; 
HRMS (m/z): [M + H] calcd for C22H19 FN3 O3 S3 488.0573, found 488.0602 
 
N-(p-tolyl)-2-((6-(4-(trifluoromethoxy)phenylsulfonamido)benzo[d]thiazol-2-yl)thio) 
acetamide (34) 
1
H NMR (400 MHz, CHLOROFORM-d) δ 9.60 (br. s., 1H), 7.80 (dd, J = 2.35, 8.80 Hz, 2H), 
7.64 (d, J = 1.96 Hz, 1H), 7.36 (d, J = 8.22 Hz, 2H), 7.28 (br. s., 1H), 7.14 (d, J = 1.76 Hz, 1H), 
7.10 (d, J = 8.41 Hz, 2H), 6.81 (br. s., 1H), 4.06 (s, 2H), 2.30 (s, 3H); 
13
C NMR (101 MHz, 
DMSO-d6
119.2, 113.7, 63.2, 37.7, 20.4; HRMS (m/z): [M +H] calcd for C23H19 F3N3 O4 S3 553.0412, 
found 553.0545 
 
 (R)-tert-butyl (3-methyl-1-oxo-1-((2-((2-oxo-2-(p-tolylamino)ethyl)thio)benzo [d]thiazol-6-
yl)amino)butan-2-yl)Carbamate (35) 
1
H NMR (400 MHz, CHLOROFORM-d), δ 9.81 (s, 1H), 9.36 (br. s., 1H), 8.13 (br. s., 1H), 7.56 
(d, J = 7.78 Hz, 1H), 7.36 - 7.43 (m, J = 8.28 Hz, 2H), 7.14 (d, J = 8.03 Hz, 1H), 7.04 - 7.11 (m, 
J = 8.03 Hz, 2H), 5.54 (d, J = 8.03 Hz, 1H), 4.24 (t, J = 6.65 Hz, 1H), 3.90 - 4.09 (m, 2H), 2.26 
(s, 3H), 2.14 (d, J = 19.07 Hz, 1H), 1.50 (s, 9H), 1.08 (d, J = 5.77 Hz, 6H); 
13
C NMR (101 MHz, 
CDCl3) δ 171.11, 166.42, 165.92, 156.85, 148.23, 135.84, 135.51, 135.19, 133.92, 129.49, 
120.47, 119.64, 118.59, 111.58, 80.55, 77.38, 77.07, 76.75, 61.14, 37.44, 30.91, 28.44, 20.86, 
19.33, 18.64.
 
 
(R)-tert-butyl (2-oxo-2-((2-((2-oxo-2-(p-tolylamino)ethyl)thio)benzo[d]thiazol-6-yl)amino)-
1-phenylethyl)carbamate (36) 
1
H NMR (400 MHz, DMSO-d6) δ 10.07 (br. s., 0H), 9.88 (br. s., 1H), 8.19 - 8.32 (m, 1H), 7.65 
(d, J = 8.78 Hz, 1H), 7.38 - 7.48 (m, 3H), 7.34 (d, J = 8.53 Hz, 3H), 7.23 - 7.29 (m, 2H), 7.21 (d, 
J = 6.53 Hz, 1H), 6.99 (d, J = 8.53 Hz, 2H), 6.20 (br. s., 1H), 5.43 (br. s., 1H), 4.06 (s, 3H), 3.42 
(br. s., 1H), 2.93 - 2.99 (m, 1H), 2.20 (s, 3H), 1.36 (br. s., 9H); 
13
C NMR (101 MHz, DMSO-d6) 
δ 165.1, 164.5, 148.2, 137.7, 135.3, 135.1, 135.0, 132.8, 128.6, 128.0, 127.3, 126.4, 120.2, 118.9, 
118.8, 118.4, 111.3, 37.0, 27.6, 20.1 
 
(R)-tert-butyl (3-methyl-1-((2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-
yl)amino)-1-oxobutan-2-yl)carbamate (37) 
1
H NMR (400 MHz, CHLOROFORM-d) δ 8.90 (br. s., 1H), 8.61 (s, 1H), 8.16 (br. s., 1H), 8.06 
(d, J = 8.53 Hz, 1H), 7.96 (d, J = 8.03 Hz, 1H), 7.88 (t, J = 8.66 Hz, 2H), 7.59 - 7.65 (m, 1H), 
7.56 (d, J = 7.53 Hz, 2H), 7.15 (d, J = 7.28 Hz, 1H), 5.37 (d, J = 7.78 Hz, 1H), 5.05 (d, J = 2.26 
Hz, 2H), 4.16 (br. s., 1H), 2.19 (br. s., 1H), 1.47 (s, 9H), 1.05 (t, J = 5.77 Hz, 6H); 
13
C NMR 
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(101 MHz, CHLOROFORM-d) δ 193.0, 170.7, 156.6, 149.4, 135.8, 134.5, 132.8, 132.4, 130.6, 
129.7, 128.9, 128.7, 127.8, 127.0, 123.9, 121.1, 118.4, 111.8, 77.3, 77.2, 77.0, 76.7, 71.5, 41.2, 
30.7, 28.4, 19.4 
(R)-tert-butyl (2-((2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)amino)-2-
oxo-1-phenylethyl)carbamate (38) 
1
H NMR (400 MHz, CHLOROFORM-d) δ 8.63 (s, 1H), 8.27 (br. s., 1H), 8.14 (br. s., 1H), 8.09 
(d, J = 8.28 Hz, 1H), 7.99 (d, J = 8.03 Hz, 1H), 7.90 (d, J = 8.53 Hz, 1H), 7.93 (d, J = 8.78 Hz, 
1H), 7.63 (d, J = 8.03 Hz, 2H), 7.55 - 7.61 (m, 1H), 7.48 (d, J = 7.03 Hz, 2H), 7.37 (d, J = 7.78 
Hz, 3H), 7.15 (d, J = 8.53 Hz, 1H), 5.77 (br. s., 1H), 5.42 (br. s., 1H), 5.06 (s, 2H), 1.45 (s, 9H) 
 
 (R)-2-amino-3-methyl-N-(2-((2-oxo-2-(p-tolylamino)ethyl)thio)benzo[d]thiazol-6-yl) 
butanamide hydrochloride (39) 
1H NMR (400 MHz, MeOD) δ 8.39 (s, 1H), 7.77 (d, J = 8.78 Hz, 1H), 7.61 (d, J = 8.53 Hz, 1H), 
7.44 (d, J = 8.03 Hz, 2H), 7.09 (d, J = 8.03 Hz, 2H), 4.32 (s, 2H), 3.97 (br. s., 1H), 2.27 (s, 3H), 
1.13 (dd, J = 6.78, 12.80 Hz, 6H); 
13C NMR (101 MHz, MeOD) δ 167.8, 166.8, 166.2, 147.6, 
135.5, 135.1, 134.0, 129.0, 120.2, 119.9, 119.5, 112.3, 60.9, 59.0, 37.6, 30.4, 19.6, 17.7, 16.6; 
HRMS (m/z): [M + Na] calcd for C21H24N4O2S2 Na 451.5601, found  451.1238 
 
(R)-2-amino-N-(2-((2-oxo-2-(p-tolylamino)ethyl)thio)benzo[d]thiazol-6-yl)-2-phenyl 
acetamide hydrochloride (40) 
1H NMR (400 MHz, MeOD) δ 8.26 - 8.37 (m, 1H), 7.69 (d, J = 8.78 Hz, 1H), 7.65 - 7.67 (m, 
1H), 7.64 (br. s., 1H), 7.51 (d, J = 1.76 Hz, 4H), 7.42 (d, J = 8.28 Hz, 2H), 7.09 (d, J = 8.03 Hz, 
2H), 5.24 (s, 1H), 4.27 (s, 2H), 2.26 (s, 3H); 
13
C NMR (101 MHz, MeOD) δ 168.8, 167.8, 167.4, 
149.5, 137.0, 136.8, 136.7, 135.5, 134.2, 131.4, 130.7, 130.5, 129.6, 121.8, 121.8, 120.7, 113.6, 
58.6, 38.9, 21.1; HRMS (m/z): [M + Na] calcd for C24H22N4ClO2S2Na 521.0298, found  
521.0345 
 
(R)-3-methyl-1-((2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)amino)-1-
oxobutan-2-aminium chloride (41) 
1
H NMR (400 MHz, DMSO-d6) δ 11.36 (br. s., 1H), 8.86 (s, 1H), 8.48 (br. s., 2H), 8.42 (s, 1H), 
8.15 (d, J = 8.03 Hz, 1H), 7.98 - 8.09 (m, 3H), 7.60 - 7.76 (m, 3H), 5.23 - 5.36 (m, 2H), 3.99 (br. 
s., 1H), 2.15 - 2.33 (m, 1H), 1.01 (d, J = 6.53 Hz, 6H); 
13
C NMR (101 MHz, DMSO-d6) δ 192.9, 
167.0, 164.7, 149.0, 135.5, 135.3, 135.1, 132.7, 132.1, 130.8, 129.7, 129.0, 128.5, 127.8, 127.2, 
123.7, 121.2, 118.9, 111.9, 66.4, 58.0, 41.1, 30.0, 18.5, 18.0; HRMS (m/z): [M + Na] calcd for 
C24H24 N3ClO2S2Na 508.0311, found  508.0896 
 
(R)-2-((2-((2-(naphthalen-2-yl)-2-oxoethyl)thio)benzo[d]thiazol-6-yl)amino)-2-oxo-1-
phenylethanaminium chloride (42) 
1
H NMR (400 MHz, DMSO-d6) d 11.50 (br. s., 1H), 8.93 (br. s., 3H), 8.86 (br. s., 1H), 8.37 (s, 
1H), 8.16 (d, J = 7.78 Hz, 1H), 7.98 - 8.09 (m, 3H), 7.67 - 7.79 (m, 5H), 7.59 - 7.67 (m, 2H), 
7.45 (d, J = 7.53 Hz, 3H), 5.28 (s, 2H); 13C NMR (101 MHz, DMSO-d6) d 192.8, 166.1, 149.1, 
145.5, 135.5, 135.3, 135.0, 133.7, 132.6, 132.1, 130.7, 129.7, 129.3, 129.0, 128.9, 128.5, 127.9, 
127.8, 127.2, 123.7, 121.2, 118.7, 111.8, 66.4, 41.0; HRMS (m/z): [M + Na] calcd for 
C27H22N3O2S2Na 507.6017, found  507.1051 
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